U.S. patent application number 14/367706 was filed with the patent office on 2015-05-14 for novel jnk inhibitor molecules for treatment of various diseases.
The applicant listed for this patent is Xigen Inflammation Ltd.. Invention is credited to Jean-Marc Combette, Catherine Deloche.
Application Number | 20150133393 14/367706 |
Document ID | / |
Family ID | 47471695 |
Filed Date | 2015-05-14 |
United States Patent
Application |
20150133393 |
Kind Code |
A1 |
Combette; Jean-Marc ; et
al. |
May 14, 2015 |
Novel JNK Inhibitor Molecules for Treatment of Various Diseases
Abstract
The present invention relates to the use of novel JNK inhibitor
molecules and their use in a method of treatment of the human or
animal body by therapy.
Inventors: |
Combette; Jean-Marc; (Saint
Cergues, FR) ; Deloche; Catherine; (Genf,
CH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Xigen Inflammation Ltd. |
Limassol |
|
CY |
|
|
Family ID: |
47471695 |
Appl. No.: |
14/367706 |
Filed: |
December 21, 2012 |
PCT Filed: |
December 21, 2012 |
PCT NO: |
PCT/EP2012/005362 |
371 Date: |
June 20, 2014 |
Current U.S.
Class: |
514/21.6 ;
530/324; 530/326; 530/327 |
Current CPC
Class: |
A61P 9/00 20180101; A61P
15/00 20180101; C07K 7/06 20130101; A61P 31/04 20180101; A61P 17/14
20180101; A61P 17/06 20180101; A61P 25/08 20180101; A61P 31/12
20180101; C12N 7/00 20130101; A61K 38/005 20130101; A61P 43/00
20180101; C07K 7/08 20130101; A61P 31/14 20180101; A61P 35/02
20180101; A61P 35/04 20180101; A61K 38/162 20130101; A61P 19/00
20180101; A61P 25/16 20180101; A61P 9/10 20180101; A61P 9/12
20180101; A61P 27/12 20180101; A61P 1/02 20180101; A61P 11/06
20180101; A61P 13/12 20180101; A61P 3/10 20180101; A61P 11/00
20180101; A61P 17/00 20180101; A61P 27/02 20180101; A61K 38/08
20130101; A61P 19/10 20180101; C07K 14/001 20130101; A61P 13/08
20180101; A61P 31/20 20180101; A61P 35/00 20180101; A61P 27/06
20180101; A61P 1/04 20180101; A61P 3/04 20180101; A61P 3/06
20180101; A61P 25/28 20180101; A61P 13/02 20180101; A61K 38/00
20130101; A61P 25/14 20180101; C12N 2740/16334 20130101; A61P 25/04
20180101; A61P 5/00 20180101; A61P 25/00 20180101; A61P 25/24
20180101; A61P 1/16 20180101; A61P 17/02 20180101; A61P 37/06
20180101; A61K 38/10 20130101; A61P 19/02 20180101; A61P 27/16
20180101; C12N 2740/16322 20130101; A61P 1/18 20180101; A61P 29/00
20180101; A61P 13/10 20180101 |
Class at
Publication: |
514/21.6 ;
530/327; 530/326; 530/324 |
International
Class: |
C07K 7/06 20060101
C07K007/06; C07K 14/00 20060101 C07K014/00; C07K 7/08 20060101
C07K007/08 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 21, 2011 |
EP |
PCT/EP2011/006481 |
Claims
1. JNK inhibitor, selected from the group consisting of: a) a JNK
inhibitor, which comprises an inhibitory (poly-)peptide sequence
according to the following general formula: TABLE-US-00013 (SEQ ID
NO: 1) X1-X2-X3-R-X4-X5-X6-L-X7-L-X8,
wherein X1 is an amino acid selected from amino acids R, P, Q and
r, wherein X2 is an amino acid selected from amino acids R, P, G
and r, wherein X3 is an amino acid selected from amino acids K, R,
k and r, wherein X4 is an amino acid selected from amino acids P
and K, wherein X5 is an amino acid selected from amino acids T, a,
s, q, k or is absent, wherein X6 is an amino acid selected from
amino acids T, D and A, wherein X7 is an amino acid selected from
amino acids N, n, r and K; and wherein X8 is an amino acid selected
from F, f and w, and wherein an amino acid residue given in capital
letters indicates an L-amino acid, while an amino acid residue
given in small letters indicates a D amino acid residue, with the
proviso that at least one of the amino acids selected from the
group consisting of X1, X2, X3, X5, X7 and X8 is/are a D-amino
acid(s), and b) a JNK inhibitor which comprises an inhibitory
(poly-)peptide sequence sharing at least at least 80% sequence
identity with SEQ ID NO: 1 as defined in a), with the proviso that
with respect to SEQ ID NO: 1 such inhibitory (poly-)peptide
sequence sharing sequence identity with SEQ ID NO: 1 maintains the
L-arginine (R) residue of SEQ ID NO: 1 at position 4 and the two
L-leucine (L) residues of SEQ ID NO: 1 at positions 8 and 10 and
that at least one of the remaining amino acids in said sequence
sharing at least at least 80% sequence identity with SEQ ID NO: 1
is a D-amino acid, for use in a method of treatment of the human or
animal body by therapy.
2. JNK inhibitor for use according to claim 1, wherein at least one
of the amino acids selected from the group consisting of X3, X5, X7
and X8 is/are a D-amino acid(s).
3. JNK inhibitor for use according to claim 1, wherein the JNK
inhibitor comprises an inhibitory (poly-)peptide sequence sharing
at least 80% sequence identity with a sequence selected from any
one of SEQ ID NOs: 2-27.
4. JNK inhibitor for use according to claim 1, wherein the
inhibitory (poly-)peptide sequence is selected from anyone of SEQ
ID NOs: 2-27.
5. JNK inhibitor for use according to claim 1, wherein the JNK
inhibitor comprises SEQ ID NO: 8 or an inhibitory (poly-)peptide
sequence sharing at least 80% sequence identity with SEQ ID NO:
8.
6. JNK inhibitor for use according to claim 1, wherein the JNK
inhibitor comprises a transporter sequence.
7. JNK inhibitor for use according to claim 6, wherein the
inhibitory (poly-)peptide sequence and the transporter sequence
overlap.
8. JNK inhibitor for use according to claim 6, wherein the
transporter sequence comprises a sequence of alternating D- and
L-amino acids according to anyone of SEQ ID NOs: 28-30.
9. JNK inhibitor for use according to claim 6, wherein said
transporter sequence is selected from any one of SEQ ID NOs:
31-170.
10. JNK inhibitor for use according to claim 6, wherein said
transporter sequence is selected from any one of SEQ ID NOs: 31-34,
46, 47 and 52-151.
11. JNK inhibitor for use according to claim 6, wherein said
transporter sequence is positioned directly N-terminal or directly
C-terminal of the inhibitory (poly-) peptide sequence.
12. JNK inhibitor for use according to claim 6, wherein the JNK
inhibitor comprises a) a sequence according to any one of SEQ ID
NOs: 171-190, or b) a sequence sharing at least 50% sequence
identity with at least one of SEQ ID NOs: 171-190, with the proviso
that said sequence sharing sequence identity anyone of SEQ ID NOs:
171-190: i) maintains the L-arginine (R) residue on position 4 in
its sequence stretch corresponding to SEQ ID NO: 1, ii) maintains
the two L-leucine (L) in its sequence stretch corresponding to SEQ
ID NO: 1, and iii) exhibits at least one D-amino acid at positions
X1, X2, X3, X5, X7 or X8 in its sequence stretch corresponding to
SEQ ID NO: 1.
13. JNK inhibitor for use according to claim 6, wherein the JNK
inhibitor comprises a) the sequence of SEQ ID NO: 172 or b) a
sequence sharing 50% sequence identity with SEQ ID NO: 172, with
the proviso that said sequence sharing 50% sequence identity with
SEQ ID NO: 172 i) maintains the L-arginine (R) residue on position
4 in its sequence stretch corresponding to SEQ ID NO: 1, ii)
maintains the two L-leucine (L) in its sequence stretch
corresponding to SEQ ID NO: 1, and iii) exhibits at least one
D-amino acid at positions X1, X2, X3, X5, X7 or X8 in its sequence
stretch corresponding to SEQ ID NO: 1.
14. JNK inhibitor comprising: a) an inhibitory (poly-)peptide
comprising a sequence selected from the group of sequences
consisting of RPTTLNLF (SEQ ID NO: 191), KRPTTLNLF (SEQ ID NO:
192), RRPTTLNLF and/or RPKRPTTLNLF (SEQ ID NO: 193), and b) a
transporter sequence selected from SEQ ID NOs: 31-34 and 46-151,
for use in a method for treatment of the human or animal body by
therapy.
15. JNK inhibitor comprising the sequence of SEQ ID NO: 194 or 195
for use in a method for treatment of the human or animal body by
therapy.
16. JNK inhibitor for use according to claim 1, wherein said method
is for treatment of the human body by therapy.
17. JNK inhibitor for use according to claim 1, wherein said JNK
inhibitor is administered intravenously, intramuscularly,
subcutaneously, intradermally, transdermally, enterally, orally,
rectally, topically, nasally, locally, intranasally, epidermally,
by patch delivery, by instillation, intravitreally,
subconjunctivally and/or intratympanically.
18. JNK inhibitor for use according to claim 1, wherein said method
is for treatment of diseases and/or disorders selected from
inflammatory diseases, diseases of the eye, diseases of the bone,
neural diseases, neuronal diseases, neurodegenerative diseases,
diseases of the skin, immune and/or autoimmune diseases, diseases
of the eye, diseases of the mouth, metabolic diseases,
cardiovascular diseases, proliferative diseases, diseases of the
ear, diseases of the intestine, diseases of the respiratory system,
acute inflammation, chronic inflammation, inflammation in the eye,
inflammation in the mouth, inflammation of the respiratory system,
inflammation of the lung, inflammation of the skin, inflammation
within the cardiovascular system, inflammation of the brain,
inflammation in the ear, mucositis, stomatitis, peri-implantitis,
retinitis, chorioiditis, keratoconjunctivitis sicca, inflammatory
bowel diseases (IBD), uveitis, anterior uveitis, intermediate
uveitis, posterior uveitis, periodontitis, COPD, asthma, pulpitis,
rheumatoid arthritis, osteoarthritis, Crohn's disease, psoriatic
arthritis, vasculitis, interstitial cystitis, acute inflammation at
a site of infection or wound, meningitis, encephalitis, pneumonia,
pharyngitis, tonsillitis, otitis, otitis media, vasculitis,
synovitis, enteritis, Crohn's disease, ulcerative colitis, graft
rejection, hearing loss, acute hearing loss, damaged hair cell
stereocilia, hair cell apoptosis, noise trauma, otitis, otitis
media, diabetes, diabetes type 1, diabetes type 2, Fabry disease,
Gaucher disease, hypothermia, hyperthermia, hypoxia, lipid
histiocytosis, lipidoses, metachromatic leukodystrophy,
mucopolysaccharidosis, Niemann Pick disease, obesity, Wolman's
disease, Alexander disease, Alzheimer's disease, amyotrophic
lateral sclerosis (ALS), apoplexy, Ataxia Telangiectasia, cut or
otherwise disrupted axons, axotomy, brain lesions, CMT
(Charcot-Marie-Tooth), corticobasal degeneration, dementia,
diseases or disorders of the nervous system, dystonia, epilepsy,
Farber's disease, Friedreich ataxia (SCA), gangliosidoses,
Guillain-Barre syndrome, hereditary spastic paraplegia,
Hirschsprung's disease, human immunodeficiency virus dementia,
Huntington's disease, infarct of the brain, ischemic stroke, Krabbe
disease, Lennox Gastaut Syndrome, lissencephaly, multiple
sclerosis, myelodysplastic syndromes, myelopathy, AIDS-related
neurodegenerative diseases, neurofibromatosis type 2 (NF-2),
neurolatyerism, neuronal apoptosis, neuronal death, neuropathic
pain, neuropathy, chemotherapy induced neuropathy, diabetes induced
neuropathy, NMDA-induced neurotoxicity, pain, Parkinson's disease,
parkinsonism, Pick's Disease, polyneuropathy, progressive
supranuclear palsy, Sandhoff disease, spina bifida, stroke, Tay
Sachs, TBI (diffuse axonal injury), treatment of dark neurone
induced for example by an inflammatory pain, West Syndrome, spinal
muscular atrophy, autoimmune diseases of the CNS, auto-inflammatory
diseases, Celiac disease, Sjogren's syndrome, systemic lupus
erythematosus, age-related macular degeneration (AMD), angioid
streaks, anterior ischemic optic neuropathy, anterior uveitis,
cataract, in particular age related cataract, central exudative
chorioretinopathy, central serous chorioretinopathy, chalazion,
chorioderemia, chorioiditis, choroidal sclerosis, conjunctivitis,
cyclitis, diabetic retinopathy, dry eye syndrome, endophthalmitis,
episcleritis, eye infection, fundus albipunctatus, gyrate atrophy
of choroid and retina, hordeolum, inflammatory diseases of the
blephara, inflammatory diseases of the choroid, inflammatory
diseases of the ciliary body, inflammatory diseases of the
conjunctiva, inflammatory diseases of the cornea, inflammatory
diseases of the iris, inflammatory diseases of the lacrimal gland,
inflammatory diseases of the orbital bone, inflammatory diseases of
the sclera, inflammatory diseases of the vitreous body,
inflammatory diseases of the uvea, inflammatory diseases of the
retina, intermediate uveitis, irititis, keratitis, Leber's disease,
multifocal choroiditis, myositis of the eye muscle, neovascular
maculopathy (e.g. caused by high myopia, tilted disc syndrome,
choroidal osteoma or the like), NMDA induced retinotoxicity,
non-chronic or chronic inflammatory eye diseases, Oguchi's disease,
optic nerve disease, orbital phlegmon, panophtalmitis, panuveitis,
post caspule opacification, posterior capsule opacification (PCO)
(a cataract after-surgery complication), posterior uveitis,
proliferative vitreoretinopathy, retinal artery occlusion, retinal
detachment, retinal diseases, retinal injuries, retinal
macroaneurysm, retinal pigment epithelium detachment, retinal vein
occlusion, retinitis, retinitis pigmentosa, retinitis punctata
albescens, retinopathy, in particular retinopathy of prematurity
and diabetic retinopathy, scleritis, Stargardt's disease, treatment
of inflamed ocular wounds and/or ocular wound edges, treatment of
intraocular inflammation after eye surgery or trauma, uveitis,
vitelliform macular dystrophy, periodontitis, in particular chronic
periodontitis, mucositis, oral desquamative disorders, oral liquen
planus, pemphigus vulgaris, peri-implantitis, pulpitis, stomatitis,
temporomandibular joint disorder, cancer and tumor diseases,
acusticus neurinoma lung carcinomas, acute lymphocytic leukemia
(L1, L2, L3), acute lymphoid leukaemia (ALL), acute myelogenous
leukemia (AML), adenocarcinomas, anal carcinoma, bronchial
carcinoma, cervix carcinoma, cervical cancer, astrocytoma,
basalioma, cancer with Bcr-Abl transformation, bladder cancer,
blastomas, bone cancer, brain metastases, brain tumours, breast
cancer, Burkitt's lymphoma, carcinoids, cervical cancer, chronic
lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), colon
cancer, colon carcinoma, corpus carcinoma, craniopharyngeomas, CUP
syndrome, virus-induced tumours, EBV-induced B cell lymphoma,
endometrium carcinoma, erytholeukemia (M6), esophagus cancer,
gallbladder cancer, gastrointestinal cancer, gastrointestinal
stromal tumors, gastrointestinal tumours, genitourinary cancer,
glaucoma, glioblastoma, gliomas, head/neck tumours, hepatitis
B-induced tumours, hepatocell carcinomas, hepatomas, herpes
virus-induced tumours, Hodgkin's syndrome, HTLV-1-induced
lymphomas, HTLV-2-induced lymphomas, insulinomas, intestinal
cancer, Kaposi's sarcoma, kidney cancer, kidney carcinomas,
laryngeal cancer, leukemia, lid tumour, liver cancer, liver
metastases, lung cancer, lymphoid cancer, lymphomas, malignant
melanomas, mammary carcinomas, mantle cell lymphoma,
medulloblastoma, megakaryoblastic leukemia (M7), melanoma, in
particular malignant melanoma, meningioma, mesothelioma, monocytic
leukemia (MS), multiple myeloma, mycosis fungoides, myeloblastic
leukemia (M1), myeloblastic leukemia (M2), myelomonocytic leukemia
(M4), neurinoma, non-Hodgkin's lymphomas, non-small cell carcinoma,
non-small cell carcinoma of the lung, oesophageal cancer,
oesophageal carcinoma, oligodendroglioma, ovarian cancer, ovarian
carcinoma, pancreatic cancer, pancreatic carcinoma, papilloma
virus-induced carcinomas, penis cancer, pituitary tumour,
plasmocytoma, promyelocytic leukemia (M3), prostate cancer,
prostate tumours, rectal tumours, rectum carcinoma, renal-cell
carcinoma, retinoblastoma, sarcomas, Schneeberger's disease, small
cell lung carcinomas, small intestine cancer, small intestine
tumours, soft tissue tumours, spinalioma, squamous cell carcinoma,
stomach cancer, testicular cancer, throat cancer, thymoma, thyroid
cancer, thyroid carcinoma, tongue cancer, undifferentiated AML
(MO), urethral cancer, uterine cancer, vaginal cancer, Von Hippel
Lindau disease, vulval cancer, Wilms' Tumor, Xeroderma pigmentosum,
arterial hypertension, arteriosclerosis, arteriosclerotic lesions,
Behcet's syndrome, bifurcations of blood vessels, cardiac
hypertrophy, cardiavascular hypertrophy, cardiomyopathies, in
particular chemotherapy induced cardiomyopathies, cerebral
ischemia, coronary heart diseases, dilatation of the abdominal
aorta, focal cerebral ischemia, global cerebral ischemia, heart
hypertrophy, infrarenal aneurism hypertension, ischemia, myocardial
infarct, in particular acute myocardial infarction, myocarditis,
reperfusion, restenosis, vasculitis, Wegener's granulomatosis,
acute respiratory distress syndrome (ARDS), asthma, chronic
illnesses involving the respiratory system, chronic obstructive
pulmonary disease (COPD), cystic fibrosis, diseases of the lung,
inflammatory lung diseases, pneumonia, pulmonary fibrosis, colitis,
atypical colitis, chemical colitis, collagenous colitis, distal
colitis, diversion colitis, fulminant colitis, indeterminate
colitis, infectious colitis, ischemic colitis, lymphocytic colitis,
microscopic colitis, Crohn's disease, gastroenteritis,
Hirschsprung's disease, inflammatory digestive diseases,
inflammatory bowel disease (IBD), Morbus Crohn, non-chronic or
chronic digestive diseases, non-chronic or chronic inflammatory
digestive diseases, regional enteritis, ulcerative colitis,
bacterial infectious diseases, viral infectious diseases, viral
encephalitis, viral induced cancers and tumours, human
immunodeficiency virus dementia, meningitis, meningoencephalitis,
encephalomyelitis, tonsillitis, Aarskog syndrome, acetaminophen
hepatotoxicity, Alder-Reilly anomaly, alopecia greata,
alpha-1-antitrypsin deficiency, anaphylaxis, apoptosis, apoptotic
cell death, atypical hemolytic uremic syndrome, basopenia,
basophilia, bipolar disorders, burns, cellular shear stress,
Chedial-Higashi syndrome, DNA damage due to chemotherapeutic drugs,
cholestasis, chromosome 11, Partial Monosomy 11q, chromosome 22,
Trisomy Mosaic, chronic granulomatous disease, hepatitis, such as
chronic or fulminant hepatitis, clinical depression, common
variable hypogammaglobulinemia, congenital C3 deficiency, CTL
protection from activation-induced cell death (AICD), deafness,
depression and depressive disorders (in particular prevention of
depressive disorders develop on a background of cytokine-induced
sickness behaviour), DiGeorge's syndrome, diseases caused by
defective apoptosis, diseases of the liver, diseases of the spine,
diseases of the uterus, diseases states and symptoms due to
exposure to DNA damaging agents and/or ionizing radiation and
resulting cellular stress, Down Syndrome, Duchenne muscular
dystrophy, ectodermal dysplasias, endometriosis, eosinopenia,
eosinophilia, exocitoxic cell death, fetal alcohol syndrome,
fibrosis, fibrotic disease, formation of fibrous tissue, free
radicals (leading to cellular stress), graft rejection, graft
versus host disease, hair loss, hemolytic uremic syndrome,
hepatotoxicity, hyperalgesia, such as diabetes induced
hyperalgesia, hyperthermia, hypoglycemia, hypothyroidism,
idiopathic hypereosinophilic syndrome, IgA nephropathy, infantile
sex-linked agammaglobulinemia, inflammatory pain, infrarenal
aneyrism, islet regeneration, islet transplantation, Job's syndrome
(hyper-IgE), lazy leukocyte syndrome, leukocyte glucose-6-phosphate
dehydrogenase deficiency, leukodystrophy, leukopenia, lymphocytic
leukocytosis, lymphocytopenia, lymphocytosis, major depression,
mania, maniac depression, Marfan syndrome, mastocytosis, May
Hegglin Anomaly, membranoproliferative glomerulonephritis Type II,
monocytopenia, monocytosis, myeloperoxidase deficiency-benign,
myopathies, neutropenia, neutrophilia, Nezelof's syndrome, organ
transplantation, oxidative stress injuries, Pelger-Huet anomaly,
polycystic kidney diseases, post-dialysis syndrome, radiation
syndromes, radiotherapy, renal diseases, renal failure, rescuing
CTL from activation induced cell death, severe combined
immunodeficiency disease, transplant rejection, transplantation,
trisomy, unipolar depression, UV-induced injuries, Wiskott Aldrich
syndrome and wound healing.
19-29. (canceled)
30. JNK inhibitor for use according to claim 1, wherein the JNK
inhibitor is used complementary to coronary artery bypass graft
surgery (CABG surgery); percutaneous transluminal coronary
angioplasty (PTCA); and/or stent treatment.
31-34. (canceled)
35. JNK inhibitor for use according to claim 1, wherein said method
is for treatment of temporomandibular joint disorder, mucositis,
stomatitis, peri-implantitis, oral liquen planus, Pemphigus
vulgaris, periodontitis, chronic periodontitis, pulpitis, uveitis,
in particular of anterior uveitis, intermediate uveitis and/or
posterior uveitis, or dry eye syndrome.
36-45. (canceled)
46. JNK inhibitor for use according to claim 1, wherein the JNK
inhibitor is administered in context of coronary artery bypass
graft surgery, percutaneous transluminal coronary angioplasty
(PTCA), or stent placement.
47-48. (canceled)
49. JNK inhibitor for use according to claim 1, wherein said method
is for treatment of acute myocardial infarction, atherosclerosis,
COPD, asthma, rheumatoid arthritis, osteoarthritis, Crohn's
disease, inflammatory bowel disease (IBD), psoriasis, diabetes,
diabetes type 1, stroke, Parkinson's disease, Alzheimer's disease,
systemic lupus erythematosus, vasculitis, Wegener's granulomatosis,
or acute hearing loss.
50-64. (canceled)
65. JNK inhibitor for use according to claim 1, wherein the JNK
inhibitor consists of the sequence of SEQ ID NO: 172.
66. Pharmaceutical composition comprising a JNK inhibitor as
defined in claim 1 and a pharmaceutically acceptable carrier.
Description
[0001] The present invention relates to the field of enzyme
inhibition, in particular to (poly-)peptide inhibitors of c-Jun
amino terminal kinase (JNK). In particular, the present invention
relates to using these JNK inhibitors in the treatment of various
diseases.
[0002] The c-Jun amino terminal kinase (JNK) is a member of the
stress-activated group of mitogen-activated protein (MAP) kinases.
These kinases have been implicated in the control of cell growth
and differentiation, and, more generally, in the response of cells
to environmental stimuli. The JNK signal transduction pathway is
activated in response to environmental stress and by the engagement
of several classes of cell surface receptors. These receptors can
include cytokine receptors, serpentine receptors and receptor
tyrosine kinases. In mammalian cells, JNK has been implicated in
biological processes such as oncogenic transformation and mediating
adaptive responses to environmental stress. JNK has also been
associated with modulating immune responses, including maturation
and differentiation of immune cells, as well as effecting
programmed cell death in cells identified for destruction by the
immune system. This unique property makes JNK signaling a promising
target for developing pharmacological intervention. Among several
neurological disorders, JNK signaling is particularly implicated in
ischemic stroke and Parkinson's disease, but also in other diseases
as mentioned further below. Furthermore, the mitogen-activated
protein kinase (MAPK) p38alpha was shown to negatively regulate the
cell proliferation by antagonizing the JNK-c-Jun-pathway. The
mitogen-activated protein kinase (MAPK) p38alpha therefore appears
to be active in suppression of normal and cancer cell proliferation
and, as a further, demonstrates the involvement of JNK in cancer
diseases (see e.g. Hui et al., Nature Genetics, Vol 39, No. 6, June
2007). It was also shown, that c-Jun N-terminal Kinase (JNK) is
involved in neuropathic pain produced by spinal nerve ligation
(SNL), wherein SNL induced a slow and persistent activation of JNK,
in particular JNK1, whereas p38 mitogen-activated protein kinase
activation was found in spinal microglia after SNL, which had
fallen to near basal level by 21 days (Zhuang et al., The Journal
of Neuroscience, Mar. 29, 2006, 26(13):3551-3560)). In 2007
(Biochemica et Biophysica Acta, pp. 1341-1348), Johnson et al.
discussed in a review the c-Jun kinase/stress-activated pathway,
the involvement of JNK signalling in diseases such as the
involvement in excitotoxicity of hippocampal neurons, liver
ischemia, reperfusion, neurodegenerative diseases, hearing loss,
deafness, neural tube birth defects, cancer, chronic inflammatory
diseases, obesity, diabetes, in particular insulin-resistant
diabetes, and proposed that it is likely that selective JNK
inhibitors are needed for treatment of various diseases with a high
degree of specificity and lack of toxicity.
[0003] Inhibition or interruption of the JNK signalling pathway is
thus a promising approach in combating disorders strongly related
to JNK signalling. However, there are only a few inhibitors of the
JNK signaling pathway known so far.
[0004] Inhibitors of the JNK signaling pathway as already known in
the prior art include e.g. upstream kinase inhibitors (for example,
CEP-1347), small chemical inhibitors of JNK (SP600125 and
AS601245), which directly affect kinase activity e.g. by competing
with the ATP-binding site of the protein kinase, and peptide
inhibitors of the interaction between JNK and its substrates (see
e.g. Kuan et al., Current Drug Targets--CNS & Neurological
Disorders, February 2005, vol. 4, no. 1, pp. 63-67; WO 2007/031280;
all incorporated herewith by reference). WO 2007/031280 discloses
small cell permeable fusion peptides, comprising a so-called TAT
transporter sequence derived from the basic trafficking sequence of
the HIV-TAT protein and an amino acid inhibitory sequence of
IB1.
[0005] WO 2007/031280 discloses in particular two specific
sequences, L-TAT-IB1 (GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD, herein SEQ
ID NO: 196) and D-TAT-IB1 (dqsrpvqpflnlttprkprpprrrqrrkkrg; herein
SEQ ID NO: 197), the latter being the retro-inverso sequence of
L-TAT-IB1. Due to the HIV TAT derived transporter sequence, these
fusion peptides are more efficiently transported into the target
cells, where they remain effective until proteolytic
degradation.
[0006] Since ATP independent peptide inhibitors of JNK are usually
more specific inhibitors, they are frequently the first choice if
it comes to inhibiting JNK. However, even the peptide inhibitors
disclosed in WO 2007/031280 are not optimal for all purposes. For
example, compound L-TAT-IB1 (herein SEQ ID NO: 196) which consists
of L amino acids only, is quickly proteolytically degraded. In
order to overcome this problem the inventors of WO 2007/031280 also
suggested D-TAT-IB1 (herein SEQ ID NO: 197), which comprises D
amino acids. To be more precise, D-TAT-IB1 exhibits the
retro-inverso sequence of L-TAT-IB1. Incorporation of D-amino acids
is made difficult by the fact that the change in stereochemistry
may lead to a loss of function. The retro-inverso approach may be
employed to reduce said risk because the use of i) only D-amino
acids ii) but in the inverse peptide sequence may more likely yield
an acceptable conformational analogue to the original peptide than
incorporating one or more D-amino acids into the original sequence.
In the case of WO 2007/031280 this approach resulted nevertheless
in a significant decrease in inhibitory capacity in comparison to
L-TAT-IB1 (see FIG. 4). Additionally, the retro-inverso peptide is
extremely stable towards proteolytic digestion with the consequence
that controlled digestions, for example in time sensitive
experiments, are hardly possible.
[0007] JNK inhibitors have been discussed, proposed and
successfully tested in the art as treatment for a variety of
disease states. Already in 1997, Dickens et al. described the c-Jun
amino terminal kinase inhibitor JIP-1 and proposed JIP-1 as
candidate compounds for therapeutic strategies for the treatment of
for example chronic myeloid leukaemia, in particular, in the
context of Bcr-Abl caused transformation of pre-B-cells (Science;
1997; 277(5326):693-696).
[0008] In 2001, Bonny and co-workers published that cell-permeable
peptide inhibitors of JNK confirm long term protection to
pancreatic .beta.-cells from IL-1.beta.-induced apoptosis and may,
thus, preserve .beta.-cells in the autoimmune destruction in the
course of diabetes (Diabetes, 50, 2001, p. 77-82).
[0009] Bonny et al. (Reviews in Neurosciences, 2005, p. 57-67)
discussed also the inhibitory action of the JNK inhibitor D-JNKI-1
and other JNK inhibitors in the context of excitotoxicity, neuronal
cell death, hypoxia, ischemia, traumatic brain damage, epilepsy,
neurodegenerative diseases, apoptosis of neurons and inner ear
sensory auditory cells etc.
[0010] In WO 98/49188 JIP-1 derived inhibitors of JNK signalling
are proposed for the treatment of neurodegenerative diseases, such
as Parkinson's disease or Alzheimer's disease; stroke and
associated memory loss, autoimmune diseases such as arthritis;
other conditions characterized by inflammation; malignancies, such
as leukemias, e.g. chronic myelogenous leukemia (CML); oxidative
damage to organs such as the liver and kidney; heart diseases; and
transplant rejections.
[0011] Borsello et al. (Nat Med, 2003, (9), p. 1180-1186) published
that a peptide inhibitor of c-Jun-N-terminal kinase protects
against excitotoxicity and cerebral ischemia.
[0012] Assi et al. have published that another specific
JNK-inhibitor, SP600125, targets tumor necrosis factor-.alpha.
production and epithelial cell apoptosis in acute murine colitis.
The authors concluded that inhibition of JNK is of value in human
inflammatory bowel disease treatment (Immunology; 2006,
118(1):112-121).
[0013] In Kennedy et al. (Cell Cycle, 2003, 2(3), p. 199-201), the
role of JNK signalling in tumor development is discussed in more
detail.
[0014] Lee Yong Hee et al. (J Biol Chem 2003, 278(5), P. 2896-2902)
showed that c-Jun N-terminal kinase (JNK) mediates feedback
inhibition of the insulin signalling cascade and have proposed that
inhibition of JNK signalling is a good therapeutic approach to
reduce insulin resistance in diabetic patients.
[0015] Milano et al. (Am J Physiol Heart Circ Physiol 2007; 192(4):
H1828-H1835) discovered that a peptide inhibitor of c-Jun
NH.sub.2-terminal kinase reduces myocardial ischemia-reperfusion
injury and infarct size in vivo. The authors of said study used a
peptide inhibitor, D-JNKI-I, a two domain peptide containing a 20
amino acid sequence of the minimal JNK-binding domain of
islet-brain-1/JNK-interacting protein-1, linked to a 10 amino acid
TAT sequence of the human immuno deficiency virus TAT protein that
mediates intracellular translocation. The authors have concluded
that a reduction in JNK activity and phosphorylation due to the
presence of said inhibitor is important in the preservation of
cardiac function in rats in the phase of ischemia and
apoptosis.
[0016] A further group has published that small peptide inhibitors
of JNKs protect against MPTP-induced nigral dopaminergic injury via
inhibiting the JNK-signalling pathway (Pan et al., Laboratory
investigation, 2010, 90, 156-167). The authors concluded that a
peptide comprising residues 153-163 of murine JIP-1 fused to TAT
peptide offers neuroprotection against MPTP injury via inhibiting
the JNK-signalling pathway and provides a therapeutic approach for
Parkinson's disease.
[0017] For hearing damage, Pirvola et al. (The Journal of
Neuroscience, 2000, 20(1); 43-50) described the rescue of hearing,
auditory hair cells and neurons by CEP-1347/KT7515, an inhibitor of
c-Jun-N-terminal kinase activation. The authors suggested in
general that therapeutic intervention in the JNK signalling cascade
may offer opportunities to treat inner ear injuries. Treatment of
hearing loss by means of administering JNK-inhibitory peptides is
also disclosed for example in WO 03/103698.
[0018] For retinal diseases and age-related macula degeneration in
particular, Roduit et al. (Apoptosis, 2008, 13(3), p. 343-353) have
likewise suggested to use JNK-inhibition as therapeutic approach.
Similar considerations relying on JNK-inhibition are disclosed for
example in WO 2010/113753 for the treatment of age-related macular
degeneration, diabetic macular edema, diabetic retinopathy, central
exudative chorioretinopathy, angioid streaks, retinal pigment
epithelium detachment, multifocal choroiditis, neovascular
maculopathy, retinopathy of prematurity, retinitis pigmentosa,
Leber's disease, retinal artery occlusion, retinal vein occlusion,
central serous chorioretinopathy, retinal macroaneurysm, retinal
detachment, proliferative vitreoretinopathy, Stargardt's disease,
choroidal sclerosis, chorioderemia, vitelliform macular dystrophy,
Oguchi's disease, fundus albipunctatus, retinitis punctata
albescens, and gyrate atrophy of choroid and retina.
[0019] Zoukhri et al. (Journal of Neurochemistry, 2006, 96,
126-135) identified that c-Jun NH.sub.2-terminal kinase mediates
interleukin-1.beta.-induced inhibition of lacrimal gland secretion.
They concluded that JNK plays a pivotal role in IL-1.beta.-mediated
inhibition of lacrimal gland secretion and subsequent dry eye.
[0020] For uveitis, Touchard et al. (Invest Ophthalmol V is Sci,
2010, 51(9); 4683-4693) have suggested to use D-JNKI 1 as effective
treatment.
[0021] For IBD (inflammatory bowel disease) Roy et al. (World J
Gastroenterol 2008, 14(2), 200-202) have highlighted the role of
the JNK signal transduction pathway therein and have proposed to
use peptidic JNK inhibitors for the treatment of said disease
state.
[0022] Beckham et al (J. Virol. 2007 July; 81(13):6984-6992) showed
that the JNK inhibitor D-JNKI-1 is effective in protecting mice
from viral encephalitis, and suggest thus JNK inhibition as
promising and novel treatment strategy for viral encephalitis.
[0023] Palin et al. (Psychopharmacology (Berl). 2008 May;
197(4):629-635) used the same JNK inhibitor, D-JNKI-1, and found
that pre-treatment with D-JNKI-1 (10 ng/mouse), but not D-TAT,
significantly inhibited all three indices of sickness induced by
central TNFalpha and suggested that JNK inhibition as means for
treating major depressive disorders that develop on a background of
cytokine-induced sickness behaviour.
[0024] In WO 2010/151638 treatment of the neurodegenerative disease
spinal muscular atrophy by way of JNK inhibition was proposed.
[0025] The above passage highlights already on basis of only some
selected publications the usefulness of JNK inhibitors in the
treatment of various diseases. Thus, there is a constant need in
the art for JNK inhibitors for use in the treatment of human (and
animal) diseases.
[0026] Thus, the problem to be solved by the present invention was
to provide further (peptide) inhibitors of JNK.
[0027] The object of the present invention is solved by the
inventor by means of the subject-matter set out below and in the
appended claims.
BRIEF DESCRIPTION OF THE FIGURES
[0028] In the following a brief description of the appended figures
will be given. The figures are intended to illustrate the present
invention in more detail. However, they are not intended to limit
the subject matter of the invention in any way.
[0029] FIG. 1: Illustration of the inhibitory efficacy of several
JNK inhibitors according to the present invention, which was
investigated by in vitro AlphaScreen assay (Amplified Luminescence
Proximity Homogeneous-Screen Assay). [0030] FIG. 1A: Inhibition of
JNK1 by SEQ ID NOs: 193, 2, 3, 5, 6, and 7. [0031] FIG. 1B:
Inhibition of JNK2 by SEQ ID NOs: 193, 2, 3, 5, 6, and 7. [0032]
FIG. 1C: Inhibition of JNK3 by SEQ ID NOs: 193, 2, 3, 5, 6, and
7.
[0033] FIG. 2: Table illustrating the inhibitory efficacy of
several JNK inhibitors (SEQ ID NOs: 193, 2, 3, 5, 6, and 7)
according to the present invention. Given are the IC50 values in
the nM range, the respective standard error of the mean and the
number of experiments performed (n).
[0034] FIG. 3: Illustration of the inhibitory efficacy of several
JNK inhibitors according to the present invention, which are fusion
proteins of a JNK inhibitory (poly-)peptide sequence and a
transporter sequence. The inhibitory efficacy was determined by
means of in vitro AlphaScreen assay (Amplified Luminescence
Proximity Homogeneous-Screen Assay). [0035] FIG. 3A: Inhibition of
JNK1 by SEQ ID NOs: 194, 195, 172, 200, 46, 173, 174, 175, 176,
177, 178, 179, 180, 181 and 197. [0036] FIG. 3B: Inhibition of JNK2
by SEQ ID NOs: 194, 195, 172, 200, 46, 173, 174, 175, 176, 177,
178, 179, 180, 181 and 197. [0037] FIG. 3C: Inhibition of JNK3 by
SEQ ID NOs: 194, 195, 172, 200, 46, 173, 174, 175, 176, 177, 178,
179, 180, 181 and 197. [0038] FIG. 3D: Inhibition of JNK1 by SEQ ID
NOs: 194, 195, 172, 200, 46, 182, 183, 184, 185, 186, 187, 188,
189, 190 and 197. [0039] FIG. 3E: Inhibition of JNK2 by SEQ ID NOs:
194, 195, 172, 200, 46, 182, 183, 184, 185, 186, 187, 188, 189, 190
and 197. [0040] FIG. 3F: Inhibition of JNK3 by SEQ ID NOs: 194,
195, 172, 200, 46, 182, 183, 184, 185, 186, 187, 188, 189, 190 and
197.
[0041] FIG. 4: Table illustrating the inhibitory efficacy of
several JNK inhibitors according to the present invention, which
are fusion proteins of a JNK inhibitory (poly-)peptide sequence and
a transporter sequence. Given are the IC50 values in the nM range,
the respective standard error of the mean (SEM) and the number of
experiments performed (n).
[0042] FIG. 5: Stability of JNK inhibitors with SEQ ID NOs: 172,
196 and 197 in 50% human serum. The JNK inhibitor with SEQ ID NO:
196 was totally degraded into amino acids residues within 6 hours
(A). The JNK inhibitor with SEQ ID NO: 172 was completely degraded
only after 14 days (B). The JNK inhibitor with SEQ ID NO: 197 was
stable at least up to 30 days (B).
[0043] FIG. 6: shows internalizations experiments using TAT derived
transporter constructs with D-amino acid/L-amino acid pattern as
denoted in SEQ ID NO: 30. The transporter sequences analyzed
correspond to SEQ ID NOs: 52-94 plus SEQ ID NOs: 45, 47, 46, 43 and
99 (FIG. 6a) and SEQ ID NOs: 100-147 (FIG. 6b). As can be seen, all
transporters with the consensus sequence rXXXrXXXr (SEQ ID NO: 31)
showed a higher internalization capability than the L-TAT
transporter (SEQ ID NO: 43). Hela cells were incubated 24 hours in
96well plate with 10 mM of the respective transporters. The cells
were then washed twice with an acidic buffer (0.2M Glycin, 0.15M
NaCl, pH 3.0) and twice with PBS. Cells were broken by the addition
of RIPA lysis buffer. The relative amount of internalized peptide
was then determined by reading the fluorescence intensity (Fusion
Alpha plate reader; PerkinElmer) of each extract followed by
background subtraction.
[0044] FIG. 7 The JNK inhibitor with the sequence of SEQ ID NO: 172
blocks LPS-induced cytokine and chemokine release in
THP1-PMA-differentiated macrophages. FIG. 7A: TNF release (THP1pma
6 h 3 ng/ml LPS); FIG. 7B: TNF.alpha. release (THP1pma 6 h 10 ng/ml
LPS); FIG. 7C: IL 6 release (THP1pma 6 h 10 ng/ml LPS); FIG. 7D:
MCP1 release (THP1pma 6 h 3 ng/ml LPS).
[0045] FIG. 8 The JNK inhibitor of SEQ ID NO: 172 blocks
LPS-induced IL6 release in THP1 differentiated macrophages with
higher potency than D-TAT-IB1 (SEQ ID NO: 197), dTAT (SEQ ID NO:
45) and SP 600125. LPS was added for 6 h (10 ng/ml).
[0046] FIG. 9 The JNK inhibitor of SEQ ID NO: 172 blocks
LPS-induced TNF.alpha. release in THP1 differentiated macrophages
with higher potency than D-TAT-IB1 (SEQ ID NO: 197), dTAT (SEQ ID
NO: 45) and SP 600125. LPS was added for 6 h (10 ng/ml).
[0047] FIG. 10 The JNK inhibitor of SEQ ID NO: 172 blocks
LPS-induced IL-6 release in PMA differentiated macrophages with
higher potency than D-TAT-IB1 (SEQ ID NO: 197) and L-TAT-IB1 (SEQ
ID NO: 196). LPS was added for 6 h.
[0048] FIG. 11 The JNK inhibitor of SEQ ID NO: 172 blocks
LPS-induced TNF.alpha. release in PMA differentiated macrophages
with higher potency than D-TAT-IB1 (SEQ ID NO: 197) and L-TAT-IB1
(SEQ ID NO: 196).
[0049] FIG. 12 The JNK inhibitor of SEQ ID NO: 172 blocks
LPS-induced TNF.alpha. release in Primary Rat Whole Blood Cells at
3 ng/ml. Given are the results for the control, 1 .mu.M of SEQ ID
NO: 172, 3 .mu.M of SEQ ID NO: 172, and 10 .mu.M of SEQ ID NO: 172
at different levels of LPS (ng/ml).
[0050] FIG. 13 The JNK inhibitor of SEQ ID NO: 172 blocks IL2
secretion by primary human T-cells in response to
PMA/Ionomycin.
[0051] FIG. 14 The JNK inhibitor of SEQ ID NO: 172 blocks IL2
secretion by primary human T-cells in response to CD3/CD28
stimulation. The JNK inhibitors used are indicated by their SEQ ID
NO: 172 and 197.
[0052] FIG. 15 Dose-dependent inhibition by JNK inhibitor with SEQ
ID NO: 172 of CD3/CD28-induced IL-2 release in primary rat
lymph-nodes purified T cells. Control rat were sacrificed and
lymph-nodes were harvested. T cells further were purified (using
magnetic negative selection) and plated into 96-well plates at
200.000 cells/well. Cells were treated with anti-rat CD3 and
anti-rat CD28 antibodies (2 .mu.g/mL). JNK inhibitor with SEQ ID
NO: 172 was added to the cultures 1 h before CD3/CD28 treatment and
IL-2 release was assessed in supernatant 24 h after treatment.
[0053] FIG. 16 Dose-dependent inhibition of CD3/CD28-induced IL-2
release in primary rat lymph-nodes purified T cells: Comparison of
several JNK inhibitors, namely SEQ ID NOs: 172, 197 and
SP600125.
[0054] FIG. 17 Dose dependent inhibition of IL-2 release in rat
whole blood stimulated with PMA+ionomycin. JNK inhibitor with SEQ
ID NO: 172 was added at three different concentrations, namely 1, 3
and 10 .mu.M 1 h before stimulation with PMA+ionomycin. Three doses
of activators were added (25/500 ng/mL, 50/750 ng/mL and 50/1000
ng/mL) for 4 h. IL-2 release was assessed in supernatant. JNK
inhibitor with SEQ ID NO: 172 at 10 .mu.M did efficiently reduce
PMA-iono-induced IL-2 release at the three tested activator
concentrations.
[0055] FIG. 18 JNK inhibition and IL-6 release in human whole
blood. The JNK inhibitor with SEQ ID NO: 172 was added at three
different concentrations, namely 1, 3 and 10 .mu.M 1 h before whole
blood stimulation with LPS (0.02 ng/mL) for 4 hours. The JNK
inhibitor with SEQ ID NO: 172 did reduce the LPS-induced IL-6
release in a dose-dependent manner.
[0056] FIG. 19 JNK inhibition and IL-2 release in human whole
blood. The JNK inhibitor with SEQ ID NO: 172 was added at three
different concentrations, namely 1, 3 and 10 .mu.M 1 h before whole
blood stimulation with PMA+ionomycin (25/700 ng/mL, 50/800 ng/ml
and 50/1000 ng/mL) for 4 hours. The JNK inhibitor with SEQ ID NO:
172 did reduce the PMA+ionomycin-induced IL-2 release in a
dose-dependent manner.
[0057] FIG. 20 JNK inhibition and IFN-.gamma. release in human
whole blood. The JNK inhibitor with SEQ ID NO: 172 was added at
three different concentrations, namely 1, 3 and 10 .mu.M 1 h before
whole blood stimulation with PMA+ionomycin (25/700 ng/mL, 50/800
ng/ml and 50/1000 ng/mL) for 4 hours. The JNK inhibitor with SEQ ID
NO: 172 did reduce the PMA+ionomycin-induced IFN-.gamma. release in
a dose-dependent manner.
[0058] FIG. 21 JNK inhibition and TNF-.alpha. release in human
whole blood. The JNK inhibitor with SEQ ID NO: 172 was added at
three different concentrations, namely 1, 3 and 10 .mu.M 1 h before
whole blood stimulation with PMA+ionomycin (25/700 ng/mL, 50/800
ng/ml and 50/1000 ng/mL) for 4 hours. The JNK inhibitor with SEQ ID
NO: 172 did reduce the PMA+ionomycin-induced TNF-.alpha. release in
a dose-dependent manner.
[0059] FIG. 22 JNK inhibition and TNF-.alpha. release in human
whole blood. The JNK inhibitor with SEQ ID NO: 172 was added at
three different concentrations, namely 1, 3 and 10 .mu.M 1 h before
whole blood stimulation with PHA-L (5 .mu.g/mL) for 3 days. The JNK
inhibitor with SEQ ID NO: 172 did reduce the PHA-L-induced
TNF-.alpha. release in a dose-dependent manner.
[0060] FIG. 23 JNK inhibition and IL-2 release in human whole
blood. The JNK inhibitor with SEQ ID NO: 172 was added at three
different concentrations, namely 1, 3 and 10 .mu.M 1 h before whole
blood stimulation with PHA-L (5 .mu.g/mL) for 3 days. The JNK
inhibitor with SEQ ID NO: 172 did reduce the PHA-L-induced IL-2
release in a dose-dependent manner.
[0061] FIG. 24 JNK inhibition and TNF-.alpha. release in human
whole blood. The JNK inhibitor with SEQ ID NO: 172 was added at
three different concentrations, namely 1, 3 and 10 .mu.M 1 h before
whole blood stimulation with CD3+/-CD28 antibodies (2 .mu.g/mL) for
3 days. The JNK inhibitor with SEQ ID NO: 172 did reduce the
CD3/CD28-induced TNF-.alpha. release in a dose-dependent
manner.
[0062] FIG. 25 Photographic illustration of in vivo
anti-inflammatory properties of the JNK inhibitors with SEQ ID NO:
197 (10 .mu.g/kg) and SEQ ID NO: 172 (10 .mu.g/kg) after CFA
(complete Freund's adjuvant) induced paw swelling. Paw swelling was
induced in the left hind paw, the right hind paw was not
treated.
[0063] FIG. 26 Graphical representation of in vivo
anti-inflammatory properties of the JNK inhibitors with SEQ ID NO:
197 (10 .mu.g/kg, n=4) and SEQ ID NO: 172 (10 .mu.g/kg, n=3) after
CFA (complete Freund's adjuvant) induced paw swelling. Indicated is
the measured circumference of the left hind paw after
treatment.
[0064] FIG. 27 Graphical representation of in vivo
anti-inflammatory properties of the JNK inhibitors with SEQ ID NO:
197 (10 .mu.g/kg) and SEQ ID NO: 172 (10 .mu.g/kg) after CFA
(complete Freund's adjuvant) induced paw swelling. Indicated is the
measured in vivo cytokine release one hour after CFA induced paw
swelling.
[0065] FIG. 28 Clinical evaluation of administration of different
amounts of the JNK inhibitor according to SEQ ID NO: 172 in albino
rats after intravenous administration (endotoxins induced uveitis
model). Form left to right: Vehicle, 0.015 mg/kg (i.v.) of SEQ ID
NO: 172; 0.18 mg/kg (i.v.) of SEQ ID NO: 172; 1.8 mg/kg (i.v.) of
SEQ ID NO: 172, 2 mg/kg (i.v.) of SEQ ID NO: 197 and 20 .mu.g
dexamethasone (administered directly by subconjunctival injection
to the eye). Indicated is the clinical score (mean and the
SEM).
[0066] FIG. 29 Responsive effects of the JNK inhibitor of SEQ ID
NO: 172 after daily intravenous administration in 14 day rat
chronic established Type II collagen arthritis (RTTC/SOL-1). Shown
is the body weight change from day 0 to day 14. From left to right:
Normal contrail+Vehicle (NaCl), Disease Control+Vehicle (NaCl), 5
mg/kg (i.v.) of SEQ ID NO: 172; 1 mg/kg (i.v.) of SEQ ID NO: 172;
0.1 mg/kg (i.v.) of SEQ ID NO: 172, 0.01 mg/kg (i.v.) of SEQ ID NO:
172, 0.05 mg/kg (i.v.) of dexamethasone. Indicated is the clinical
score (mean and the SEM). n=4/normal group, n=8/treatment group;
*p.ltoreq.1.05 1-way ANOVA to disease control+Vehicle (NaCl)
[0067] FIG. 30 Responsive effects of the JNK inhibitor of SEQ ID
NO: 172 after daily intravenous administration in 14 day rat
chronic established Type II collagen arthritis (RTTC/SOL-1). Shown
is the ankle diameter (in) over time. n=4/normal group,
n=8/treatment group; *p.ltoreq.0.05 2-way RM ANOVA to disease
control+Vehicle (NaCl).
[0068] FIG. 31 Responsive effects of the JNK inhibitor of SEQ ID
NO: 172 after daily intravenous administration in 14 day rat
chronic established Type II collagen arthritis (RTTC/SOL-1).
Illustrated are the ankle histopathology scores regarding
inflammation, pannus, cartilage damage and bone resorption. n=8 in
the treatment group. *p.ltoreq.0.05 Mann-Whitney U test to disease
control+Vehicle (NaCl).
[0069] FIG. 32 Responsive effects of the JNK inhibitor of SEQ ID
NO: 172 after daily intravenous administration in 14 day rat
chronic established Type II collagen arthritis (RTTC/SOL-1).
Illustrated are the knee histopathology scores regarding
inflammation, pannus, cartilage damage and bone resorption. n=8 in
the treatment group. *p.ltoreq.0.05 Mann-Whitney U test to disease
control+Vehicle (NaCl).
[0070] FIG. 33 Clinical scoring by slit lamp 24 hours after EIU
induction and administration of JNK inhibitor according to SEQ ID
NO: 172 (1 mg/kg i.v.) at different times prior to EIU induction.
From left to right: Vehicle (0 hours); SEQ ID NO: 172 4 weeks prior
to EIU induction; SEQ ID NO: 172 2 weeks prior to EIU induction;
SEQ ID NO: 172 1 week prior to EIU induction; SEQ ID NO: 172 48
hours prior to EIU induction; SEQ ID NO: 172 24 hours prior to EIU
induction; SEQ ID NO: 172 0 hours prior to EIU induction;
Dexamethasone (2 mg/kg i.v.) 0 hours prior to EIU induction.
Mean.+-.SEM. *p<0.05 versus vehicle, **p<0.01 versus
vehicle.
[0071] FIG. 34 Number of PMN cells per section quantified 24 hours
after EIU induction and administration of JNK inhibitor according
to SEQ ID NO: 172 (1 mg/kg i.v.) at different times prior to EIU
induction. From left to right: Vehicle (0 hours); SEQ ID NO: 172 4
weeks prior to EIU induction; SEQ ID NO: 172 2 weeks prior to EIU
induction; SEQ ID NO: 172 1 week prior to EIU induction; SEQ ID NO:
172 48 hours prior to EIU induction; SEQ ID NO: 172 24 hours prior
to EIU induction; SEQ ID NO: 172 0 hours prior to EIU induction;
Dexamethasone (2 mg/kg i.v.) 0 hours prior to EIU induction.
Mean.+-.SEM. *p<0.05 versus vehicle, **p<0.01 versus
vehicle.
[0072] FIG. 35 shows the mean calculated TBUT AUC values for
animals with scopolamine induced dry eye syndrome. Shown are the
results for animals treated with vehicle, 3 different
concentrations of an all-D-retro-inverso JNK-inhibitor
(poly-)peptide with the sequence of SEQ ID NO: 197, 3 different
concentrations of a JNK-inhibitor (poly-)peptide with the sequence
of SEQ ID NO: 172, and the results for animals treated with
cyclosporine.
[0073] FIG. 36 shows the mean calculated PRTT AUCs for animals with
scopolamine induced Dry Eye (Day 7-21). Shown are the results for
animals treated with vehicle, 3 different concentrations of an
all-D-retro-inverso JNK-inhibitor (poly-)peptide with the sequence
of SEQ ID NO: 197, 3 different concentrations of a JNK-inhibitor
(poly-)peptide with the sequence of SEQ ID NO: 172, and the results
for animals treated with cyclosporine.
[0074] FIG. 37 shows the mean histological Cornea Lesion Scores for
animals with scopolamine induced dry eye syndrome. Shown are the
results for animals treated with vehicle, 3 different
concentrations of an all-D-retro-inverso JNK-inhibitor
(poly-)peptide with the sequence of SEQ ID NO: 197, 3 different
concentrations of a JNK-inhibitor (poly-)peptide with the sequence
of SEQ ID NO: 172, and the results for animals treated with
cyclosporine.
JNK INHIBITORS
[0075] In a first aspect the present invention relates to a JNK
inhibitor, which comprises an inhibitory (poly-)peptide sequence
according to the following general formula:
TABLE-US-00001 (SEQ ID NO: 1) X1-X2-X3-R-X4-X5-X6-L-X7-L-X8,
[0076] wherein X1 is an amino acid selected from amino acids R, P,
Q and r, [0077] wherein X2 is an amino acid selected from amino
acids R, P, G and r, [0078] wherein X3 is an amino acid selected
from amino acids K, R, k and r, [0079] wherein X4 is an amino acid
selected from amino acids P and K, [0080] wherein X5 is an amino
acid selected from amino acids T, a, s, q, k or is absent, [0081]
wherein X6 is an amino acid selected from amino acids T, D and A,
[0082] wherein X7 is an amino acid selected from amino acids N, n,
r and K; and [0083] wherein X8 is an amino acid selected from F, f
and w, [0084] with the proviso that at least one, at least two, at
least three, at least four, at least five or six of the amino acids
selected from the group consisting of X1, X2, X3, X5, X7 and X8
is/are a D-amino acid(s), preferably with the proviso that at least
one, at least two, at least three or four of the amino acids
selected from the group consisting of X3, X5, X7 and X8 is/are a
D-amino acid(s), for use in a method for treatment of the human or
animal body by therapy.
[0085] The inhibitory (poly-)peptide sequence of the JNK inhibitor
according to the present invention comprises L-amino acids and in
most embodiments D-amino acids. Unless specified otherwise, L-amino
acid residues are indicated herein in capital letters, while D
amino acid residues are indicated in small letters. Glycine may be
indicated in capital or small letters (since there is no D- or
L-glycine). The amino acid sequences disclosed herein are always
given from N- to C-terminus (left to right) unless specified
otherwise. The given amino acid sequence may be modified or
unmodified at the C- and/or N-terminus, e.g. acetylation at the
C-terminus and/or amidation or modification with cysteamide at the
N-terminus. For sake of clarity such possible but entirely optional
modifications at the C- and/or N-terminus of the amino acid
sequences disclosed herein are for sake of clarity not specifically
indicated.
[0086] The JNK inhibitors of the present invention are
(poly-)peptide inhibitors of the c-Jun N-terminal kinase (JNK).
Said inhibitors inhibit the kinase activity of c-Jun N-terminal
kinase (JNK), i.e. prevent or reduce the extent of phosphorylation
of JNK substrates such as c-Jun, ATF2 and/or Elk-1. A person
skilled in the art will understand that the term "inhibitor", as
used herein, does not comprise compounds which irreversibly destroy
the c-Jun N-terminal kinase (JNK) molecule and/or kinase activity.
Furthermore, the term "inhibiting JNK activity" as used herein,
refers to the inhibition of the kinase activity of c-Jun N-terminal
kinase (JNK).
[0087] Furthermore, as used herein, a JNK inhibitor comprises at
least one functional unit of a polymer of amino acids, i.e. a
(poly-)peptide sequence. Moreover, this at least one functional
polymer of amino acids provides for inhibition of JNK activity. The
amino acid monomers of said inhibitory (poly-)peptide sequence are
usually linked to each other via peptide bonds, but (chemical)
modifications of said peptide bond(s) or of side chain residues may
be tolerable, provided the inhibitory activity (inhibition of JNK
activity) is not totally lost, i.e. the resulting chemical entity
still qualifies as JNK inhibitor as functionally defined herein.
The term "(poly-)peptide" shall not be construed as limiting the
length of the (poly-)peptide unit. Preferably, the inhibitory
(poly-)peptide sequence of the JNK inhibitors of the present
invention is less than 500, 490, 480, 470, 460, 450, 440, 430, 420,
410, 400, 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290,
280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160,
150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55,
50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34,
33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17,
16, 15, 14, 13, or less than 12 amino acids long. Preferably, the
inhibitory (poly-)peptide sequence does not have less than 10 amino
acid residues, more preferably not less than 11 amino acid
residues.
[0088] Furthermore, a "JNK inhibitor" of the present invention
inhibits JNK activity, e.g. exhibits with regard to the inhibition
of human JNK mediated phosphorylation of a c-Jun substrate (SEQ ID
NO: 198) an IC 50 value of: [0089] a) less than 3000 nM, more
preferably less than 2000 nM, even more preferably less than 1000
nM, even more preferably less than 500 nM, even more preferably
less than 250 nM, even more preferably less than 200 nM, even more
preferably less than 150 nM, most preferably less than 100 nM with
regard to inhibition of human JNK1, [0090] b) less than 3000 nM,
more preferably less than 2000 nM, even more preferably less than
1000 nM, even more preferably less than 500 nM, even more
preferably less than 250 nM, even more preferably less than 200 nM,
even more preferably less than 150 nM, most preferably less than
100 nM with regard to inhibition of human JNK2, and/or [0091] c)
less than 3000 nM, more preferably less than 2000 nM, even more
preferably less than 1000 nM, even more preferably less than 500
nM, even more preferably less than 250 nM, even more preferably
less than 200 nM, even more preferably less than 150 nM, most
preferably less than 100 nM with regard to inhibition of human
JNK3.
[0092] For some applications it is preferred that the inhibitor
inhibits human JNK2 and/or human JNK3 according to the above
definition, but not JNK1 according to the above definition.
[0093] Whether JNK activity is inhibited or not, may easily be
assessed by a person skilled in the art. There are several methods
know in the art. One example is a radioactive kinase assay or a
non-radioactive kinase assay (e.g. Alpha screen test; see for
example Guenat et al. J Biomol Screen, 2006; 11: pages
1015-1026).
[0094] A JNK inhibitor according to the present invention may thus
for example comprise an inhibitory (poly-)peptide sequence
according to any of SEQ ID NOs: 2 to 27 (see table 1).
TABLE-US-00002 TABLE 1 Examples for inhibitory (poly-)peptide
sequences of JNK-inhibitors according to the present invention
Amino acid sequence SEQ ID NO: rPKRPTTLNLF 2 RPkRPTTLNLF 3
RPKRPaTLNLF 4 RPKRPTTLnLF 5 RPKRPTTLrLF 6 RPKRPTTLNLf 7 RPkRPaTLNLf
8 RPkRPTTLNLf 9 RPkRPTTLrLf 10 RRrRPTTLNLf 11 QRrRPTTLNLf 12
RPkRPTTLNLw 13 RPkRPTDLNLf 14 RRrRPTTLrLw 15 QRrRPTTLrLw 16
RRrRPTDLrLw 17 QRrRPTDLrLw 18 RRrRPaTLNLf 19 QRrRPaTLNLf 20
RrKRPaTLNLf 21 RPkRPsTLNLf 22 RPkRPqTLNLf 23 RPkRPkTLNLf 24
rGKRKALKLf 25 rGKRKALrLf 26 RRrRKALrLf 27
[0095] The JNK inhibitor according to the present invention may
also be a JNK inhibitor (variant) which comprises an inhibitory
(poly-)peptide sequence sharing at least 50%, more preferably at
least 55%, more preferably at least 60%, more preferably at least
65%, more preferably at least 70%, more preferably at least 75%,
more preferably at least 80%, more preferably at least 85%, most
preferably at least 90% sequence identity with a sequence selected
from SEQ ID NOs: 1-27, in particular with SEQ ID NO: 8,
with the proviso that with regard to the respective sequence
selected from SEQ ID NOs: 1-27, such inhibitory (poly-)peptide
sequence sharing sequence identity [0096] a) maintains the
L-arginine (R) residue on position 4, [0097] b) maintains the two
L-leucine (L) residues at position 8 and 10 (positions 7 and 9 with
regard to SEQ ID NOs: 25-27), [0098] c) exhibits one, two, three,
four, five or six D-amino acid(s) at the respective positions
corresponding to the amino acids selected from the group consisting
of X1, X2, X3, X5, X7 and X8 of SEQ ID NO: 1 and respective
positions in SEQ ID NOs: 2-27, more preferably exhibits one, two,
three or four D-amino acid(s) at the positions corresponding to the
amino acids selected from the group consisting of X3, X5, X7 and X8
of SEQ ID NO: 1 and respective positions in SEQ ID NOs: 2-27, and
[0099] d) still inhibits JNK activity (i.e. is a JNK inhibitor as
defined herein).
[0100] Certainly, variants disclosed herein (in particular JNK
inhibitor variants comprising an inhibitory (poly-)peptide sequence
sharing--within the above definition--a certain degree of sequence
identity with a sequence selected from SEQ ID NOs: 1-27), share
preferably less than 100% sequence identity with the respective
reference sequence.
[0101] In view of said definition and for sake of clarity the
residues which may not be changed in variants of JNK inhibitors
comprising SEQ ID NOs: 1-27 (see a) and b) in the above definition)
are underlined in table 1.
[0102] The non-identical amino acids are preferably the result of
conservative amino acid substitutions.
[0103] Conservative amino acid substitutions, as used herein, may
include amino acid residues within a group which have sufficiently
similar physicochemical properties, so that a substitution between
members of the group will preserve the biological activity of the
molecule (see e.g. Grantham, R. (1974), Science 185, 862-864).
Particularly, conservative amino acid substitutions are preferably
substitutions in which the amino acids originate from the same
class of amino acids (e.g. basic amino acids, acidic amino acids,
polar amino acids, amino acids with aliphatic side chains, amino
acids with positively or negatively charged side chains, amino
acids with aromatic groups in the side chains, amino acids the side
chains of which can enter into hydrogen bridges, e.g. side chains
which have a hydroxyl function, etc.). Conservative substitutions
are in the present case for example substituting a basic amino acid
residue (Lys, Arg, His) for another basic amino acid residue (Lys,
Arg, His), substituting an aliphatic amino acid residue (Gly, Ala,
Val, Leu, Ile) for another aliphatic amino acid residue,
substituting an aromatic amino acid residue (Phe, Tyr, Trp) for
another aromatic amino acid residue, substituting threonine by
serine or leucine by isoleucine. Further conservative amino acid
exchanges will be known to the person skilled in the art. The
isomer form should preferably be maintained, e.g. K is preferably
substituted for R or H, while k is preferably substituted for r and
h.
[0104] Further possible substitutions within the above definition
for JNK inhibitor variants are for example if: [0105] a) one, two
or more of X1, X2, X3, X4, X5, X6, X7 and/or X8 of SEQ ID NO: 1 or
the corresponding positions within the respective sequence selected
from SEQ ID NOs: 2-27 are substituted for A or a, [0106] b) X1 or
X8 of SEQ ID NO: 1 or the corresponding position within the
respective sequence selected from SEQ ID NOs: 2-27 is deleted;
[0107] c) X5 of SEQ ID NO: 1 or the corresponding position within
the respective sequence selected from SEQ ID NOs: 2-27 is E, Y, L,
V, F or K; [0108] d) X5 of SEQ ID NO: 1 or the corresponding
position within the respective sequence selected from SEQ ID NOs:
2-27 is E, L, V, F or K; or [0109] e) one, two or three of X1, X2,
X3 of SEQ ID NO: 1 or the corresponding positions within the
respective sequence selected from SEQ ID NOs: 2-27 are neutral
amino acids.
[0110] As used herein, the term "% sequence identity", has to be
understood as follows: Two sequences to be compared are aligned to
give a maximum correlation between the sequences. This may include
inserting "gaps" in either one or both sequences, to enhance the
degree of alignment. A % identity may then be determined over the
whole length of each of the sequences being compared (so-called
global alignment), that is particularly suitable for sequences of
the same or similar length, or over shorter, defined lengths
(so-called local alignment), that is more suitable for sequences of
unequal length. In the above context, an amino acid sequence having
a "sequence identity" of at least, for example, 95% to a query
amino acid sequence, is intended to mean that the sequence of the
subject amino acid sequence is identical to the query sequence
except that the subject amino acid sequence may include up to five
amino acid alterations per each 100 amino acids of the query amino
acid sequence. In other words, to obtain an amino acid sequence
having a sequence of at least 95% identity to a query amino acid
sequence, up to 5% (5 of 100) of the amino acid residues in the
subject sequence may be inserted or substituted with another amino
acid or deleted. For purposes of determining sequence identity, the
substitution of an L-amino acid for a D-amino acid (and vice versa)
is considered to yield a non-identical residue, even if it is
merely the D- (or L-isomer) of the very same amino acid.
[0111] Methods for comparing the identity and homology of two or
more sequences are well known in the art. The percentage to which
two sequences are identical can for example be determined by using
a mathematical algorithm. A preferred, but not limiting, example of
a mathematical algorithm which can be used is the algorithm of
Karlin et al. (1993), PNAS USA, 90:5873-5877. Such an algorithm is
integrated in the BLAST family of programs, e.g. BLAST or NBLAST
program (see also Altschul et al, 1990, J. Mol. Biol. 215, 403-410
or Altschul et al. (1997), Nucleic Acids Res, 25:3389-3402),
accessible through the home page of the NCBI at world wide web site
ncbi.nlm.nih.gov) and FASTA (Pearson (1990), Methods Enzymol. 183,
63-98; Pearson and Lipman (1988), Proc. Natl. Acad. Sci. U.S.A 85,
2444-2448.). Sequences which are identical to other sequences to a
certain extent can be identified by these programmes. Furthermore,
programs available in the Wisconsin Sequence Analysis Package,
version 9.1 (Devereux et al, 1984, Nucleic Acids Res., 387-395),
for example the programs BESTFIT and GAP, may be used to determine
the % identity between two polypeptide sequences. BESTFIT uses the
"local homology" algorithm of (Smith and Waterman (1981), J. Mol.
Biol. 147, 195-197.) and finds the best single region of similarity
between two sequences.
[0112] Certainly, the JNK inhibitor according to the present
invention may comprise--aside of the inhibitory (poly-)peptide
sequence mentioned above--additional sequences, domains, labels
(e.g. fluorescent or radioactive labels), epitopes etc. as long as
the ability to inhibit JNK activity as defined herein is not lost.
For example, the JNK inhibitor according to the present invention
may also comprise a transporter sequence. A "transporter sequence"
as used herein, is a (poly-)peptide sequence providing for
translocation of the molecule it is attached to across biological
membranes. Accordingly, a JNK inhibitor according to the present
invention comprising a transporter sequence is preferably capable
of translocating across biological membranes. Thus, such JNK
inhibitor of the present invention may more readily enter a cell, a
cellular subcompartment and/or into the nucleus of a cell.
[0113] Said transporter sequence may be joined for example (e.g.
directly) N-terminally or (e.g. directly) C-terminally to the
inhibitory (poly-)peptide sequence of the JNK inhibitor. The
transporter sequence and the inhibitory (poly-)peptide sequence may
also be spaced apart, e.g. may be separated by intermediate
sequences. It is also contemplated that the transporter sequence
may be positioned entirely elsewhere in the JNK inhibitor molecule
than the inhibitory (poly-)peptide sequence, in particular if the
JNK inhibitor is a more complex molecule (e.g. comprising several
domains, is a multimeric conjugate etc.). It is also contemplated
that the transporter sequence and the inhibitory (poly-)peptide
sequence may overlap as long as the JNK inhibitory activity is
maintained. Examples for such overlap are given further below.
[0114] Transporter sequences for use with the JNK inhibitor of the
present invention may be selected from, without being limited
thereto, transporter sequences derived from HIV TAT (HIV), e.g.
native proteins such as e.g. the TAT protein (e.g. as described in
U.S. Pat. Nos. 5,804,604 and 5,674,980, each of these references
being incorporated herein by reference), HSV VP22 (Herpes simplex)
(described in e.g. WO 97/05265; Elliott and O'Hare, Cell 88 :
223-233 (1997)), non-viral proteins (Jackson et al, Proc. Natl.
Acad. Sci. USA 89 : 10691-10695 (1992)), transporter sequences
derived from Antennapedia, particularly from Drosophila
antennapedia (e.g. the antennapedia carrier sequence thereof), FGF,
lactoferrin, etc. or derived from basic peptides, e.g. peptides
having a length of 5 to 15 amino acids, preferably 10 to 12 amino
acids and comprising at least 80%, more preferably 85% or even 90%
basic amino acids, such as e.g. arginine, lysine and/or histidine,
or may be selected from e.g. arginine rich peptide sequences, such
as RRRRRRRRR (R.sub.9; SEQ ID NO: 152), RRRRRRRR (R.sub.8; SEQ ID
NO: 153), RRRRRRR (R.sub.7; SEQ ID NO: 154), RRRRRR (R.sub.6, SEQ
ID NO: 155), RRRRR (R.sub.6, SEQ ID NO: 156) etc., from VP22, from
PTD-4 proteins or peptides, from RGD-K.sub.16, from PEPT1/2 or
PEPT1/2 proteins or peptides, from SynB3 or SynB3 proteins or
peptides, from PC inhibitors, from P21 derived proteins or
peptides, or from JNKI proteins or peptides.
[0115] Examples of transporter sequences for use in the JNK
inhibitor of the present invention are in particular, without being
limited thereto, basic transporter sequences derived from the HIV-1
TAT protein. Preferably, the basic transporter sequence of the
HIV-1 TAT protein may include sequences from the human
immunodeficiency virus HIV-1 TAT protein, e.g. as described in,
e.g., U.S. Pat. Nos. 5,804,604 and 5,674,980, each incorporated
herein by reference. In this context, the full-length HIV-1 TAT
protein has 86 amino acid residues encoded by two exons of the HIV
TAT gene. TAT amino acids 1-72 are encoded by exon 1, whereas amino
acids 73-86 are encoded by exon 2. The full-length TAT protein is
characterized by a basic region which contains two lysines and six
arginines (amino acids 49-57) and a cysteine-rich region which
contains seven cysteine residues (amino acids 22-37). The basic
region (i.e., amino acids 49-57) was thought to be important for
nuclear localization. Ruben, S. et al., J. Virol. 63: 1-8 (1989);
Hauber, J. et al., J. Virol. 63 1181-1187 (1989). The cysteine-rich
region mediates the formation of metal-linked dimers in vitro
(Frankel, A. D. et al, Science 240: 70-73 (1988); Frankel, A. D. et
al, Proc. Natl. Acad. Sci. USA 85: 6297-6300 (1988)) and is
essential for its activity as a transactivator (Garcia, J. A. et
al., EMBO J. 7: 3143 (1988); Sadaie, M. R. et al., J. Virol. 63:1
(1989)). As in other regulatory proteins, the N-terminal region may
be involved in protection against intracellular proteases
(Bachmair, A. et al., Cell 56: 1019-1032 (1989)). Preferred TAT
transporter sequences for use in the JNK inhibitor of the present
invention are preferably characterized by the presence of the TAT
basic region amino acid sequence (amino acids 49-57 of
naturally-occurring TAT protein); the absence of the TAT
cysteine-rich region amino acid sequence (amino acids 22-36 of
naturally-occurring TAT protein) and the absence of the TAT exon
2-encoded carboxy-terminal domain (amino acids 73-86 of
naturally-occurring TAT protein). More preferably, the transporter
sequence in the JNK inhibitor of the present invention may be
selected from an amino acid sequence containing TAT residues 48-57
or 49 to 57 or variants thereof.
[0116] Preferably, the transporter sequence in a given JNK
inhibitor of the present invention also exhibits D-amino acids, for
example in order to improve stability towards proteases.
Particularly preferred are transporter sequences which exhibit a
specific order of alternating D- and L-amino acids. Such order of
alternating D- and L-amino acids (the motif) may follow--without
being limited thereto--the pattern of any one of SEQ ID NOs:
28-30:
TABLE-US-00003 (SEQ ID NO: 28)
d.sub.lLLL.sub.xd.sub.mLLL.sub.yd.sub.n; (SEQ ID NO: 29)
dLLLd(LLLd).sub.a; and/or (SEQ ID NO: 30) dLLLdLLLd;
wherein: [0117] d is a D-amino acid; [0118] L is a L-amino acid;
[0119] a is 0-3, preferably 0-2, more preferably 0, 1, 2 or 3, even
more preferably 0, 1, or 2 and most preferably 1; [0120] l, m and n
are independently from each other 1 or 2, preferably 1; [0121] x
and y are independently from each other 0, 1 or 2, preferably
1.
[0122] Said order of D- and L-amino acids (motif) becomes relevant
when the transporter sequence is synthesized, i.e. while the amino
acid sequence (i.e. the type of side chain residues) remains
unaltered, the respective isomers alternate. For example, a known
transporter sequence derived from HIV TAT is RKKRRQRRR (SEQ ID NO:
43). Applying the D-/L amino acid order of SEQ ID NO: 30 thereto
would yield rKKRrQRRr (SEQ ID NO: 46).
[0123] In a particular embodiment the transporter sequence of the
JNK inhibitor of the present invention may comprise at least one
sequence according to rXXXrXXXr (SEQ ID NO: 31), wherein: [0124] r
represents an D-enantiomeric arginine; [0125] X is any L-amino acid
(including glycine); and wherein each X may be selected
individually and independently of any other X within SEQ ID NO: 31.
Preferably at least 4 out of said 6.times.L-amino acids within SEQ
ID NO: 31 are K or R. In another embodiment the JNK inhibitor
according to the present invention comprises the transporter
sequence rX.sub.1X.sub.2X.sub.3rX.sub.4X.sub.5X.sub.6r (SEQ ID NO:
32), wherein X.sub.1 is K, X.sub.2 is K, X.sub.3 is R and X.sub.4,
X.sub.5, and X.sub.6 are any L-amino acid (including glycine)
selected independently from each other. Similarly, the transporter
sequence of the JNK inhibitor according to the present invention
may comprise the sequence
rX.sub.1X.sub.2X.sub.3rX.sub.4X.sub.5X.sub.6r (SEQ ID NO: 33),
wherein X.sub.4 is Q, X.sub.5 is R, X.sub.6 is R and X.sub.1,
X.sub.2, and X.sub.3 are any L-amino acid (including glycine)
selected independently from each other. The inventive JNK inhibitor
may also comprise the sequence
rX.sub.1X.sub.2X.sub.3rX.sub.4X.sub.5X.sub.6r (SEQ ID NO: 34),
wherein one, two, three, four, five or six X amino acid residues
are chosen from the group consisting of: X.sub.1 is K, X.sub.2 is
K, X.sub.3 is R, X.sub.4 is Q, X.sub.5 is R, X.sub.6 is R, while
the remaining X amino acid residues not selected from above group
may be any L-amino acid (including glycine) and are selected
independently from each other. X.sub.1 is then preferably Y and/or
X.sub.4 is preferably K or R.
[0126] Examples of transporter sequences for use in the inventive
JNK inhibitor molecule may be selected, without being limited
thereto, from sequences as given in table 2 below, (SEQ ID NOs:
31-170) or from any fragment or variant or chemically modified
derivative thereof (preferably it retains the function of
translocating across a biological membrane).
TABLE-US-00004 TABLE 2 Examples for transporter (poly-)peptide
sequences for use in the JNK-inhibitors according to the present
invention SEQ ID SEQUENCE/PEPTIDE NAME NO AA SEQUENCE r3 (generic)
31 9 rXXXrXXXr r3 (generic; right half) 32 9
rKKRrX.sub.4X.sub.5X.sub.6r r3 (generic; left half) 33 9
rX.sub.1X.sub.2X.sub.3rQRRr r3 (generic; individual) 34 9
rX.sub.1X.sub.2X.sub.3rX.sub.4X.sub.5X.sub.6r TAT (1-86) 35 86
MEPVDPRLEP WKHPGSQPKT ACTNCYCKKC CFHCQVCFIT KALGISYGRK KRRQRRRPPQ
GSQTHQVSLS KQPTSQSRGD PTGPKE TAT (37-72) 36 36 CFITKALGIS
YGRKKRRQRR RPPQGSQTHQ VSLSKQ TAT (37-58) 37 22 CFITKALGIS
YGRKKRRQRR RP TAT (38-58)GGC 38 24 FITKALGISY GRKKRRQRRR PGGC TAT
CGG(47-58) 39 15 CGGYGRKKRR QRRRP TAT (47-58)GGC 40 15 YGRKKRRQRR
RPGGC TAT (1-72) Mut 41 56 MEPVDPRLEP WKHPGSQPKT AFITKALGIS
YGRKKRRQRR Cys/Ala 72 RPPQGSQTHQ VSLSKQ L-TAT (s1a) 42 10
GRKKRRQRRR (NH.sub.2-GRKKRRQRRR-COOH) L-TAT (s1b) 43 9 RKKRRQRRR
(NH.sub.2-GRKKRRQRRR-COOH) L-TAT (s1c) 44 11 YDRKKRRQRRR D-TAT 45 9
rrrqrrkkr r.sub.3-L-TAT 46 9 rKKRrQRRr r.sub.3-L-TATi 47 9
rRRQrRKKr .beta.A-r.sub.3-L-TAT 48 9 .beta.A-rKKRrQRRr (.beta.A:
beta alanine) .beta.A-r.sub.3-L-TATi 49 9 .beta.A-rRRQrRKKr
(.beta.A: beta alanine) FITC-.beta.A-r.sub.3-L-TAT 50 9
FITC-.beta.A-rKKRrQRRr (.beta.A: beta alanine)
FITC-.beta.A-r.sub.3-L-TATi 51 9 FITC-.beta.A-rRRQrRKKr (.beta.A:
beta alanine) TAT(s2-1) 52 9 rAKRrQRRr TAT(s2-2) 53 9 rKARrQRRr
TAT(s2-3) 54 9 rKKArQRRr TAT(s2-4) 55 9 rKKRrARRr TAT(s2-5) 56 9
rKKRrQARr TAT(s2-6) 57 9 rKKRrQRAr TAT(s2-7) 58 9 rDKRrQRRr
TAT(s2-8) 59 9 rKDRrQRRr TAT(s2-9) 60 9 rKKDrQRRr TAT(s2-10) 61 9
rKKRrDRRr TAT(s2-11) 62 9 rKKRrQDRr TAT(s2-12) 63 9 rKKRrQRDr
TAT(s2-13) 64 9 rEKRrQRRr TAT(s2-14) 65 9 rKERrQRRr TAT(s2-15) 66 9
rKKErQRRr TAT(s2-16) 67 9 rKKRrERRr TAT(s2-17) 68 9 rKKRrQERr
TAT(s2-18) 69 9 rKKRrQREr TAT(s2-19) 70 9 rFKRrQRRr TAT(s2-20) 71 9
rKFRrQRRr TAT(s2-21) 72 9 rKKFrQRRr TAT(s2-22) 73 9 rKKRrFRRr
TAT(s2-23) 74 9 rKKRrQFRr TAT(s2-24) 75 9 rKKRrQRFr TAT(s2-25) 76 9
rRKRrQRRr TAT(s2-26) 77 9 rKRRrQRRr TAT(s2-27) 78 9 rKKKrQRRr
TAT(s2-28) 79 9 rKKRrRRRr TAT(s2-29) 80 9 rKKRrQKRr TAT(s2-30) 81 9
rKKRrQRKr TAT(s2-31) 82 9 rHKRrQRRr TAT(s2-32) 83 9 rKHRrQRRr
TAT(s2-33) 84 9 rKKHrQRRr TAT(s2-34) 85 9 rKKRrHRRr TAT(s2-35) 86 9
rKKRrQHRr TAT(s2-36) 87 9 rKKRrQRHr TAT(s2-37) 88 9 rIKRrQRRr
TAT(s2-38) 89 9 rKIRrQRRr TAT(s2-39) 90 9 rKKIrQRRr TAT(s2-40) 91 9
rKKRrIRRr TAT(s2-41) 92 9 rKKRrQIRr TAT(s2-42) 93 9 rKKRrQRIr
TAT(s2-43) 94 9 rLKRrQRRr TAT(s2-44) 95 9 rKLRrQRRr TAT(s2-45) 96 9
rKKLrQRRr TAT(s2-46) 97 9 rKKRrLRRr TAT(s2-47) 98 9 rKKRrQLRr
TAT(s2-48) 99 9 rKKRrQRLr TAT(s2-49) 100 9 rMKRrQRRr TAT(s2-50) 101
9 rKMRrQRRr TAT(s2-51) 102 9 rKKMrQRRr TAT(s2-52) 103 9 rKKRrMRRr
TAT(s2-53) 104 9 rKKRrQMRr TAT(s2-54) 105 9 rKKRrQRMr TAT(s2-55)
106 9 rNKRrQRRr TAT(s2-56) 107 9 rKNRrQRRr TAT(s2-57) 108 9
rKKNrQRRr TAT(s2-58) 109 9 rKKRrNRRr TAT(s2-59) 110 9 rKKRrQNRr
TAT(s2-60) 111 9 rKKRrQRNr TAT(s2-61) 112 9 rQKRrQRRr TAT(s2-62)
113 9 rKQRrQRRr TAT(s2-63) 114 9 rKKQrQRRr TAT(s2-64) 115 9
rKKRrKRRr TAT(s2-65) 116 9 rKKRrQQRr TAT(s2-66) 117 9 rKKRrQRQr
TAT(s2-67) 118 9 rSKRrQRRr TAT(s2-68) 119 9 rKSRrQRRr TAT(s2-69)
120 9 rKKSrQRRr TAT(s2-70) 121 9 rKKRrSRRr TAT(s2-71) 122 9
rKKRrQSRr TAT(s2-72) 123 9 rKKRrQRSr TAT(s2-73) 124 9 rTKRrQRRr
TAT(s2-74) 125 9 rKTRrQRRr TAT(s2-75) 126 9 rKKTrQRRr TAT(s2-76)
127 9 rKKRrTRRr TAT(s2-77) 128 9 rKKRrQTRr TAT(s2-78) 129 9
rKKRrQRTr TAT(s2-79) 130 9 rVKRrQRRr TAT(s2-80) 131 9 rKVRrQRRr
TAT(s2-81) 132 9 rKKVrQRRr TAT(s2-82) 133 9 rKKRrVRRr TAT(s2-83)
134 9 rKKRrQVRr TAT(s2-84) 135 9 rKKRrQRVr TAT(s2-85) 136 9
rWKRrQRRr TAT(s2-86) 137 9 rKWRrQRRr TAT(s2-87) 138 9 rKKWrQRRr
TAT(s2-88) 139 9 rKKRrWRRr TAT(s2-89) 140 9 rKKRrQWRr TAT(s2-90)
141 9 rKKRrQRWr TAT(s2-91) 142 9 rYKRrQRRr TAT(s2-92) 143 9
rKYRrQRRr TAT(s2-93) 144 9 rKKYrQRRr TAT(s2-94) 145 9 rKKRrYRRr
TAT(s2-95) 146 9 rKKRrQYRr TAT(s2-96) 147 9 rKKRrQRYr
TAT(s2-97) 148 8 rKKRrQRr TAT(s2-98) 149 9 rKKRrQRrK TAT(s2-99) 150
9 rKKRrQRrR r.sub.3R.sub.6 151 9 rRRRrRRRr L-R.sub.9 152 9
RRRRRRRRR L-R.sub.8 153 8 RRRRRRRR L-R.sub.7 154 7 RRRRRRR
L-R.sub.6 155 6 RRRRRR L-R.sub.5 156 5 RRRRR r.sub.9 157 9
rrrrrrrrr r.sub.5R.sub.4 (D/L) 158 9 rRrRrRrRr r.sub.5R.sub.4
(DD/LL) 159 9 rrRRrrRRr PTD-4 160 11 YARAAARQARA PTD-4 (variant 1)
161 11 WARAAARQARA PTD-4 (variant 2) 162 11 WARAQRAAARA L-P1
Penetratin 163 16 RQVKVWFQNRRMKWKK D-P1 Penetratin 164 16
KKWKMRRNQFWVKVQR JNKI, bestfit 165 17 WKRAAARKARAMSLNLF JNKI,
bestfit (variant 1) 166 17 WKRAAARAARAMSLNLF MDCK transcytose 167 9
RYRGDLGRR sequence YKGL 168 4 YKGL P1 169 4 RRTK P66 170 4 RRPK
[0127] As mentioned above, transporter sequences may also be
selected from fragments or variants of the above sequences of table
2 (with the proviso that such fragment or variant retain preferably
the function to provide for translocation across biological
membranes). In this specific context, variants and/or fragments of
those transporter sequences preferably comprise a peptide sequence
sharing at least 10%, at least 20%, at least 30%, at least 40%, at
least 50%, at least 60%, at least 70%, at least 80% or at least
85%, preferably at least 90%, more preferably at least 95% and most
preferably at least 99% sequence identity over the whole length of
the sequence of such a transporter sequence as defined in Table 2.
In this specific context, a "fragment" of a transporter sequence as
defined in Table 2, is preferably to be understood as a truncated
sequence thereof, i.e. an amino acid sequence, which is
N-terminally, C-terminally and/or intrasequentially truncated
compared to the amino acid sequence of the original sequence.
[0128] Furthermore, a "variant" of a transporter sequence or its
fragment as defined above, is preferably to be understood as a
sequence wherein the amino acid sequence of the variant differs
from the original transporter sequence or a fragment thereof as
defined herein in one or more mutation(s), such as one or more
substituted, (or, if necessary, inserted and/or deleted) amino
acid(s). Preferably, variants of such a transporter sequence as
defined above have the same biological function or specific
activity compared to the respective original sequence, i.e. provide
for transport, e.g. into cells or the nucleus. In this context, a
variant of such a transporter sequence as defined above may for
example comprise about 1 to 50, 1 to 20, more preferably 1 to 10
and most preferably 1 to 5, 4, 3, 2 or 1 amino acid alterations.
Variants of such a transporter sequence as defined above may
preferably comprise conservative amino acid substitutions. The
concept of conservative amino acid substitutions is known in the
art and has already been set out above for the JNK inhibitory
(poly-)peptide sequence and applies here accordingly.
[0129] The length of a transporter sequence incorporated in the JNK
inhibitor of the present invention may vary. It is contemplated
that in some embodiments the transporter sequence of the JNK
inhibitor according to the present invention is less than 150, less
than 140, less than 130, less than 120, less than 110, less than
100, less than 90, less than 80, less than 70, less than 60, less
than 50, less than 40, less than 30, less than 20, and/or less than
10 amino acids in length.
[0130] Whether a specific transporter sequence is still functional
in the context of the JNK inhibitor according to the present
invention may easily be determined by a person skilled in the art.
For instance, the JNK inhibitor comprising a transporter domain may
be fused to a label, e.g. a fluorescent protein such as GFP, a
radioactive label, an enzyme, a fluorophore, an epitope etc. which
can be readily detected in a cell. Then, the JNK inhibitor
comprising the transporter sequence and the label is transfected
into a cell or added to a culture supernatant and permeation of
cell membranes can be monitored by using biophysical and
biochemical standard methods (for example flow cytometry,
(immuno)fluorescence microscopy etc.).
[0131] Specific examples of JNK inhibitors according to the present
invention comprising a transporter sequence are given in table
3:
TABLE-US-00005 TABLE 3 Examples for JNK inhibitors comprising an
inhibitory (poly-)peptide sequence and a transporter sequence Amino
acid sequence AA SEQ ID NO: rKKRrQRRrRPkRPTTLNLf 20 171
rKKRrQRRrRPkRPaTLNLf 20 172 rKKRrQRRrRPkRPTTLrLf 20 173
rKKRrQRRrRPTTLNLf 17 174 rKKRrQRrRPTTLNLf 16 175
rKKRrQRRrRPkRPTTLNLw 20 176 rKKRrQRRrRPkRPTDLNLf 20 177
rKKRrQRRrRPTTLrLw 17 178 rKKRrQRrRPTTLrLw 16 179 rKKRrQRRrRPTDLrLw
17 180 rKKRrQRrRPTDLrLw 16 181 rKKRrQRRrRPaTLNLf 17 182
rKKRrQRrRPaTLNLf 16 183 rKKRrQRrKRPaTLNLf 17 184
rKKRrQRRrRPkRPsTLNLf 20 185 rKKRrQRRrRPkRPTTLNLf 20 186
rKKRrQRRrRPkRPkTLNLf 20 187 rKKRrQRRrGKRKALKLf 18 188
rKKRrQRRrGKRKALrLf 18 189 rKKRrQRRrRKALrLf 16 190
[0132] As mentioned above, in a particular embodiment of the
present invention the transporter sequence and the inhibitory
(poly-)peptide sequence may overlap. In other words, the N-terminus
of the transporter sequence may overlap with the C-terminus of the
inhibitory (poly-)peptide sequence or the C-terminus of the
transporter sequence may overlap with the N-terminus of the
inhibitory (poly-)peptide sequence. The latter embodiment is
particularly preferred. Preferably, the transporter sequence
overlaps by one, two or three amino acid residues with the
inhibitory (poly-) peptide sequence. In such scenario a given
transporter sequence may overlap with SEQ ID NO:1 or the respective
variants thereof at position 1 (X1), position 1 and 2 (X1, X2),
positions 1, 2 and 3 (X1, X2, X3).
[0133] SEQ ID NOs: 174, 175, 178, 179, 180, 181, 182, 183, 184,
188, 189 and 190 are good examples for JNK inhibitors according to
the present invention, wherein transporter sequence and the
inhibitory (poly-)peptide sequence overlap, e.g. rKKRrQRRrRPTTLNLf
(SEQ ID NO: 174) is an overlap of SEQ ID NO: 46 (underlined) and
SEQ ID NO: 11 (italics).
[0134] Certainly the JNK inhibitor according to the present
invention may also be selected from JNK inhibitors, which are a
variant of any one of the JNK inhibitors according to SEQ ID NOs:
171-190. Preferably, such variant shares at least 50%, more
preferably at least 55%, more preferably at least 60%, more
preferably at least 65%, more preferably at least 70%, more
preferably at least 75%, more preferably at least 80%, more
preferably at least 85%, more preferably at least 90%, most
preferably at least 95% sequence identity with the sequence of SEQ
ID NOs: 171-190, in particular with SEQ ID NO: 172,
with the proviso that with respect to the inhibitory (poly-)peptide
sequence within said sequences of SEQ ID NOs: 171-190 (see for
reference inhibitory (poly-)peptide sequence of SEQ ID NO: 1 and
specific examples of SEQ ID NOs: 2-27)) such sequence sharing
sequence identity [0135] a) maintains the L-arginine (R) residue on
position 4 within the inhibitory (poly-)peptide sequence, [0136] b)
maintains the two L-leucine (L) residues at position 8 and 10
(positions 7 and 9 with regard to SEQ ID NOs: 25-27) within the
inhibitory (poly-)peptide sequence, [0137] c) exhibits at least
one, at least two, at least three, at least four, at least five or
six D-amino acid(s) at the respective positions corresponding to
the amino acids selected from the group consisting of X1, X2, X3,
X5, X7 and or X8 of SEQ ID NO: 1 and respective positions in SEQ ID
NOs: 2-27, more preferably exhibits at least one, at least two, at
least three or four D-amino acid(s) at the positions corresponding
to the amino acids selected from the group consisting of X3, X5, X7
and X8 of SEQ ID NO: 1 and respective positions in SEQ ID NOs:
2-27, and [0138] d) still inhibits JNK activity (i.e. is a JNK
inhibitor as defined herein).
[0139] In view of said definition and for sake of clarity the
residues which may not be changed in variants of JNK inhibitors
comprising SEQ ID NOs: 171-190 (see a) and b) in the above
definition) are underlined in table 3.
[0140] The non-identical amino acids in the variants of JNK
inhibitors comprising SEQ ID NOs: 171-190 are preferably the result
of conservative amino acid substitutions (see above). Certainly,
the further possible substitutions mentioned above are also
contemplated for variants of JNK inhibitors comprising SEQ ID NOs:
171-190. Likewise, the present invention certainly also
contemplates variants of any one of the JNK inhibitors according to
SEQ ID NOs: 171-190, which deviate from the original sequence not
or not exclusively in the inhibitory (poly-)peptide sequence, but
exhibits variant residues in the transporter sequence. For variants
and fragments of transporter sequences see in particular respective
disclosure above.
[0141] As mentioned previously, the transporter sequence and the
JNK inhibitory (poly)-peptide sequence of the JNK inhibitors
according to the present invention need not necessarily be directly
joined to each other. They may also be spaced apart, e.g. by
intermediate (poly-)peptide sequences. Preferred intermediate
sequences separating the inhibitory (poly-)peptide sequences and
other (functional) sequences such as transporter sequences consist
of short peptide sequences less than 10 amino acids in length like
a hexamer, a pentamer, a tetramer, a tripeptide or even only a
dipeptide or a single amino acid residue. Particularly preferred
intermediate sequence are one, two or more copies of di-proline,
di-glycine, di-arginine and/or di-lysine, all either in L-amino
acid form only, or in D-amino acid form only, or with mixed D- and
L-amino acids. Certainly, other known peptide spacer sequences may
be employed as well.
[0142] A particularly preferred JNK inhibitor according to the
present invention comprises SEQ ID NO: 8 (or a sequence sharing
sequence identity with SEQ ID NO: 8 with the scope and limitations
defined further above) and a transporter sequence. The transporter
sequence is preferably selected from any one of SEQ ID Nos: 31-170
or variants thereof as defined herein, even more preferably from
any one of SEQ ID NOs: 31-34 and 46-151. A particularly preferred
embodiment of a JNK inhibitor according to the present invention is
a JNK inhibitor comprising SEQ ID NO: 8 and SEQ ID NO: 46 (or
sequences sharing respective sequence identity thereto within the
scope and limitations defined further above). A preferred example
is a JNK inhibitor comprising the sequence of SEQ ID NO: 172 or
respective variants thereof varying in the transporter sequence
and/or the inhibitory (poly-)peptide sequence as defined
herein.
[0143] In a further aspect the present invention relates to a JNK
inhibitor comprising [0144] a) an inhibitory (poly-)peptide
comprising a sequence from the group of sequences consisting of
RPTTLNLF (SEQ ID NO: 191), KRPTTLNLF (SEQ ID NO: 192), RRPTTLNLF
and/or RPKRPTTLNLF (SEQ ID NO: 193), and [0145] b) a transporter
sequence, preferably a transporter sequence selected from the
transporter sequences disclosed in table 2 or variants/fragments
thereof, even more preferably selected from SEQ ID NOs: 31-34 and
46-151 or respective variants or fragments thereof.
[0146] The transporter sequence and the inhibitory (poly-)peptide
sequence may overlap. Preferred transporter sequences for said
embodiment of the invention are particularly the transporter
sequence of SEQ ID NO: 46, preferably joined (e.g. directly) to the
N-Terminus of the inhibitory (poly-)peptide sequence.
[0147] A JNK inhibitor of the present invention may also be a JNK
inhibitor comprising or consisting of the sequence
GRKKRRQRRRPPKRPTTLNLFPQVPRSQD (SEQ ID NO: 194), or the sequence
GRKKRRQRRRPTTLNLFPQVPRSQD (SEQ ID NO: 195).
[0148] In a further aspect the present invention relates to a
(poly-)peptide comprising a transporter sequence selected from the
group of sequences consisting of rKKRrQRr (SEQ ID NO: 148),
rKKRrQRrK (SEQ ID NO: 149), and/or rKKRrQRrR (SEQ ID NO: 150).
[0149] As used herein, comprising a certain sequence or a certain
SEQ ID NO: usually implies that (at least) one copy of said
sequence is present, e.g. in the JNK inhibitor molecule. For
example, one inhibitory (poly-)peptide sequence will usually
suffice to achieve sufficient inhibition of JNK activity. However,
the inventor certainly contemplate that the use of two or more
copies of the respective sequence (e.g. two or more copies of an
inhibitory (poly-)peptide sequence of different or same type and/or
two or more copies of a transporter sequence of different or the
same type) may also employed as long as the overall ability of the
resulting molecule to inhibit JNK activity is not abolished (i.e.
the respective molecule is still a JNK inhibitor as defined
herein).
[0150] The inventive JNK inhibitors may be obtained or produced by
methods well-known in the art, e.g. by chemical synthesis via
solid-phase peptide synthesis using Fmoc
(9-fluorenylmethyloxycarbonyl) strategy, i.e. by successive rounds
of Fmoc deprotection and Fmoc-amino acid coupling cycles. A
commercial service offering such peptide synthesis is provided by
many companies, for example the company PolyPeptide
(Stra.beta.bourg, France).
[0151] The JNK inhibitors for use according to the present
invention may optionally be further modified, in particular at the
amino acid residues of the inhibitory (poly-peptide) sequence.
Possible modifications may for example be selected from the group
consisting of: [0152] (i) radioactive labels, i.e. radioactive
phosphorylation or a radioactive label with sulphur, hydrogen,
carbon, nitrogen, etc.; [0153] (ii) colored dyes (e.g. digoxygenin,
etc.); [0154] (iii) fluorescent groups (e.g. fluorescein, etc.);
[0155] (iv) chemoluminescent groups; [0156] (v) groups for
immobilization on a solid phase (e.g. His-tag, biotin, strep-tag,
flag-tag, antibodies, epitopes, etc.); [0157] (vi) pegylation,
[0158] (vii) glycosylation, [0159] (viii) hesylation, [0160] (ix)
protease cleavage sites (e.g. for controlled release of the JNK
inhibitor) [0161] (x) peptide backbone modifications (e.g.
(.PSI.CH.sub.2--NH) bonds) [0162] (xi) protection of amino acid
side chain residues, [0163] (xii) protection of N- and/or
C-terminus (e.g. N-terminal amidation or C-terminal acetylation)
[0164] (xiii) a combination of elements of two or more of the
elements mentioned under (i) to (xii).
[0165] Particularly preferred are modifications selected from (i)
to (xi) and combinations of elements of two or more of the elements
mentioned under (i) to (xi). In this context the present invention
relates in a further aspect to a JNK inhibitor as disclosed herein
modified with modifications selected from (i) to (xi) or modified
with a combination of two or more of the elements mentioned under
(i) to (xi), and a pharmaceutical composition (see below)
comprising such modified JNK inhibitor.
Pharmaceutical Compositions
[0166] The JNK inhibitors as defined according to the invention can
be formulated in a pharmaceutical composition, which may be applied
in the prevention or treatment of any of the diseases as defined
herein. Typically, such a pharmaceutical composition used according
to the present invention includes as an active component a JNK
inhibitor as defined herein, in particular a JNK inhibitor
comprising or consisting of an inhibitory (poly-)peptide sequence
according to SEQ ID NO: 1, as defined herein. Preferably, the
active compound is a JNK inhibitor comprising or consisting of an
inhibitory (poly-)peptide sequence according to any one of SEQ ID
NOs: 2-27; or, if a transporter sequence is attached, according to
any one of SEQ ID NOs: 171-190.
[0167] The inventors of the present invention additionally found,
that the JNK-inhibitors as defined herein, in particular if fused
to a transporter sequence; exhibit a particular well uptake rate
into cells involved in the diseases of the present invention.
Therefore, the amount of a JNK-inhibitor inhibitor in the
pharmaceutical composition to be administered to a subject,
may--without being limited thereto--have a very low dose. Thus, the
dose may be much lower than for peptide drugs known in the art,
such as DTS-108 (Florence Meyer-Losic et al., Clin Cancer Res.,
2008, 2145-53). This has several positive aspects, for example a
reduction of potential side reactions and a reduction in costs.
[0168] Preferably, the dose (per kg bodyweight) is in the range of
up to about 10 mmol/kg, preferably up to about 1 mmol/kg, more
preferably up to about 100 pmol/kg, even more preferably up to
about 10 pmol/kg, even more preferably up to about 1 pmol/kg, even
more preferably up to about 100 nmol/kg, most preferably up to
about 50 nmol/kg.
[0169] Thus, the dose range may preferably be from about 1 pmol/kg
to about 1 mmol/kg, from about 10 pmol/kg to about 0.1 mmol/kg,
from about 10 pmol/kg to about 0.01 mmol/kg, from about 50 pmol/kg
to about 1 pmol/kg, from about 100 pmol/kg to about 500 nmol/kg,
from about 200 pmol/kg to about 300 nmol/kg, from about 300 pmol/kg
to about 100 nmol/kg, from about 500 pmol/kg to about 50 nmol/kg,
from about 750 pmol/kg to about 30 nmol/kg, from about 250 pmol/kg
to about 5 nmol/kg, from about 1 nmol/kg to about 10 nmol/kg, or a
combination of any two of said values.
[0170] In this context, prescription of treatment, e.g. decisions
on dosage etc. when using the above pharmaceutical composition is
typically within the responsibility of general practitioners and
other medical doctors, and typically takes account of the disorder
to be treated, the condition of the individual patient, the site of
delivery, the method of administration and other factors known to
practitioners. Examples of the techniques and protocols mentioned
above can be found in REMINGTON'S PHARMACEUTICAL SCIENCES, 16th
edition, Osol, A. (ed), 1980. Accordingly, a "safe and effective
amount" for components of the pharmaceutical compositions as used
according to the present invention means an amount of each or all
of these components, that is sufficient to significantly induce a
positive modification of diseases or disorders strongly related to
JNK signalling as defined herein. At the same time, however, a
"safe and effective amount" is small enough to avoid serious
side-effects, that is to say to permit a sensible relationship
between advantage and risk. The determination of these limits
typically lies within the scope of sensible medical judgment. A
"safe and effective amount" of such a component will vary in
connection with the particular condition to be treated and also
with the age and physical condition of the patient to be treated,
the severity of the condition, the duration of the treatment, the
nature of the accompanying therapy, of the particular
pharmaceutically acceptable carrier used, and similar factors,
within the knowledge and experience of the accompanying doctor. The
pharmaceutical compositions according to the invention can be used
according to the invention for human and also for veterinary
medical purposes.
[0171] The pharmaceutical composition as used according to the
present invention may furthermore comprise, in addition to one or
more of the JNK inhibitors, a (compatible) pharmaceutically
acceptable carrier, excipient, buffer, stabilizer or other
materials well known to those skilled in the art.
[0172] In this context, the expression "(compatible)
pharmaceutically acceptable carrier" preferably includes the liquid
or non-liquid basis of the composition. The term "compatible" means
that the constituents of the pharmaceutical composition as used
herein are capable of being mixed with the pharmaceutically active
component as defined above and with one another component in such a
manner that no interaction occurs which would substantially reduce
the pharmaceutical effectiveness of the composition under usual use
conditions. Pharmaceutically acceptable carriers must, of course,
have sufficiently high purity and sufficiently low toxicity to make
them suitable for administration to a person to be treated.
[0173] If the pharmaceutical composition as used herein is provided
in liquid form, the pharmaceutically acceptable carrier will
typically comprise one or more (compatible) pharmaceutically
acceptable liquid carriers. The composition may comprise as
(compatible) pharmaceutically acceptable liquid carriers e.g.
pyrogen-free water; isotonic saline or buffered (aqueous)
solutions, e.g. phosphate, citrate etc. buffered solutions,
vegetable oils, such as, for example, groundnut oil, cottonseed
oil, sesame oil, olive oil, corn oil and oil from theobroma;
polyols, such as, for example, polypropylene glycol, glycerol,
sorbitol, mannitol and polyethylene glycol; alginic acid, etc.
Particularly for injection of the pharmaceutical composition as
used herein, a buffer, preferably an aqueous buffer, may be
used.
[0174] If the pharmaceutical composition as used herein is provided
in solid form, the pharmaceutically acceptable carrier will
typically comprise one or more (compatible) pharmaceutically
acceptable solid carriers. The composition may comprise as
(compatible) pharmaceutically acceptable solid carriers e.g. one or
more compatible solid or liquid fillers or diluents or
encapsulating compounds may be used as well, which are suitable for
administration to a person. Some examples of such (compatible)
pharmaceutically acceptable solid carriers are e.g. sugars, such
as, for example, lactose, glucose and sucrose; starches, such as,
for example, corn starch or potato starch; cellulose and its
derivatives, such as, for example, sodium carboxymethylcellulose,
ethylcellulose, cellulose acetate; powdered tragacanth; malt;
gelatin; tallow; solid glidants, such as, for example, stearic
acid, magnesium stearate; calcium sulphate, etc.
[0175] The precise nature of the (compatible) pharmaceutically
acceptable carrier or other material may depend on the route of
administration. The choice of a (compatible) pharmaceutically
acceptable carrier may thus be determined in principle by the
manner in which the pharmaceutical composition as used according to
the invention is administered. The pharmaceutical composition as
used according to the invention can be administered, for example,
systemically. Routes for administration include, for example,
parenteral routes (e.g. via injection), such as intravenous,
intramuscular, subcutaneous, intradermal, or transdermal routes,
etc., enteral routes, such as oral, or rectal routes, etc., topical
routes, such as nasal, or intranasal routes, etc., or other routes,
such as epidermal routes or patch delivery. Also contemplated (in
particular for eye related diseases) are instillation,
intravitreal, and subconjunctival administration. Likewise
administration may occur intratympanical, for example if ear
related diseases are treated.
[0176] The suitable amount of the pharmaceutical composition to be
used can be determined by routine experiments with animal models.
Such models include, without implying any limitation, rabbit,
sheep, mouse, rat, dog and non-human primate models. Preferred unit
dose forms for injection include sterile solutions of water,
physiological saline or mixtures thereof. The pH of such solutions
should be adjusted to about 7.4. Suitable carriers for injection
include hydrogels, devices for controlled or delayed release,
polylactic acid and collagen matrices. Suitable pharmaceutically
acceptable carriers for topical application include those, which
are suitable for use in lotions, creams, gels and the like. If the
compound is to be administered per orally, tablets, capsules and
the like are the preferred unit dose form. The pharmaceutically
acceptable carriers for the preparation of unit dose forms, which
can be used for oral administration are well known in the prior
art. The choice thereof will depend on secondary considerations
such as taste, costs and storability, which are not critical for
the purposes of the present invention, and can be made without
difficulty by a person skilled in the art.
[0177] Pharmaceutical compositions for oral administration may be
in tablet, capsule, powder or liquid form. A tablet may include a
solid carrier as defined above, such as gelatin, and optionally an
adjuvant. Liquid pharmaceutical compositions for oral
administration generally may include a liquid carrier as defined
above, such as water, petroleum, animal or vegetable oils, mineral
oil or synthetic oil. Physiological saline solution, dextrose or
other saccharide solution or glycols such as ethylene glycol,
propylene glycol or polyethylene glycol may be included.
[0178] For intravenous, cutaneous or subcutaneous injection, or
injection at the site of affliction, the active ingredient will be
in the form of a parenterally acceptable aqueous solution which is
pyrogen-free and has suitable pH, isotonicity and stability. Those
of relevant skill in the art are well able to prepare suitable
solutions using, for example, isotonic vehicles such as Sodium
Chloride Injection, Ringer's Injection, Lactated Ringer's
Injection. Preservatives, stabilizers, buffers, antioxidants and/or
other additives may be included, as required. Whether it is a
polypeptide, peptide, or nucleic acid molecule, other
pharmaceutically useful compound according to the present invention
that is to be given to an individual, administration is preferably
in a "prophylactically effective amount or a "therapeutically
effective amount" (as the case may be), this being sufficient to
show benefit to the individual. The actual amount administered, and
rate and time-course of administration, will depend on the nature
and severity of what is being treated.
[0179] Treatment of a disease as defined herein typically includes
administration of a pharmaceutical composition as defined above.
The JNK inhibitors of the present invention will modulate the JNK
activity in the subject. The term "modulate" includes in particular
the suppression of phosphorylation of c-jun, ATF2 or NFAT4 in any
of the above diseases, for example, by using at least one JNK
inhibitor comprising or consisting of an inhibitory (poly)peptide
sequence according to any of sequences of SEQ ID NOs: 2 to 27,
potentially comprising an additional transporter sequence, as a
competitive inhibitor of the natural c-jun, ATF2 and NFAT4 binding
site in a cell. The term "modulate" also includes suppression of
hetero- and homomeric complexes of transcription factors made up
of, without being limited thereto, c-jun, ATF2, or NFAT4 and their
related partners, such as for example the AP-1 complex that is made
up of c-jun, AFT2 and c-fos.
[0180] Treatment of a subject with the pharmaceutical composition
as disclosed above may be typically accomplished by administering
(in vivo) an ("therapeutically effective") amount of said
pharmaceutical composition to a subject, wherein the subject may be
e.g. a human subject or an animal. The animal is preferably a
non-human mammal, e.g., a non-human primate, mouse, rat, dog, cat,
cow, horse or pig. The term "therapeutically effective" means that
the active component of the pharmaceutical composition is of
sufficient quantity to ameliorate the diseases and disorders as
discussed herein.
Diseases and Disorders
[0181] The gist of the present invention is to use the above
disclosed JNK inhibitors and pharmaceutical compositions in a
method for treatment of the human or animal body by therapy, in
particular of the human body. As mentioned above JNK signalling is
involved in a multitude of diverse disease states and disorder and
inhibition of said signalling has proposed and successfully tested
for many of these. The inventors of the present invention found
that the JNK inhibitors disclosed herein are effective JNK
inhibitors and are thus equally suitable for the treatment of the
diseases as disclosed in the art.
[0182] Treatment of a human or animal body by therapy, as used
herein, refers to any kind of therapeutic treatment of a respective
subject. It includes for example prevention of onset of the disease
or symptoms (prophylaxis), i.e. typically prior to manifestation of
the disease in the patient. The term also includes the "mere"
treatment of symptoms of a given disease, i.e. the treatment will
ameliorate pathogenesis by reducing disease associated symptoms,
without necessarily curing the underlying cause of the disease and
symptoms. Certainly, curing the underlying cause of the disease is
also encompassed by the term. The term also encompasses a treatment
which delays or even stops progression of the respective
disease.
[0183] In one embodiment the JNK inhibitors according to the
present invention may be administered for example prophylactically
prior to potential onset of a foreseeable disorder, e.g. prior to a
planned surgical intervention or planned exposure to stressful
stimuli. A surgical intervention could for example bear the risk of
inflammation of the respective wound or neighbouring tissue (e.g.
dry eye syndrome after surgical eye treatment, peri-implantitis
after dental implantation treatment, rejection of the graft after
transplantation, etc.). Exposure to stressful stimuli like
radiation could lead to apoptosis of affected tissue and cells. In
such scenario the JNK inhibitors according to the present invention
may for example be administered at least once up to about 4 weeks
in advance. The JNK inhibitors may for example be administered at
least 24 hours, at least 48 hours, at least 1 week, at least 2
weeks or 4 weeks in advance.
[0184] The diseases and disorders to be treated with the JNK
inhibitors as disclosed herein may be acute or chronic.
[0185] Due to the involvement of JNK signalling in a vast diversity
of pathological conditions, the JNK inhibitors of the present
invention may for example be used for the treatment of diseases of
various organs, such as diseases of the eye, diseases of the bone,
neural diseases, neuronal diseases, neurodegenerative diseases,
diseases of the skin, immune and/or autoimmune diseases, diseases
of the eye, diseases of the mouth, inflammatory diseases, metabolic
diseases, cardiovascular diseases, proliferative diseases (in
particular cancers and tumors), diseases of the ear, diseases of
the intestine, diseases of the respiratory system (e.g. lung
diseases), infectious diseases, and various other diseases.
[0186] The JNK inhibitors of the present invention may be used for
example for the treatment of inflammatory diseases including for
example acute inflammation as well as chronic inflammation. The JNK
inhibitors of the present invention may be used to treat any type
of tissue inflammation, e.g. inflammation in the eye, inflammation
in the mouth, inflammation of the respiratory system including in
particular the lung, inflammation of the skin, inflammation within
the cardiovascular system, inflammation of the brain, inflammation
in the ear, etc. Some non-limiting examples for such inflammatory
disease states are mucositis, stomatitis, peri-implantitis,
retinitis, chorioiditis, keratoconjunctivitis sicca, inflammatory
bowel diseases (IBD), uveitis (e.g. anterior uveitis, intermediate
uveitis, posterior uveitis), periodontitis, COPD, asthma, pulpitis,
rheumatoid arthritis, osteoarthritis, Crohn's disease, psoriatic
arthritis, vasculitis, interstitial cystitis; acute inflammation at
a site of infection or wound, meningitis, encephalitis, pneumonia,
pharyngitis, tonsillitis, otitis (including otitis media),
vasculitis, synovitis, enteritis, Crohn's disease, ulcerative
colitis, graft rejection etc.
[0187] The JNK inhibitors as disclosed herein may for example be
used in methods of treatment of ear diseases (in particular
diseases of the inner ear), hearing loss (in particular acute
hearing loss), damaged hair cell stereocilia, hair cell apoptosis,
noise trauma, otitis, otitis media etc. Hearing loss and associated
hair cell apoptosis are non-limiting examples for disorders
resulting from stress situations for cells in which JNK inhibition
can modulate the stress response and for example block
apoptosis.
[0188] The JNK inhibitors of the present invention may also be used
for the treatment of metabolic disorders, for example for the
treatment of diabetes (type 1 or type 2, in particular type 1),
Fabry disease, Gaucher disease, hypothermia, hyperthermia hypoxia,
lipid histiocytosis, lipidoses, metachromatic leukodystrophy,
mucopolysaccharidosis, Niemann Pick disease, obesity, and Wolman's
disease. Hypothermia, hyperthermia and hypoxia are again
non-limiting examples for stress situations for cells in which JNK
inhibition can modulate the stress response and for example block
apoptosis.
[0189] Likewise, the JNK inhibitors of the present invention may be
used for the treatment of neural, neuronal and/or neurodegenerative
diseases, respectively. Examples for such diseases are for example
Alexander disease, Alzheimer's disease, amyotrophic lateral
sclerosis (ALS), apoplexy, Ataxia Telangiectasia, cut or otherwise
disrupted axons, axotomy, brain lesions, CMT (Charcot-Marie-Tooth),
corticobasal degeneration, dementia, diseases or disorders of the
nervous system, dystonia, epilepsy, Farber's disease, Friedreich
ataxia (SCA), gangliosidoses, Guillain-Barre syndrome, hereditary
spastic paraplegia, Hirschsprung's disease, human immunodeficiency
virus dementia, Huntington's disease, infarct of the brain,
ischemic stroke, Krabbe disease, Lennox Gastaut Syndrome,
lissencephaly, multiple sclerosis, myelodysplastic syndromes,
myelopathy, AIDS-related neurodegenerative diseases,
neurofibromatosis type 2 (NF-2), neurolatyerism, neuronal
apoptosis, neuronal death, neuropathic pain, neuropathy,
chemotherapy induced neuropathy, diabetes induced neuropathy,
NMDA-induced neurotoxicity, pain, Parkinson's disease,
parkinsonism, Pick's Disease, polyneuropathy, progressive
supranuclear palsy, Sandhoff disease, spina bifida, stroke, Tay
Sachs, TBI (diffuse axonal injury), treatment of dark neurone
induced for example by an inflammatory pain, West Syndrome, spinal
muscular atrophy etc.
[0190] With respect to autoimmune disorders, the JNK inhibitor
peptides of the present invention may for example be used in a
method of treatment of autoimmune diseases of the CNS,
auto-inflammatory diseases, Celiac disease; Sjogren's syndrome,
systemic lupus erythematosus etc.
[0191] Examples for bone diseases which may be treated with the JNK
inhibitors of the present invention are for example arthritis, disc
herniation, fibrodysplasia ossificans progressiva (FOP),
osteoarthritis, osteopetrosis, osteoporosis, in particular diabetes
induced osteoporosis, Paget's Disease, rheumatoid arthritis,
etc.
[0192] Examples for skin diseases which may be treated with the JNK
inhibitors of the present invention are for example psoriasis and
lupus erythematosus.
[0193] Diseases of the eye, which may be treated with the JNK
inhibitors of the present invention involve for example age-related
macular degeneration (AMD); angioid streaks; anterior ischemic
optic neuropathy; anterior uveitis; cataract, in particular age
related cataract; central exudative chorioretinopathy; central
serous chorioretinopathy; chalazion; chorioderemia; chorioiditis;
choroidal sclerosis; conjunctivitis; cyclitis; diabetic
retinopathy; dry eye syndrome; endophthalmitis; episcleritis; eye
infection; fundus albipunctatus; gyrate atrophy of choroid and
retina; hordeolum; inflammatory diseases of the blephara;
inflammatory diseases of the choroid; inflammatory diseases of the
ciliary body; inflammatory diseases of the conjunctiva;
inflammatory diseases of the cornea; inflammatory diseases of the
iris; inflammatory diseases of the lacrimal gland; inflammatory
diseases of the orbital bone; inflammatory diseases of the sclera;
inflammatory diseases of the vitreous body; inflammatory diseases
of the uvea; inflammatory diseases of the retina; intermediate
uveitis; irititis; keratitis; Leber's disease; multifocal
choroiditis; myositis of the eye muscle; neovascular maculopathy
(e.g. caused by high myopia, tilted disc syndrome, choroidal
osteoma or the like); NMDA induced retinotoxicity; non-chronic or
chronic inflammatory eye diseases; Oguchi's disease; optic nerve
disease; orbital phlegmon; panophtalmitis; panuveitis; post caspule
opacification; posterior capsule opacification (PCO) (a cataract
after-surgery complication); posterior uveitis; proliferative
vitreoretinopathy; retinal artery occlusion; retinal detachment,
retinal diseases; retinal injuries; retinal macroaneurysm; retinal
pigment epithelium detachment; retinal vein occlusion; retinitis;
retinitis pigmentosa; retinitis punctata albescens; retinopathy, in
particular retinopathy of prematurity and diabetic retinopathy;
scleritis; Stargardt's disease; treatment of inflamed ocular wounds
and/or ocular wound edges; treatment of intraocular inflammation
after eye surgery or trauma; uveitis; vitelliform macular
dystrophy; etc.
[0194] Exemplary diseases of the mouth which may be treated with
the JNK inhibitors as disclosed herein are periodontitis, in
particular chronic periodontitis; mucositis, oral desquamative
disorders, oral liquen planus, pemphigus vulgaris, pulpitis;
stomatitis; temporomandibular joint disorder, peri-implantitis
etc.
[0195] Likewise the JNK inhibitors of the present invention may--as
already previously proposed for other JNK inhibitors--be used for
the treatment of proliferative diseases like cancer and tumor
diseases, such as acusticus neurinoma lung carcinomas; acute
lymphocytic leukemia (L1, L2, L3); acute lymphoid leukaemia (ALL);
acute myelogenous leukemia (AML); adenocarcinomas; anal carcinoma;
bronchial carcinoma; cervix carcinoma; cervical cancer;
astrocytoma; basalioma; cancer with Bcr-Abl transformation; bladder
cancer; blastomas; bone cancer; brain metastases; brain tumours;
breast cancer; Burkitt's lymphoma; carcinoids; cervical cancer;
chronic lymphocytic leukaemia (CLL); chronic myeloid leukaemia
(CML); colon cancer; colon carcinoma; corpus carcinoma;
craniopharyngeomas; CUP syndrome; virus-induced tumours;
EBV-induced B cell lymphoma; endometrium carcinoma; erytholeukemia
(M6); esophagus cancer; gallbladder cancer; gastrointestinal
cancer; gastrointestinal stromal tumors; gastrointestinal tumours;
genitourinary cancer; glaucoma; glioblastoma; gliomas; head/neck
tumours; hepatitis B-induced tumours; hepatocell carcinomas;
hepatomas; herpes virus-induced tumours; Hodgkin's syndrome;
HTLV-1-induced lymphomas; HTLV-2-induced lymphomas; insulinomas;
intestinal cancer; Kaposi's sarcoma; kidney cancer; kidney
carcinomas; laryngeal cancer; leukemia; lid tumour; liver cancer;
liver metastases; lung cancer; lymphoid cancer; lymphomas;
malignant melanomas; mammary carcinomas; mantle cell lymphoma;
medulloblastoma; megakaryoblastic leukemia (M7); melanoma, in
particular malignant melanoma; meningioma; mesothelioma; monocytic
leukemia (MS); multiple myeloma; mycosis fungoides; myeloblastic
leukemia (M1); myeloblastic leukemia (M2); myelomonocytic leukemia
(M4); neurinoma; non-Hodgkin's lymphomas; non-small cell carcinoma;
non-small cell carcinoma of the lung; oesophageal cancer;
oesophageal carcinoma; oligodendroglioma; ovarian cancer; ovarian
carcinoma; pancreatic cancer; pancreatic carcinoma; papilloma
virus-induced carcinomas; penis cancer; pituitary tumour;
plasmocytoma; promyelocytic leukemia (M3); prostate cancer;
prostate tumours; rectal tumours; rectum carcinoma; renal-cell
carcinoma; retinoblastoma; sarcomas; Schneeberger's disease; small
cell lung carcinomas; small intestine cancer; small intestine
tumours; soft tissue tumours; spinalioma; squamous cell carcinoma;
stomach cancer; testicular cancer; throat cancer; thymoma; thyroid
cancer; thyroid carcinoma; tongue cancer; undifferentiated AML
(MO); urethral cancer; uterine cancer; vaginal cancer; Von Hippel
Lindau disease; vulval cancer; Wilms' Tumor; Xeroderma pigmentosum;
etc.
[0196] Since JNK signalling is also involved in many cardiovascular
diseases and disorders, the use of JNK inhibitors in the treatment
of such diseases has already been suggested in the past. The
inhibitors of the present invention may be used accordingly, e.g.
for the treatment of cardiovascular diseases such as arterial
hypertension; arteriosclerosis; arteriosclerotic lesions; Behcet's
syndrome; bifurcations of blood vessels; cardiac hypertrophy;
cardiavascular hypertrophy; cardiomyopathies, in particular
chemotherapy induced cardiomyopathies; cerebral ischemia; coronary
heart diseases; dilatation of the abdominal aorta; focal cerebral
ischemia; global cerebral ischemia; heart hypertrophy; infrarenal
aneurism hypertension; ischemia; myocardial infarct, in particular
acute myocardial infarction; myocarditis; reperfusion; restenosis;
vasculitis; Wegener's granulomatosis; etc.
[0197] The JNK inhibitors of the present invention may in the
context of cardiovascular diseases also be used complementary to
coronary artery bypass graft surgery (CABG surgery); percutaneous
transluminal coronary angioplasty (PTCA); and/or stent treatment,
for example to prevent or treat intimal hyperplasia resulting from
said (surgical) treatment.
[0198] Diseases of the respiratory system and in particular lung
diseases which may be treated effectively with the JNK inhibitors
of the present invention are for example acute respiratory distress
syndrome (ARDS); asthma; chronic illnesses involving the
respiratory system; chronic obstructive pulmonary disease (COPD);
cystic fibrosis; inflammatory lung diseases; pneumonia; pulmonary
fibrosis; etc.
[0199] Like the inhibitors in the prior art the inhibitors of the
present invention may also be used to treat disease of the
intestinal tract, e.g. colitis (e.g. atypical colitis, chemical
colitis; collagenous colitis, distal colitis, diversion colitis;
fulminant colitis, indeterminate colitis, infectious colitis,
ischemic colitis, lymphocytic colitis, or microscopic colitis),
Crohn's disease, gastroenteritis, Hirschsprung's disease,
inflammatory digestive diseases; inflammatory bowel disease (IBD),
Morbus Crohn, non-chronic or chronic digestive diseases,
non-chronic or chronic inflammatory digestive diseases; regional
enteritis; ulcerative colitis etc.
[0200] The JNK inhibitors of the present invention may also serve
as therapeutic agent for the treatment of infectious diseases
resulting from e.g. bacterial or viral infection. The JNK
inhibitors as disclosed herein may for example prevent or
ameliorate inflammatory reactions caused by said infections.
Examples for such diseases states, which are not considered to be
limiting, are viral encephalitis; viral induced cancers (e.g. as
mentioned above), human immunodeficiency virus dementia,
meningitis, meningoencephalitis, encephalomyelitis, tonsillitis,
etc.
[0201] There are many other diseases, disease states and disorders
for which the JNK inhibitors of the present invention can be used
as treatment, for example Aarskog syndrome, acetaminophen
hepatotoxicity; Alder-Reilly anomaly; alopecia greata;
alpha-1-antitrypsin deficiency; anaphylaxis; apoptosis; apoptotic
cell death; atypical hemolytic uremic syndrome; basopenia;
basophilia; bipolar disorders; burns; cellular shear stress;
Chedial-Higashi syndrome; DNA damage due to chemotherapeutic drugs;
cholestasis; chromosome 11, Partial Monosomy 11q; chromosome 22,
Trisomy Mosaic; chronic granulomatous disease; hepatitis, such as
chronic or fulminant hepatitis; clinical depression; common
variable hypogammaglobulinemia; congenital C3 deficiency; CTL
protection from activation-induced cell death (AICD); deafness;
depression and depressive disorders (in particular prevention of
depressive disorders develop on a background of cytokine-induced
sickness behaviour), DiGeorge's syndrome; diseases caused by
defective apoptosis; diseases of the liver; diseases of the spine;
diseases of the uterus; diseases states and symptoms due to
exposure to DNA damaging agents and/or ionizing radiation and
resulting cellular stress; Down Syndrome; Duchenne muscular
dystrophy; ectodermal dysplasias; endometriosis; eosinopenia;
eosinophilia; exocitoxic cell death; fetal alcohol syndrome;
fibrosis; fibrotic disease; formation of fibrous tissue; free
radicals (leading to cellular stress); graft rejection; Graft
versus host Disease; hair loss; hemolytic uremic syndrome;
hepatotoxicity; hyperalgesia, such as diabetes induced
hyperalgesia; hyperthermia; hypoglycemia; hypothyroidism;
idiopathic hypereosinophilic syndrome; IgA nephropathy; infantile
sex-linked agammaglobulinemia; inflammatory pain; infrarenal
aneyrism; islet regeneration; islet transplantation; Job's syndrome
(hyper-IgE); lazy leukocyte syndrome; leukocyte glucose-6-phosphate
dehydrogenase deficiency; leukodystrophy; leukopenia; lymphocytic
leukocytosis; lymphocytopenia; lymphocytosis; major depression;
mania; maniac depression; Marfan syndrome; mastocytosis; May
Hegglin Anomaly; membranoproliferative glomerulonephritis Type II;
monocytopenia; monocytosis; myeloperoxidase deficiency-benign;
myopathies; neutropenia; neutrophilia; Nezelof's syndrome; organ
transplantation; oxidative stress injuries; Pelger-Huet anomaly;
polycystic kidney diseases; post-dialysis syndrome; radiation
syndromes; radiotherapy; renal diseases; renal failure; rescuing
CTL from activation induced cell death; severe combined
immunodeficiency disease; transplant rejection; transplantation;
trisomy; unipolar depression; UV-induced injuries; Wiskott Aldrich
syndrome; wound healing; etc.
[0202] The inventors of the present invention consider
temporomandibular joint disorder, mucositis, stomatitis, oral
liquen planus (desquamative disorder), Pemphigus vulgaris
(desquamative disorder), periodontitis, chronic periodontitis,
pulpitis, peri-implantitis, uveitis (anterior uveitis, intermediate
uveitis, posterior uveitis), keratoconjunctivitis sicca (dry eye
syndrome), coronary artery bypass graft surgery (CABG surgery),
acute myocardial infarction, prevention of intimal hyperplasia
following percutaneous transluminal coronary angioplasty (PTCA),
prevention of intimal hyperplasia following stent placement,
atherosclerosis, COPD, asthma, rheumatoid arthritis,
osteoarthritis, Crohn's disease, inflammatory bowel disease (IBD),
psoriasis, diabetes, stroke, Parkinson's disease, Alzheimer's
disease, systemic lupus erythematosus, and vasculitis, in
particular Wegener's granulomatosis, to be particularly useful for
treatment with the JNK inhibitors of the present invention.
[0203] A person skilled in the art will readily realize that the
above mentioned disease states and disorders may belong to more
than one of the above mentioned disease classes. For example,
bronchial carcinoma is certainly not only a proliferative disease
but would also belong in the group of diseases of the respiratory
system including lung diseases. Thus, the above mentioned
classification of individual diseases is not considered to be
limiting or concluding but is considered to of exemplary nature
only. It does not preclude that individual disease states recited
in one class are factually also suitable examples for the
application of the JNK inhibitors of the present invention as
treatment in another class of disease states. A person skilled in
the art will readily be capable of assigning the different disease
states and disorders to matching classifications.
[0204] Finally, as mentioned above, the present invention
contemplates the use of a JNK inhibitor as defined herein for the
treatment of various diseases states and disorders. The present
invention does not contemplate to use the JNK inhibitors as defined
herein for immunizing non-human animals, e.g. for the production of
monoclonal antibodies. Such methods are herein not considered to be
methods for treatment of the animal body by therapy.
[0205] All references cited herein are herewith incorporated by
reference.
EXAMPLES
[0206] In the following, particular examples illustrating various
embodiments and aspects of the invention are presented. However,
the present invention shall not to be limited in scope by the
specific embodiments described herein. Indeed, various
modifications of the invention in addition to those described
herein will become readily apparent to those skilled in the art
from the foregoing description, accompanying figures and the
examples below. All such modifications fall within the scope of the
appended claims.
Example 1
Synthesis of JNK Inhibitor SEQ ID NO: 172
[0207] As illustrative example, synthesis of the JNK inhibitor with
SEQ ID NO: 172 is set out below. A person skilled in the art will
know that said synthesis may also be used for and easily adapted to
the synthesis of any other JNK inhibitor according to the present
invention.
[0208] The JNK inhibitor with SEQ ID NO: 172 was manufactured by
solid-phase peptide synthesis using the Fmoc
(9-fluorenylmethyloxycarbonyl) strategy. The linker between the
peptide and the resin was the Rink amide linker
(p-[Fmoc-2,3-dimethoxybenzyl]-phenoxyacetic acid). The peptide was
synthesized by successive Fmoc deprotection and Fmoc-amino acid
coupling cycles. At the end of the synthesis, the completed peptide
was cleaved by trifluoroacetic acid (TFA) directly to yield the
crude C-terminal amide, which was then purified by preparative
reverse phase HPLC. The purified fractions were pooled in a
homogeneous batch that is treated by ion exchange chromatography to
obtain its acetate salt. The peptide was then freeze-dried.
1.1 Solid Phase Synthesis of the Peptide
[0209] Except when noted, the manufacturing took place at room
temperature (22.degree. C..+-.7.degree. C.) in an air-filtered
environment. The scale of synthesis was 0.7 mmoles of the starting
amino acid on the resin, for an expected yield of about 1 g of
purified peptide. Synthesis was performed manually in a 30-50 mL
reactor equipped with a fritted disk with mechanical stirring
and/or nitrogen bubbling.
1.2 Preparation of the Resin
[0210] The p-methylbenzhydrylamide resin (MBHA-resin) was first
washed with dichloromethane/dimethylformamide/diisoproplyethylamine
under nitrogen. The washed resin was then coupled to the Rink amide
linker (p-[Fmox-2,4-dimethoxybenzyl]-phenoxyacetic acid) in PyBOB
(benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium
hexafluorophosphate)/diisopropylethylamine/1-hydroxybenzotriazole
to yield Fmoc-Rink amide-MBNA resin.
1.3 Coupling of Amino Acids
[0211] Amino acids were coupled to the resin using the following
cycle:
[0212] The Fmoc-Rink amide-MBHA resin was deprotected by washing it
in 35% (v/v) piperidine/dimethylformamide, followed by
dimethylformamide. The deprotection reaction took approximately 16
minutes. Fmoc-protected amino acids (e.g., 2 eq of amino acid and
HOBt (1-hydroxybenzotriazole) in dimethylformamide/dichloromethane
(50/50) were added to the resin followed by addition of 2 eq of the
coupling agent diisopropylcarbodiimide (DIC). The coupling reaction
took from one hour to overnight depending upon the respective amino
acid being added. Volumes were calculated on a basis of 0.5 mL/100
mg of peptide-resin and adjusted after each cycle. After coupling,
the resin was washed 3 times with DMF. Completeness of coupling was
tested by the ninhydrin test (or Kaiser test 1) on primary amines
and the chloranyl test 2 on secondary amines. On some occasions,
the chloranyl test may be associated with a ninhydrin test as a
security control. In case the coupling test indicated
incompleteness of reaction, coupling was repeated with a lower
excess (0.5-1 eq) of amino acid, PYBOP, HOBT in
dimethylformamide/dichloromethane and diisopropylethylamine.
Functionality of the resin was measured and generally 0.6-0.2
meq/g, depending on the original loading of the resin. After the
last amino acid has been coupled, the peptide-resin was deprotected
as usual and then washed 5 times with DCM before drying in an oven
under vacuum at 30.degree. C. After the peptide-resin had dried,
the yield of the solid-phase synthesis was calculated as the ratio
of the weight increase of the peptide resin compared to the
theoretical weight increase calculated from the initial loading of
the resin. The yield may be close to 100%.
1.4 Cleavage and Deprotection
[0213] The peptide was cleaved from the resin in a mixture of
trifluoroacetic acid/1,2-ethanedthiol/thioanisole/water/phenol
(88/2.2/4.4/4.4/7 v/v), also called TFA/K reagent, for 4 hours at
room temperature. The reaction volume was 1 mL/100 mg of peptide
resin. During addition of the resin to the reagent, the mixture
temperature was regulated to stay below 30.degree. C.
1.5 Extraction of the Peptide from the Resin:
[0214] The peptide was extracted from the resin by filtration
through a fritted disc. After concentration on a rotavapor to 1/3
of its volume, the peptide was precipitated by cold t-butyl methyl
ether and filtered. The crude peptide was then dried under vacuum
at 30.degree. C.
1.6 Preparative HPLC Purification:
[0215] The crude peptide was then purified by reverse-phase HPLC to
a purity of >95%. The purified fractions were concentrated on a
rotavaporator and freeze-dried.
1.7 Ion Exchange Chromatography
[0216] The concentrated freeze-dried pools of purified peptide with
the sequence of SEQ ID NO: 172 was dissolved in water and purified
by ion exchange chromatography on Dowex acetate, 50-100 mesh
resin.
[0217] The required starting reagents for the synthesis were:
TABLE-US-00006 CAS Registry Molecular Number Chemical Name Weight
Fmoc-Rink amide linker 145069-56-3 p-[Fmoc-2,4-dimethoxybenzyl]-
539.6 phenoxyacetic acid Fmoc-D-Ala-OH, H.sub.2O 79990-15-1
N-alpha-Fmoc-D-alanine 311.3 Fmoc-Arg(Pbf)-OH 154445-77-9
N-alpha-Fmoc-N [2,2,4,6,7- 648.8 pentamethyldihydrobenzofuran-5-
sulfonyl]-arginine Fmoc-D-Arg(Pbf)-OH 187618-60-6 N-alpha-Fmoc-N
[2,2,4,6,7- 648.8 pentamethyldihydrobenzofuran-5-
sulfonyl]-D-arginine Fmoc-Asn(Trt)-OH 132388-59-1
N-alpha-Fmoc-N--trityl-asparagine 596.7 Fmoc-Gln(Trt)-OH
132327-80-1 N-alpha-Fmoc-N--trityl-glutamine 610.7 Fmoc-Leu-OH
35661-60-0 N-alpha-Fmoc-leucine 353.4 Fmoc-Lys(Boc)-OH 71989-26-9
N-alpha-Fmoc-N-Boc-lysine 468.5 Fmoc-D-Lys(Boc)-OH 143824-78-6
N-alpha-Fmoc-N-Boc-D-lysine 468.5 Fmoc-D-Phe-OH 86123-10-6
N-alpha-Fmoc-D-phenylalanine 387.4 Fmoc-Pro-OH 71989-31-6
N-alpha-Fmoc-proline 337.4 Fmoc-Thr(tBu)-OH 71989-35-0
N-alpha-Fmoc-O-t-butyl-threonine 397.5
[0218] Other JNK inhibitors of the present invention may be
prepared in similar manner.
Example 2
Inhibitory Efficacy of Selected JNK Inhibitors According to the
Present Invention
[0219] In the following a standard operating procedure will be set
forth describing how the Inhibitory efficacy of JNK inhibitors
according to the present invention was measured. The method allows
to measure in vitro, in a non radioactive standardized assay, the
ability of a candidate compound to decrease the phosphorylation of
the c-Jun specific substrate by JNK. Moreover, it will be
illustrated how to determine the inhibitory effect (IC50) and the
Ki of a chosen compound for JNK. The method is suitable to verify
whether a candidate compound does or does not inhibit JNK activity.
and a person skilled in the art will certainly understand how to
adapt the below methods for his specific purposes and needs.
2.1 Material
AlphaScreen Reagent and Plate:
[0220] His-JNK1 (ref 14-327, Upstate, 10 .mu.g in 100 .mu.l:
concentration: 2.2 .mu.M) 5 nM final [0221] His-JNK2 (ref 14-329,
Upstate, 10 .mu.g in 100 .mu.l: concentration: 2 .mu.M) 5 nM final
[0222] His-JNK3 (ref 14-501, Upstate, 10 .mu.g in 100 .mu.l:
concentration: 1.88 .mu.M) 5 nM final [0223] Anti-Phospho-cJun (ref
06-828, Upstate, lot DAM1503356, concentration: 44.5 .mu.M) 10 nM
final [0224] Biotin-cJun (29-67): sequence:
Biotin--SNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVG (SEQ ID NO: 198),
lot 100509 (mw 4382.11, P 99.28%) dissolved H.sub.2O,
concentration: 10 mM) 30 nM final [0225] ATP (ref AS001A,
Invitrogen, lot S0860B, concentration 100 mM)) 5 .mu.M final [0226]
SAD beads (ref 6760617M, PerkinElmer, lot 540-460-A, concentration
5 mg/ml) 20 .mu.g/ml final [0227] AprotA beads (ref 6760617M,
PerkinElmer, lot 540-460-A, concentration 5 mg/ml) 20 .mu.g/ml
final [0228] Optiplate 384well white plate (ref 6007299,
PerkinElmer, lot 654280/2008) [0229] 96well plate for peptide
dilution (ref 82.1581, Sarstedt) [0230] TopSeals-A (ref 6005185,
Perkin Elmer, Lot 65673) [0231] Bioluminescent energy transfer
reading [0232] The bioluminescent energy transfer was read on the
Fusion Alpha Plate reader (Perkin Elmer).
Pipette:
[0232] [0233] An electronic EDP3 pipette 20-300 (Ref 17007243;
Rainin) was used to fill in the plate with the Enzme-Antibody mix,
the Substrate-ATP mix and the Beads. [0234] A PIPETMAN.RTM. Ultra
multichannel 8.times.20 (Ref 21040; Gilson) was used to fill in the
plate with the inhibitory compounds.
Buffer and Solutions
[0234] [0235] Kinase Buffer: 20 mM Tris-base pH 7.4, 10 mM
MgCl.sub.2, 1 mM DTT, 100 .mu.M Na.sub.3VO.sub.4, 0.01% Tween, (1%
DMSO) [0236] Stop Buffer: 20 mM Tris-base pH 7.4, 200 mM NaCl, 80
mM EDTA-K (pH de 8 with KOH instead of NaOH), 0.3% BSA [0237] JNK
dilution Kinase buffer: 50 mM Tris-base pH 7.4, 150 mM NaCl, 0.1 mM
EGTA, 0.03% Brij-35, 270 mM sucrose, 0.1%
.beta.-mercaptoethanol.
2.2 Method
[0238] To assess inhibitory effect of the peptides, a standard
AlphaScreen assay (see for example Guenat et al. J Biomol Screen,
2006; 11: pages 1015-1026) was performed. The different components
were prepared and subsequently mixed as indicated. The plates were
sealed and incubated as following:
TABLE-US-00007 5 .mu.l JNK + Antibody 5 .mu.l TP kinase +/-
inhibitor Pre-incubation 30 min 5 .mu.l Biotin-cJun + ATP
Incubation 60 min at 24.degree. C. 10 .mu.l Beads SAD + A protA
Incubation 60 min in the dark at 24.degree. C.
[0239] To avoid contamination, the mixes were added with the
pipette in different corner of the well. After the filling in of
the plate with each mix, the plate was tapped (Keep one side fix
and let the opposite side tap the table) to let the mix go down the
walls of the wells.
[0240] The bioluminescent energy transfer was read on the Fusion
Alpha Plate reader (Perkin Elmer).
[0241] All compounds should at least be tested in triplicate in 3
independent experiments for each isoform of JNK. Possibly
concentrations of the compounds to be tested were 0, 0.03 nM, 0.1
nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 .mu.M, 3
.mu.M, 10 .mu.M, 30 .mu.M, and 100 .mu.M. Controls were samples
either without JNK or without substrate (c-Jun).
Mix Preparation
JNK1, JNK2 and JNK3 5 nM
Biotin-dun 30 nM
[0242] ATP 5 .mu.M; Anti phospho-cJun (S63) 10 nM Bille SAD/AprotA
20 .mu.g/ml Antibody [final]=10 nM (anti Phospho dun (S63))
Detection part: [Mix] X5 (5 .mu.l in final volume of 25 .mu.l)
[Stock]=44.5 .mu.M (ref 06-828, Upstate, Lot DAM1503356)
[0243] 10 nM.fwdarw.50 nM in Kinase Buffer JNK1, JNK2 and JNK3
[final]=5 nM Reaction part: [Mix] X3 (5 .mu.l in final volume of 15
p1)
[Stock]=
[0244] 2.2 .mu.M for JNK1 (ref 14-327, Upstate, lot D7KN022CU)
[0245] 2.0 .mu.M for JNK2 (ref 14-329, Upstate, lot 33221CU) [0246]
1.88 .mu.M for JNK3 (ref 14-501, Upstate, lot D7CN041CU) 5
nM.fwdarw.15 nM in Antibody Buffer
Inhibitor:
[0247] Reaction part: [Mix] X3 (5 .mu.l in final volume of 15
p1)
[Stock]=10 mM
[0248] 100 .mu.M .fwdarw. 300 .mu.M in Kinase Buffer 30 .mu.M
.fwdarw. 90 .mu.M in Kinase Buffer 10 .mu.M .fwdarw. 30 .mu.M in
Kinase Buffer 0.03 nM .fwdarw. 0.09 nM in Kinase Buffer And 0 nM
.fwdarw. Kinase Buffer ##EQU00001##
[0249] Two series of 10 times serial dilutions were performed in a
96 well plate, one beginning with 300 .mu.M to 0 nM, the second
with 90 .mu.M to 0.03 nM. The peptides are added in the 384 plates
with an 8 channels multipipette (ref F14401, Gilson,
8.times.20).
ATP [final]=5 .mu.M Reaction part: [Mix] X3 (5 .mu.l in final
volume of 15 .mu.l)
[Stock]=100 mM (ref AS001A, Invitrogen, lot 50860B)
5 .mu.M.fwdarw.15 .mu.M in Kinase Buffer
[0250] Biotin c-Jun [final]=30 nM Reaction part: [Mix] X3 (5 .mu.l
in final volume of 15 .mu.l)
[Stock]=10 mM
[0251] 30 nM.fwdarw.30 nM in ATP Buffer Beads SAD/A ProtA
[final]=20 .mu.g/ml (Light sensitive) Detection part: [Mix] X 2.5
(10 .mu.l in final volume of 25 .mu.l) [Stock]=5 mg/ml.fwdarw.20
.mu.g/ml 50 .mu.g/ml in STOP Buffer Mix in the dark room (green
Light) or in the darkness.
Analysis of the IC50 Curves:
[0252] The analysis was performed by the GraphPad Prism4 software
with the following equation: Sigmoidal dose-response (No
constraint).
Y=Bottom+(Top-Bottom)/(1+10 ((Log EC50-X)))
[0253] The outliers data were avoided using Grugg's test.
Comparison of the IC50:
[0254] The analysis was performed by the GraphPad Prism4 software
with the following test: One way ANOVA test followed by a Tukey's
Multiple Comparison Test. P<0.05 was considerate as
significant.
[0255] The Km of the ATP for JNK and the Km of biotin-cJun specific
peptide were determined in the report AlphaScreen standardization
assay
[0256] The mathematical relation between Ki and IC50
(Ki=IC50/(1+([Substrate]/Km of the substrate)) may be used to
calculate the Ki values.
Example 3
Internalization Experiments and Analysis
3.1 Materials and Methods for Uptake Experiments
[0257] a) Cell Line: [0258] The cell line used for this experiment
was HL-60 (Ref CCL-240, ATCC, Lot 116523)
[0259] b) Culture Medium and Plates [0260] RPMI (Ref 21875-091,
Invitrogen, Lot 8296) or DMEM (Ref 41965, Invitrogen, Lot 13481)
complemented on May 5, 2008 with: [0261] 10% FBS (Ref A64906-0098,
PAA, Lot A15-151): decomplemented at 56.degree. C., 30 min, on Apr.
4, 2008. [0262] 1 mM Sodium Pyruvate (Ref S8636, Sigma, Lot
56K2386) [0263] Penicillin (100 unit/ml)/Streptomycin (100
.mu.g/ml) (Ref P4333, Sigma, Lot 106K2321) [0264] PBS 10.times.
(Ref 70011, Invitrogen, Lot 8277): diluted to 1.times. with sterile
H.sub.2O [0265] Trypsine-0.05% EDTA (Ref L-11660, PAA, Lot
L66007-1194) [0266] 6 well culture plates (Ref 140675, Nunc, Lot
102613) [0267] 24 well culture plates (Ref 142475, Nunc, Lot
095849) [0268] 96 well culture plates (Ref 167008, Nunc, Lot
083310) [0269] 96 well plates for protein dosing (Ref 82.1581,
Sarstedt) [0270] 96 well plates for fluorescence measurement (Ref
6005279, Perkin Elmer)
[0271] c) Solutions [0272] Poly-D-lysine coating solution (Sigma
P9011 Lot 095K5104): 25 .mu.g/ml final diluted in PBS 1.times.
[0273] Acidic wash buffer: 0.2M Glycin, 0.15M NaCl, pH 3.0 [0274]
Ripa lysis buffer: 10 mM NaH.sub.2PO.sub.4 pH 7.2, 150 mM NaCl, 1%
Triton X-100, 1 mM EDTA pH 8.0, 200 .mu.M Na.sub.3VO.sub.2, 0.1%
SDS, 1.times. protease inhibitor cocktail (Ref 11873580001, Roche,
Lot 13732700)
[0275] d) Microscopy and Fluorescence Plate Reader [0276] Cells
were observed and counted using an inverted microscope (Axiovert 40
CFL; Zeiss; 20.times.). [0277] The fluorescence was read with the
Fusion Alpha Plate reader (Perkin Elmer).
[0278] e) Method [0279] FITC marked peptide internalization was
studied on suspension cells. Cells were plated into poly-DL-lysine
coated dishes at a concentration of 1.times.10.sup.6 cells/ml.
Plates were then incubated for 24 h at 37.degree. C., 5% CO.sub.2
and 100% relative humidity prior to the addition of a known
concentration of peptide. After peptide addition, the cells were
incubated 30 min, 1, 6 or 24 h at 37.degree. C., 5% CO.sub.2 and
100% relative humidity. Cells were then washed twice with an acidic
buffer (Glycin 0.2 M, NaCl 0.15 M, pH 3.0) in order to remove the
cell-surface adsorbed peptide (see Kameyama et al., (2007),
Biopolymers, 88, 98-107). The acidic buffer was used as peptides
rich in basic amino acids adsorb strongly on the cell surfaces,
which often results in overestimation of internalized peptide. The
cell wash using an acidic buffer was thus employed to remove the
cell-surface adsorbed peptides. The acid wash was carried out in
determining cellular uptake of Fab/cell-permeating peptide
conjugates, followed by two PBS washes. Cells were broken by the
addition of the RIPA lysis buffer. The relative amount of
internalized peptide was then determined by fluorescence after
background subtraction and protein content normalization. [0280]
The steps are thus: [0281] 1. Cell culture [0282] 2. Acidic wash
and cellular extracts [0283] 3. Analysis of peptide internalization
with a fluorescence plate reader
[0284] f) Cell Culture and Peptide Treatment
[0285] The 6 well culture plates are coated with 3 ml of Poly-D-Lys
(Sigma P9011; 25 .mu.g/ml in PBS), the 24 well plates with 600
.mu.l and the 96 well plates with 125 .mu.l and incubated for 4 h
at 37.degree. C., CO.sub.2 5% and 100% relative humidity.
[0286] After 4 hours the dishes were washed twice with 3.5 ml PBS,
700 .mu.l or 150 .mu.l PBS for the 6, 24 or 96 well plates,
respectively.
[0287] The cells were plated into the dishes in 2.4 ml medium
(RPMI) at plating densities of 1'000'000 cells/ml for suspension
cells. After inoculation, the plates were incubated at 37.degree.
C., 5% CO.sub.2 and 100% relative humidity for 24 hours prior to
the addition of the peptide. Adherent cells should be at a density
of 90-95% the day of treatment and were plated in DMEM:
TABLE-US-00008 Surface of culture Nb adherent Nb suspension well
(cm.sup.2) Medium cells cells 96 well 0.3 100-200 .mu.l
8'000-30'000.sup. .sup. 100'000 24 well 2 500-1000 .mu.l
100'000-200'000 .sup. 500'000-1'000'000 35 mm (P35)/6 well 10 2.4
ml 250'000-2'100'000 2'400'000 60 mm (P60) 20 3.5 ml 15 * 10.sup.5
1'000'000/ml 10 cm (P100) 60 10 ml 15-60 * 10.sup.5
[0288] The cells were treated with the desired concentration of
FITC labeled peptide (stock solution at a concentration of 10 mM in
H.sub.2O).
[0289] Following peptide addition, the cells were incubated 0 to 24
hours (e.g. 30 min, 1, 6 or 24 hours) at 37.degree. C., CO.sub.2 5%
and 100% relative humidity.
[0290] Acidic Wash and Cellular Extracts:
[0291] The extracts were cooled on ice.
[0292] Suspension cells (or cells, which don attach well to the
dish):
[0293] Transfer the cells in <<Falcon 15 ml>>. To
recover the maximum of cells, wash the dish with 1 ml of PBS.
[0294] Harvest the cells 2 min at 2400 rpm max.
[0295] Suspend the cells in 1 ml cold PBS.
[0296] Transfer the cells into a coated "Eppendorf tube" (coated
with 1 ml of poly D-Lys for 4 hours and washed twice with 1 ml
PBS).
[0297] Wash three times with 1 ml of cold acidic wash buffer and
centrifuge 2 min at 2400 rpm max.
[0298] Beware of the spreading of the cells in the "eppendorf".
[0299] Wash twice with 1 ml cold PBS to neutralize.
[0300] Add 50 .mu.l of lysis RIPA Buffer.
[0301] Incubate 30 min-1 h on ice with agitation.
Adherent Cells:
[0302] Wash three times with 3 ml, 1 ml or 200 .mu.l (for 6, 24 or
96 well plates, respectively) of cold acidic wash buffer. Beware of
the cells who detach from the dish.
[0303] Wash twice with 1 ml cold PBS (for 6, 24 or 96 well plates,
respectively) to neutralize.
[0304] Add 50 .mu.l of lysis RIPA buffer.
[0305] Incubate 30 min-1 h on ice with agitation.
[0306] Scrap the cells with a cold scrapper. The 24 and 96 well
plates were directly centrifuged at 4000 rpm at 4.degree. for 15
min to remove the cellular debris. Then the supernatants (100 or 50
ml respectively for the 24 or 96 well plates) were directly
transferred in a dark 96 well plated. The plates were read by a
fluorescence plate reader (Fusion Alpha, Perkin Elmer).
[0307] Transfer the lysate in a coated "eppendorf" (coated with 1
ml of poly D-Lys for 4 hours and wash twice with 1 ml PBS).
[0308] The lysed cells were then centrifuged 30 min at 10000 g at
4.degree. C. to remove the cellular debris.
[0309] Remove the supernatant and store it at -80.degree. C. in a
coated "Eppendorf tube" (coated with 1 ml of poly D-Lys for 4 hours
and washed twice with 1 ml PBS).
[0310] Analysis of Peptide Internalization with a Fluorescence
Plate Reader:
[0311] The content of each protein extract was determined by a
standard BCA assay (Kit N.degree. 23225, Pierce), following the
instructions of the manufacturer.
[0312] The relative fluorescence of each sample is determined after
reading 10 .mu.l of each sample in a fluorescence plate reader
(Fusion Alpha, Perkin Elmer), background subtraction and
normalization by protein concentration.
3.2 Uptake Experiments
[0313] The time dependant internalization (uptake) of FITC-labeled
TAT derived transporter constructs into cells of the HL-60 cell
line was carried out as described above using sequences transporter
peptides of SEQ ID NOs: 52-96, 43, and 45-47. These sequences are
listed below in Table 4.
TABLE-US-00009 TABLE 4 Transporter sequence tested in uptake
experiments SEQ peptide No: ID abbreviateion NO: in FIG. 6 46
r3-L-TAT H2N dR K K R dR Q R R dR CONH2 52 1 H2N dR A K R dR Q R R
dR CONH2 53 2 H2N dR K A R dR Q R R dR CONH2 54 3 H2N dR K K A dR Q
R R dR CONH2 55 4 H2N dR K K R dR A R R dR CONH2 56 5 H2N dR K K R
dR Q A R dR CONH2 57 6 H2N dR K K R dR Q R A dR CONH2 58 7 H2N dR D
K R dR Q R R dR CONH2 59 8 H2N dR K D R dR Q R R dR CONH2 60 9 H2N
dR K K D dR Q R R dR CONH2 61 10 H2N dR K K R dR D R R dR CONH2 62
11 H2N dR K K R dR Q D R dR CONH2 63 12 H2N dR K K R dR Q R D dR
CONH2 64 13 H2N dR E K R dR Q R R dR CONH2 65 14 H2N dR K E R dR Q
R R dR CONH2 66 15 H2N dR K K E dR Q R R dR CONH2 67 16 H2N dR K K
R dR E R R dR CONH2 68 17 H2N dR K K R dR Q E R dR CONH2 69 18 H2N
dR K K R dR Q R E dR CONH2 70 19 H2N dR F K R dR Q R R dR CONH2 71
20 H2N dR K F R dR Q R R dR CONH2 72 21 H2N dR K K F dR Q R R dR
CONH2 73 22 H2N dR K K R dR F R R dR CONH2 74 23 H2N dR K K R dR Q
F R dR CONH2 75 24 H2N dR K K R dR Q R F dR CONH2 76 25 H2N dR R K
R dR Q R R dR CONH2 77 26 H2N dR K R R dR Q R R dR CONH2 78 27 H2N
dR K K K dR Q R R dR CONH2 79 28 H2N dR K K R dR R R R dR CONH2 80
29 H2N dR K K R dR Q K R dR CONH2 81 30 H2N dR K K R dR Q R K dR
CONH2 82 31 H2N dR H K R dR Q R R dR CONH2 83 32 H2N dR K H R dR Q
R R dR CONH2 84 33 H2N dR K K H dR Q R R dR CONH2 85 34 H2N dR K K
R dR H R R dR CONH2 86 35 H2N dR K K R dR Q H R dR CONH2 87 36 H2N
dR K K R dR Q R H dR CONH2 88 37 H2N dR I K R dR Q R R dR CONH2 89
38 H2N dR K I R dR Q R R dR CONH2 90 39 H2N dR K K I dR Q R R dR
CONH2 91 40 H2N dR K K R dR I R R dR CONH2 92 41 H2N dR K K R dR Q
I R dR CONH2 93 42 H2N dR K K R dR Q R I dR CONH2 94 43 H2N dR L K
R dR Q R R dR CONH2 45 44 H2N dR K K dQ dR dR dK dK dR CONH2
(D-TAT) 47 45 H2N dR R R Q dR R K K dR CONH2 (r3-L-TATi) 46 46 H2N
dR K K R dR Q R R dR CONH2 (r3-L-TAT) 43 47 H2N R K K R dR Q R R R
CONH2 (L-TAT) 99 48 H2N dR K K R dR Q R R dR CONH2 100 49 H2N dR M
K R dR Q R R dR CONH2 101 50 H2N dR K M R dR Q R R dR CONH2 102 51
H2N dR K K M dR Q R R dR CONH2 103 52 H2N dR K K R dR M R R dR
CONH2 104 53 H2N dR K K R dR Q M R dR CONH2 105 54 H2N dR K K R dR
Q R M dR CONH2 106 55 H2N dR N K R dR Q R R dR CONH2 107 56 H2N dR
K N R dR Q R R dR CONH2 108 57 H2N dR K K N dR Q R R dR CONH2 109
58 H2N dR K K R dR N R R dR CONH2 110 59 H2N dR K K R dR Q N R dR
CONH2 111 60 H2N dR K K R dR Q R N dR CONH2 112 61 H2N dR Q K R dR
Q R R dR CONH2 113 62 H2N dR K Q R dR Q R R dR CONH2 114 63 H2N dR
K K Q dR Q R R dR CONH2 115 64 H2N dR K K R dR K R R dR CONH2 116
65 H2N dR K K R dR Q Q R dR CONH2 117 66 H2N dR K K R dR Q R Q dR
CONH2 118 67 H2N dR S K R dR Q R R dR CONH2 119 68 H2N dR K S R dR
Q R R dR CONH2 120 69 H2N dR K K S dR Q R R dR CONH2 121 70 H2N dR
R K R dR S R R dR CONH2 122 71 H2N dR K R R dR Q S R dR CONH2 123
72 H2N dR K K R dR Q R S dR CONH2 124 73 H2N dR T K R dR Q R R dR
CONH2 125 74 H2N dR K T R dR Q R R dR CONH2 126 75 H2N dR K K T dR
Q R R dR CONH2 127 76 H2N dR K K R dR T R R dR CONH2 128 77 H2N dR
K K R dR Q T R dR CONH2 129 78 H2N dR K K R dR Q R T dR CONH2 130
79 H2N dR V K R dR Q R R dR CONH2 131 80 H2N dR K V R dR Q R R dR
CONH2 132 81 H2N dR K K V dR Q R R dR CONH2 133 82 H2N dR K K R dR
V R R dR CONH2 134 83 H2N dR K K R dR Q V R dR CONH2 135 84 H2N dR
K K R dR Q R V dR CONH2 136 85 H2N dR W K R dR Q R R dR CONH2 137
86 H2N dR K W R dR Q R R dR CONH2 138 87 H2N dR K K W dR Q R R dR
CONH2 139 88 H2N dR K K R dR W R R dR CONH2 140 89 H2N dR K K R dR
Q W R dR CONH2 141 90 H2N dR K K R dR Q R W dR CONH2 142 91 H2N dR
Y K R dR Q R R dR CONH2 143 92 H2N dR K Y R dR Q R R dR CONH2 144
93 H2N dR K K Y dR Q R R dR CONH2 145 94 H2N dR K K R dR Y R R dR
CONH2 146 95 H2N dR K K R dR Q Y R dR CONH2 147 96 H2N dR K K R dR
Q R Y dR CONH2
[0314] In the above table D amino acids are indicated by a small
"d" prior to the respective amino acid residue (e.g. dR=D-Arg).
[0315] For a few sequences synthesis failed in the first approach
unfortunately due to technical reasons. These sequences are
abbreviated in FIG. 6 as 1, 2, 3, 4, 5, 6, 7, 8, 43, 52, 53, 54,
55, 56, 57, 85, 86, 87, 88, 89, and 90. However, the remaining
sequences were used in the internalization experiments.
[0316] The results are shown in FIG. 6.
[0317] As can be seen in FIG. 6, after 24 hours incubation, all
transporters with the consensus sequence rXXXrXXXr (SEQ ID NO: 31)
showed a higher internalization capability than the L-TAT
transporter (SEQ ID NO: 43). Hela cells were incubated 24 hours in
96well plate with 10 mM of the r3-L-TAT-derived transporters. The
cells were then washed twice with an acidic buffer (0.2M Glycin,
0.15M NaCl, pH 3.0) and twice with PBS. Cells were broken by the
addition of RIPA lysis buffer. The relative amount of internalized
peptide was then determined by reading the fluorescence intensity
(Fusion Alpha plate reader; PerkinElmer) of each extract followed
by background subtraction
[0318] As can be seen in FIG. 6, one positions appears to be
critical for highest transporter activity and for improved kinetics
of transport activity: Y in position 2 (peptide N.degree. 91
corresponding to SEQ ID NO: 142).
[0319] The conclusion of this experiment is as follows: [0320]
After 24 hours incubation, all transporters with the consensus
sequence rXXXrXXXr (SEQ ID NO: 31) (see Table 2 for a selection of
possible sequences) showed a higher internalization capability than
the L-TAT transporter (SEQ ID NO: 43) (FIG. 6). Those results fully
validate the consensus sequence rXXXrXXXr (SEQ ID NO: 31). [0321]
One position is critical for highest transporter activity and (FIG.
6): Y in position 2 (sequence 91 corresponding to SEQ ID NO:
142).
[0322] Accordingly, such TAT derived sequences as shown in Table 4
are preferred, which exhibit an Y in position 2, particularly when
the sequence exhibits 9 aa and has the consensus sequence rXXXrXXXr
(SEQ ID NO: 31).
Example 4
Measurement of Cytokine and Chemokine Release
[0323] In the following the procedure will be set forth describing
how the released amount of several human cytokines after ligand
induced secretion from human cells (Blood, WBC, PBMC, purified
primary lymphocytes, cell lines, . . . ) was measured.
[0324] The technique used is a Sandwich ELISA, which allows
measuring the amount of antigen between two layers of antibodies
(i.e. capture and detection antibody). The antigen to be measured
must contain at least two antigenic sites capable of binding to
antibody, since at least two antibodies act in the sandwich. Either
monoclonal or polyclonal antibodies can be used as the capture and
detection antibodies in Sandwich ELISA systems. Monoclonal
antibodies recognize a single epitope that allows fine detection
and quantification of small differences in antigen. A polyclonal is
often used as the capture antibody to pull down as much of the
antigen as possible. The advantage of Sandwich ELISA is that the
sample does not have to be purified before analysis, and the assay
can be very sensitive (up to 2 to 5 times more sensitive than
direct or indirect).
[0325] The method may be used to determine the effect of the JNK
inhibitors of the present invention in vitro/cell culture. At non
toxic doses, compound efficacy is indicated by the decrease of the
cytokine levels (the variation of optical density (absorbance at
450 nm)) as compared to non-treated samples and is monitored by
ELISA. Results are express in ng/ml.
4.1 Material
[0326] 96 well plate: [0327] for collecting the supernatants (Ref
82.1581, Sarstedt) [0328] for ELISA (F96 maxisorp, Ref 442404,
Nunc) [0329] TopSeal-A: 96well microplate seals (Ref 600585,
PerkinElmer). [0330] ELISA reagent [0331] Coating buffer ELISA:
0.1M NaCarbonate pH 9.5 (=7.13 g NaHCO.sub.3 (ref 71627,
Fluka)+1.59 g Na.sub.2CO.sub.3 (ref 71345, Fluka) in 1 litre H2O,
pH to 9.5 with NaOH concentrated) [0332] Wash buffer ELISA: PBS
1.times.+0.01% Tween20. Prepare 1 litre PBS 1.times. (PBS10.times.:
ref 70011, GIBCO) and add 100 ul of Tween20 (ref P1379, Sigma)
slowly while mixing with magnetic agitator) [0333] Assay diluent:
PBS 1.times.+10% FBS (Ref A15-151, PAA, decomplemented at
56.degree. C., 30 min). [0334] DAKO TMB (ref 51599, DAKO):
commercial substrate solution [0335] Stop Solution: 1M
H.sub.3PO.sub.4 (.fwdarw.for 200 ml=177 ml H.sub.2O+23 ml
H.sub.3PO.sub.4 85% (ref 345245, Aldrich). [0336] ELISA Kit
(reagent for 20 plates) [0337] IFN-.gamma.: Human IFN-ELISA set, BD
OptEIA.TM. (ref 555142, DB). [0338] IL-1.beta.: Human IL-1 ELISA
set II, BD OptEIA.TM. (ref 557953, BD) [0339] IL-10: Human IL-10
ELISA set II, BD OptEIA.TM. (ref 555157, DB). [0340] IL-12: Human
IL-12 (p70) ELISA set, BD OptEIA.TM. (ref 555183, DB). [0341]
IL-15: Human IL-15 ELISA Set, BD OptEIA.TM. (ref 559268, DB).
[0342] IL-2: Human IL-2 ELISA set, BD OptEIA.TM. (ref 555190, DB).
[0343] IL-4: Human IL-4 ELISA set, BD OptEIA.TM. (ref 555194, DB).
[0344] IL-5: Human IL-5 ELISA set, BD OptEIA.TM. (ref 555202, DB).
[0345] IL-6: Human IL-6 ELISA setI, BD OptEIA.TM. (ref 555220, DB).
[0346] IL-8: Human IL-8 ELISA set, BD OptEIA.TM. (ref 555244, DB).
[0347] MCP-1: Human MCP-1 ELISA set, BD OptEIA.TM. (ref 555179, BD)
[0348] TNF-.alpha.: Kit human TNF ELISA set, BD OptEIA.TM. (ref
555212, DB). [0349] Absorbance reading: The absorbance was read on
the Fusion Alpha Plate reader (Perkin Elmer). [0350] Repeating
pipettes, digital pipettes or multichannel pipettes.
4.2 Method
[0351] Preparation of the Samples [0352] The samples are culture
medium supernatant from cultured human cells (typically whole
blood, WBC, PBMC, Purified subtype of WBC, cancerous cell lines).
Remove any particulate material by centrifugation (400 g 5 min
4.degree. C.) and assay immediately or store samples at -20.degree.
C. Avoid repeated freeze-thaw cycles. [0353] One hour before using,
defrost the samples on ice and centrifuge them. At step 11, dilute
the samples in assay diluent directly into the plate (add first
assay diluent, then the samples and pipette up and down):
[0354] Preparation of Standard [0355] After warming lyophilized
standard to room temperature, carefully open vial to avoid loss of
material. Reconstitute lyophilized standard with the proposed
volume of deionized water to yield a stock standard. Allow the
standard to equilibrate for at least 15 minutes before making
dilutions. Vortex gently to mix. After reconstitution, immediately
aliquot standard stock in polypropylene vials at 50 p1 per vial and
freeze at -20.degree. C. for up to 6 months. If necessary, store at
2-8.degree. C. for up to 8 hours prior to aliquotting/freezing. Do
not leave reconstituted standard at room temperature. [0356]
Immediately before use, prepare a ten point standard curve using
2-fold serial dilutions in reagent Diluent. A high standard of 4000
pg/ml is recommended.
[0357] Preparation of Detector Mix [0358] One-step incubation of
Biotin/SAv reagents. Add required volume of Detection Antibody to
Assay Diluent. Within 15 minutes prior to use, add required
quantity of Enzyme Reagent, vortex or mix well. For recommended
dilutions, see lot-specific Instruction/Analysis Certificate.
Discard any remaining Working Detector after use.
[0359] Coating with Capture Antibody [0360] 1. Coat the wells of a
PVC microtiter plate with 100 .mu.L per well of Capture Antibody
diluted in Coating Buffer. For recommended antibody coating
dilution, see lot-specific Instruction/Analysis Certificate. [0361]
2. Cover the plate with an adhesive plastic and incubate overnight
at 4.degree. C. [0362] 3. Remove the coating solution and wash the
plate by filling the wells with 150 .mu.l wash buffer. [0363] 4.
The solutions or washes are removed by flicking the plate over a
sink. [0364] 5. Repeat the process two times for a total of three
washes. [0365] 6. After the last wash, remove any remaining wash
buffer by patting the plate on a paper towel.
[0366] Blocking [0367] 7. Block the remaining protein-binding sites
in the coated wells by adding 100 .mu.l reagent Diluent per well.
[0368] 8. Cover the plate with an adhesive plastic and incubate for
1 h at room temperature. [0369] 9. During the incubation, start
preparing the standard.
[0370] Adding Samples [0371] 10. Do one wash as in step 3 with 150
.mu.l of wash buffer. The plates are now ready for sample addition.
[0372] 11. Add 50 .mu.l of appropriately diluted samples in assay
diluent to each well. For accurate quantitative results, always
compare signal of unknown samples against those of a standard
curve. Standards (triplicates) and blank must be run with each
cytokine to ensure accuracy. [0373] 12. Cover the plate with an
adhesive plastic and incubate for 2 h at room temperature.
[0374] Incubation with Detection Antibody and Secondary Antibody
[0375] 13. Wash the plate four times with 150 .mu.l wash buffer
like step 3. [0376] 14. Add 50 .mu.l of detector MIX (detection
antibody+Secondary Streptavidin-HRP antibody in assay diluent) to
each well at recommended dilutions (see lot-specific
Instruction/Analysis Certificate). [0377] 15. Cover the plate with
an adhesive plastic and incubate for 1 h at room temperature light
protect. [0378] 16. Wash the plate six times with 150 .mu.l wash
buffer as in step 3. [0379] 17. Add 50 .mu.l DAKO TMB solution to
each well, incubate for 15-20 min at room temperature, in the dark,
not sealed. [0380] 18. Add 50 .mu.l of stop solution to each well.
Gently tap the plate to ensure thorough mixing. [0381] 19. Mix the
plate 5 min at 500 rpm on a plate mixer. [0382] 20. Read the
optical density at 450 nm. (Program: Cytokine_ELISA on Fusion Alpha
Plate reader).
Data Analysis
[0383] Average the triplicate readings for each standard control
and each sample. Subtract the average zero standard optical density
(O.D). Create a standard curve plotting the log of the cytokine
concentration versus the log of the O.D and the best fit line can
be determined by regression analysis. If samples have been diluted,
the concentration read from the standard curve must be multiplied
by the dilution factor. A standard curve should be generated for
each set of samples assayed. The outliers data were avoided using
Grugg's test. Then the data which weren't in the interval of two
times the SD, were discard. The independent experiments are taken
into account if the positive control showed data as previously
observed. The independent experiments are pooled (N>3).
[0384] The data are presented in pg/ml of cytokine release or in %,
compared to the induced condition without inhibitor treatment.
Example 5
THP1 Differentiation--Stimulation for Cytokine Release
[0385] In the following the procedure will be set forth describing
how cytokine production from human PMA differentiated THP1 cells
challenged by LPS for 6 h was induced in order to test the ability
of JNK inhibitors of the present invention, in particular of a JNK
inhibitor with SEQ ID NO: 172, to reduce stimulation-induced
cytokine release. THP1 cells were stimulated ex-vivo by different
ligands for the readout of cytokine release. At non toxic doses,
JNK inhibitor efficacy is indicated by the decrease of the cytokine
levels as compared to non-treated samples and is monitored by
ELISA. The toxicity of the compound are evaluated by the reduction
of a tetrazolium salt (MTS) to formazan, giving a purple
colour.
Procedure:
[0386] a. Material [0387] Cell Line: THP-1 (Ref TIB-202, ATCC, lot
57731475) [0388] Culture medium, reagent and plates [0389] RPMI
(Ref 21875-091, Invitrogen) complemented with: [0390] 10% FBS (Ref
A15-151, PAA): decomplemented at 56.degree. C., 30 min. [0391] 10
mM Hepes (Ref H0887, Sigma) [0392] 50 M-mercaptoethanol (Ref 63690,
Fluka: stock at 14.3M): add 5601 of 50 mM aliquots in PBS stocked
at -20.degree. C.) [0393] 1 mM Sodium Pyruvate (Ref S8636, Sigma)
[0394] Penicilline (100 unit/ml)/Streptomycine (100 g/ml) (Ref
P4333, Sigma) [0395] The RPMI medium is then filtrated with a 0.22
M filter (Ref SCGPU05RE, Millipore). [0396] PBS 10.times. (Ref
70011, Invitrogen): diluted to 1.times. with sterile H.sub.2O
[0397] DMSO: Ref 41444, Fluka [0398] PMA (phorbol 12-myristate
13-acetate, Ref P1585, Sigma, concentration 1 mM=616.8 ug/ml in
DMSO at -20.degree. C.). Use directly at a final concentration of
100 nM in RPMI (1 ul in 10 ml of medium). [0399] LPS ultrapure
(Lipopolysaccharide, Ref tirkeklps, Invivogen, concentration 5
mg/ml): Stock solution of LPS: 3 g/ml in PBS at 4.degree. C. Use
directly to prepare a 4.times. concentrated solution of 40 ng/ml in
RPMI medium (min 1800 l/plate; for 5 plates: 125 l of LPS 3
g/ml+9250 l RPMI). [0400] 96 well plate: [0401] for adherent cell
culture (Ref 167008, Nunc) [0402] for collecting the supernatants
(Ref 82.1581, Sarstedt) [0403] for ELISA (F96 maxisorp, Ref 442404,
Nunc) [0404] Coating solutions: poly-D-lysine (Ref P9011, Sigma):
25 g/ml final diluted in PBS 1.times. [0405] ELISA reagent and kits
[0406] Coating buffer ELISA: 0.1 M NaCarbonate pH 9.5 (=7.13 g
NaHCO.sub.3 (ref 71627, Fluka)+1.59 g Na.sub.2CO.sub.3 (ref 71345,
Fluka) in 1 liter H2O, pH to 9.5 with NaOH concentrated) [0407]
Wash buffer ELISA: PBS 1.times.+0.01% Tween20 (ref P1379, Sigma,
lot 094K0052)(=prepare 1 liter PBS 1.times. and add 100 ul of
Tween20 slowly while mixing with magnetic agitator) [0408] Assay
diluent: PBS 1.times.+10% FBS (Ref A15-151, PAA, decomplemented at
56.degree. C., 30 min). [0409] DAKO TMB (ref S1599, DAKO):
commercial substrate solution [0410] Stop Solution: 1M
H.sub.3PO.sub.4 (.fwdarw.for 200 ml=177 ml H.sub.2O+23 ml
H.sub.3PO.sub.4 85% (ref 345245, Aldrich). [0411] TNF-: Kit human
TNF ELISA set, BD OptEIA (ref 555212, DB). [0412] Cytotoxicity
measurement: CellTiter 96 reagent (ref G3581, Promega) [0413]
Control compound: SP600125 (ref ALX-270-339-MO25, Alexis,
concentration: 20 mM DMSO) [0414] Absorbance reading: The
absorbance was read on the Fusion Alpha Plate reader (Perkin
Elmer). [0415] Repeating pipettes, digital pipettes or multichannel
pipettes. [0416] TopSeal-A: 96well microplate seals (Ref 600585,
PerkinElmer). b. Method
Well Coating
[0417] The plates had been coated with 200 l of poly D-Lysine
(1.times.) and incubated 2 hours at 37.degree. C., CO.sub.2 5% and
100% relative humidity.
Cell Plating
[0418] After 2 hours the wells were washed twice with 200 l PBS
1.times. (use immediately or leave with 200 l of PBS 1.times. at
37.degree. C. till use, but no more than 3 days).
[0419] The cells were counted. The desired number of cells was
taken and resuspended in the amount of media necessary to get a
dilution of 1'000'000 cells/ml. 100 nM of PMA was added to induce
the differentiation of the THP1 from suspension monocytes to
adherent macrophages. The cells were plated into the wells in 100 l
medium at plating densities of 100'000 cells/well. After
inoculation, the plates were incubated at 37.degree. C., 5% CO2 and
100% relative humidity 3 days to let them differentiate, prior to
the addition of experimental drugs.
Cell Treatment
[0420] After 3 days, the adherent cells were observed with the
microscope. The media containing PMA was aspirated and replaced by
100 l of fresh RPMI media without PMA (no washing step with PBS
1.times.).
[0421] Experimental drug were prepared at the concentration of 10
mM in H.sub.2O or DMSO and stored at -80.degree. C. Prior to each
daily use, one aliquot of JNK inhibitor was defrost and diluted to
reach a 4.times. concentrated solution (120 M) in RPMI medium and
then to the desired concentration in RPMI. The SP600125 was diluted
to reach a 4.times. concentrated solution (40 M) in RPMI medium and
then to the desired concentration in RPMI containing 0.8% DMSO.
[0422] The plates were treated with 50 l of medium or a solution of
4.times. the final desired drug concentration (0, 100 nM, 1, 3, 10
or 30 M final for JNK compound or at 0, 10, 100 nM, 1, 3 or 10 M
final for the SP600125 positive control). Following drug addition,
the plates were incubated for an additional 1 h at 37.degree. C.,
5% CO.sub.2 and 100% relative humidity.
[0423] After 1 hours, the secretion of TNF was induced by the
addition of 501 of a 4.times. concentrated dilution of LPS
ultrapure (3 ng/ml final).
Assay
[0424] After 6 hours, 1001 of the supernatant were transferred to
new 96well plates. Those plates were sealed and stored at
-20.degree. till the analysis by ELISA (e.g. see example 4) of the
secretion of the cytokines.
[0425] The cytotoxic effect of the compounds was evaluated by MTS
absorbance (e.g. see example 4) and cells were observed using an
inverted microscope (Axiovert 40 CFL; Zeiss; 10.times.).
Data Analysis
[0426] Analyses of the data are performed as indicated in the ELISA
(see example 4). Briefly, for ELISA: Average the triplicate
readings for each standard control and each sample. Subtract the
average zero standard optical density (O.D). Create a standard
curve plotting the log of the cytokine concentration versus the log
of the O.D and the best fit line can be determined by regression
analysis. If samples have been diluted, the concentration read from
the standard curve must be multiplied by the dilution factor. A
standard curve should be generated for each set of samples assayed.
The outliers data were avoid using Grugg's test. Then the data
which weren't in the interval of two times the SD, were discard.
The independent experiments are taken into account if the positive
control showed data as previously observed. The independent
experiments are pooled (N>3).
[0427] For the Cytotoxicity effect evaluation: on each plate of
each independent experiment taken into account for the cytokine
release experiment analysis, the average of the absorbance of the
medium alone was considerate as the background and subtracted to
each absorbance value. The average of triplicate of the non treated
cells of each compound was considerate as the 100% viability. The
average of triplicate of each compound was normalized by its 100%.
The outliers data were avoid using Grugg's test. Then the data
which weren't in the interval of two times the SD, were discard.
The independent experiments are pooled (N>3).
[0428] All statistical comparisons of conditions were performed by
the GraphPad Prism4 software with the following test: One way ANOVA
test followed by a Tukey's Multiple Comparison Test. P<0.05 was
considerate as significant.
Example 6
JNK Inhibitor of SEQ ID NO: 172 and TNF.alpha. Release in Primary
Rat or Human Whole Blood Cells
[0429] Whole blood is collected from anesthetized rat or human
healthy volunteers using a venipuncture connected to a pre-labeled
vacuum tube containing sodium citrate. Tubes are gently mixed by
inversion 7-8 times; and are then kept at RT until stimulation. JNK
inhibitor of SEQ ID NO: 172 is prepared 6 times concentrated in
PBS, and 30 .mu.l/well of mix is added into 96-well plate. Whole
blood is diluted by 1:2 in PBS and 120 .mu.l of diluted blood is
added in each well where either PBS alone or JNK inhibitor of SEQ
ID NO: 172 has been previously added. Whole blood is incubated at
37.degree. C.; 85 rpm (Stuart Orbital incubator SI500) for 60 min.
Activators (LPS) are the prepared, 30 .mu.l/well of LPS, 6 times
concentrated. After 60 min incubation, LPS is added to the blood,
blood is mixed by pipetting up and down, and then kept for 4 h
under agitation (85 rpm), at 37.degree. C. After the 4 h
incubation, the plates are centrifuged at about 770 g, 4.degree. C.
for 15 min in a pre-cooled centrifuge. Supernatants are finally
collected and kept at -20.degree. C. until cytokine measurement.
Cytokine (IL-6, IL-2, IFN.gamma. and TNF.alpha.) were then measured
using standard Elisa kits (e.g. from R&D Systems: DuoSet
Elisas; or from BD Biosciences: BD Opteia Set Elisa). Results are
expressed as pg/ml of supernatant of the measured cytokine.
[0430] A similar experiment was conducted with PMA+ionomycin
instead of LPS as activator/stimulant.
Example 7
Half-Life of Specific JNK Inhibitors Disclosed Herein
[0431] The JNK inhibitors with the sequence of SEQ ID NOs: 196,
197, and 172 (0.1 mM final concentration) were digested in human
serum (10 and 50% in PBS 1.times.). The experiment was performed as
described by Tugyi et al. (Proc Natl Acad Sci USA, 2005, 413-418).
The remaining intact peptide was quantified by UPLC-MS. Stability
was assessed for SEQ ID NOs: 196, 197, and 172 identically but in
two separate assays. While the JNK inhibitor with SEQ ID NO: 196
was totally degraded into amino acids residues within 6 hours, the
JNK inhibitor with SEQ ID NO: 172 was completely degraded only
after 14 days. The JNK inhibitor with SEQ ID NO: 197 was still
stable after 30 days.
Example 8
Dose-Dependent Inhibition by JNK Inhibitor with Sequence of SEQ ID
NO: 172 of CD3/CD28-Induced IL-2 Release in Rat Primary T-Cells
[0432] Control animal were sacrificed, lymph nodes (LN) were
harvested and kept in complete RPMI medium. LN were smashed with
complete RPMI on 70 .mu.m filter using a 5 ml piston. A few drops
of media were added to keep strainer wet. Cells were centrifuged
for 7 min at 450 g and 4.degree. c. Pellet was resuspended in 5 ml
fresh medium. Cells were passed again through cell strainer. An
aliquot of cells was counted, while cells were centrifuged again 10
min at 1400 rpm and 4.degree. c. Cells were resuspended in MACS
buffer (80 .mu.l of MACS buffer per 10.sup.7 cells). 10 .mu.l of
anti-rat MHC microbeads were added per 10 million cells, cells were
incubated for 15 min at 4.degree.-8.degree. c. Cells were washed
with 15 ml MACS buffer and centrifuge for 7 min at 700 g and
4.degree. C. Pellet was resuspended in 500 .mu.l MACS buffer per
10.sup.8 cells. One LS column was placed in the magnetic field of
the MACS separator per animal. Column was first rinsed with 3 ml of
MACS buffer. One tube was placed below the column in ice to collect
cells=T cells (negative selection so we collect what is eluted).
Cell suspension was added and elute was collected on ice. Column
was washed 3 times with 3 mL MACS buffer. Eluted T cells were
centrifuges for 7 min at 700 g and 4.degree. C. Resuspended cells
were counted and plated at density of 200000 cells/well in 100
.mu.l of complete medium. Plates were precoated the day before
experiment with 2 .mu.g/mL of CD3 antibody, and the day of
experiment plates were washed three times with PBS. Cells were
treated with 100 .mu.l of (poly-)peptide JNK inhibitor (SEQ ID NO:
172), two times concentrated for 1 h before ligand activation.
After 1 h of pretreatment with (poly-)peptide JNK inhibitor (SEQ ID
NO: 172), cells were then stimulated with 2 .mu.g/mL of anti CD28
antibody for 24 h. After 24 h of stimulation; supernatant were
collected and stored at -20.degree. C. until analysis. Cytokines
were then measured using standard Elisa kits. Results are expressed
as pg/ml of supernatant of the measured cytokine.
[0433] In a further experiment, essentially the same protocol as
set forth above was used, but in addition to the (poly-)peptide JNK
inhibitors with SEQ ID NO: 172, JNK inhibitors with the sequence of
SEQ ID NO: 197 and the drug molecule SP600125 were also tested thus
allowing to compare the effects of these inhibitors on the
inhibition of CD3/CD28-induced IL-2 release.
Example 9
JNK Inhibitor and TNF.alpha./IL-2 Release in Human Whole Blood
[0434] Whole blood from human healthy volunteers was collected
using a venipuncture connected to a pre-labeled vacuum tube
containing sodium citrate. Tubes are gently mixed by inversion 7-8
times; and are then kept at RT until stimulation. 350 .mu.l of
RPMI+P/S were added into 1.2 ml-96-well plate. 10 times
concentrated of SEQ ID NO: 172 was prepared in RPMI+P/S (50 .mu.l
per well). 50 .mu.l was added into 1.2 ml-96 well plates. 50 .mu.l
of whole blood was then added in each well where either medium
alone or JNK inhibitor has been previously added. Whole blood was
incubated at 37.degree. C., 5% CO2 for 60 min. 50 .mu.l/well of
ligands diluted in RPMI+P/S was prepared, corresponding to the
final dilution 10 times concentrated. After 60 min of incubation,
ligand was added; wells were then mixed by pipetting up and down
the blood. Whole blood was incubated for 3 days at 37.degree. C.
(wells were mixed by pipetting each well up and down once per day).
At the end of incubation, plates were mixed and then centrifuged at
2500 rpm, 4.degree. C. for 15 min in a pre-cooled centrifuge.
Cytokine were then measured using standard Elisa kits. Results are
expressed as pg/ml of supernatant of the measured cytokine.
[0435] A similar experiment was carried out with slight
modifications. In the case of CD3/CD8 stimulation, CD3 antibody was
coated at 2 .mu.g/mL in PBS overnight at 4.degree. C. The day of
experiment, wells were washed three times with PBS and left in PBS
until use at 37.degree. C. CD28 antibody was added 1 h after SEQ ID
NO: 172 at final concentration of 2 .mu.g/mL; supernatants were
collected after 3 days of stimulation.
Example 10
Anti-Inflammatory Potency in a Rat Model of Endotoxins Induced
Uveitis (EIU)
[0436] The anti-inflammatory potency of the JNK inhibitor of SEQ ID
NO: 172 was tested in albino rats following intravenous
administration (EIU/LPS model). The aim of this study was to
determine the effects of single intravenous injections of SEQ ID
NO: 172 (0.015, 0.18, and 1.80 mg/kg) on the inflammatory response
in an endotoxins-induced uveitis albino rat model and to compare
these affects to those obtained with prior art JNK inhibitor of SEQ
ID NO: 197 (2 mg/kg). As a further control served phosphate sodic
dexamethasone.
[0437] Sixty (60) male Lewis rats were randomly divided into six
(6) groups of ten (10) animals each. EIU was induced by footpad
injection of lipopolysaccharide (LPS, 1 mg/kg). NaCl (0.9%), SEQ ID
NO: 197 at 2 mg/kg and SEQ ID NO: 172 at three concentrations (1.80
mg/kg, 0.18 mg/kg and 0.015 mg/kg) were administered by intravenous
injection. Phosphate sodic dexamethasone (20 .mu.g/eye) was
administered by sub-conjunctival injection in both eyes. 24 hours
after LPS injection, inflammatory response was evaluated by
clinical scoring.
[0438] The intensity of clinical ocular inflammation was scored on
a scale from 0 to 4 for each eye: [0439] Grade 0 no inflammation
[0440] Grade 1 slight iris and conjunctival vasodilation [0441]
Grade 2 moderate iris and conjunctival vasodilation with flare
[0442] Grade 3 intense iris and conjunctival vasodilation with
flare [0443] Grade 4 intense inflammatory reaction [0444] (+1)
fibrin formation and seclusion of pupils
[0445] Twenty-four hours after LPS induction, clinical scores for
the vehicle-treated rats were 3.6.+-.0.2 (mean.+-.SEM, n=20) with a
median of 4 (range, 2-5). A significant reduction (p<0.001) in
the severity of the ocular inflammation was detected 24 hours after
induction and intravenous treatment with SEQ ID NO: 197 (2 mg/kg)
(mean score: 2.2.+-.0.3, median: 2), corresponding to a 40%
decrease of EIU scores compared with the score observed in vehicle
group. Intravenous treatment with SEQ ID NO: 172, at approximately
the same dose (1.80 mg/kg) reduced also significantly the severity
of the ocular inflammation by 42% (mean score: 2.1.+-.0.3, median:
2, p=0.001). The lower doses (0.18 and 0.015 mg/kg) reduced by 33%
(mean score: 2.4.+-.0.3, median: 2) and 36% (mean score:
2.3.+-.0.3, median: 2) the inflammation, respectively. The
reduction was significant with p<0.001.
[0446] A sub-conjunctival treatment with dexamethasone (20
.mu.g/eye), used as positive control drug also significantly
reduced the clinical scores by 79% (mean score: 0.8.+-.0.2, median:
0.5, p<0.001).
[0447] Under these experimental conditions, it can be stated that a
single intravenous injection of SEQ ID NO: 197 at 2 mg/kg partially
prevented the endotoxin-induced inflammation observed in the
anterior chamber. In comparison, SEQ ID NO: 172 intravenously
injected at 0.015, 0.18, 1.80 mg/kg also reduced the
endotoxin-induced inflammation in the anterior chamber.
Example 11
Dose-Responsive Effects after Intravenous Administration of JNK
Inhibitor after 14 Days in a Rat Model of Chronic Established Type
II Collagen Arthritis
[0448] Rat collagen arthritis is an experimental model of
polyarthritis that has been widely used for preclinical testing of
numerous anti-arthritic agents that are either under preclinical or
clinical investigation or are currently used as therapeutics in
this disease. The hallmarks of this model are reliable onset and
progression of robust, easily measurable polyarticular
inflammation, marked cartilage destruction in association with
pannus formation, and mild to moderate bone resorption and
periosteal bone proliferation.
[0449] Intravenous (IV) efficacy of the JNK inhibitor of SEQ ID NO:
172 administered daily (QD) for 14 days (arthritis d1-14) for
inhibition of the inflammation (paw swelling), cartilage
destruction, and bone resorption that occurs in established type II
collagen arthritis in rats was determined in said experimental
model.
[0450] Animals (8/group for arthritis) were anesthetized with
Isoflurane and injected with 300 .mu.l of Freund's Incomplete
Adjuvant (Difco, Detroit, Mich.) containing 2 mg/ml bovine type II
collagen (Elastin Products, Owensville, Mo.) at the base of the
tail and 2 sites on the back on days 0 and 6. On day 10 of the
study (arthritis d0), onset of arthritis occurred and rats were
randomized into treatment groups. Randomization into each group was
done after ankle joint swelling was obviously established in at
least one hind paw.
[0451] Female Lewis rats with established type II collagen
arthritis were treated daily (QD) on arthritis days 1-14 by the
intravenous (IV) route with vehicle (NaCl), SEQ ID NO: 172 (0.01,
0.1, 1, or 5 mg/kg), or the reference compound dexamethasone (Dex,
0.05 mg/kg). Animals were terminated on arthritis day 14. Efficacy
evaluation was based on animal body weights, daily ankle caliper
measurements, ankle diameter expressed as area under the curve
(AUC), terminal hind paw weights, and histopathologic evaluation of
ankles and knees of selected groups.
[0452] Scoring of Joints Collagen arthritic ankles and knees are
given scores of 0-5 for inflammation, pannus formation and bone
resorption according to the following criteria:
Knee and/or Ankle Inflammation [0453] 0 Normal [0454] 0.5 Minimal
focal inflammation [0455] 1 Minimal infiltration of inflammatory
cells in synovium/periarticular tissue [0456] 2 Mild infiltration
[0457] 3 Moderate infiltration with moderate edema [0458] 4 Marked
infiltration with marked edema [0459] 5 Severe infiltration with
severe edema
Ankle Pannus
0 Normal
[0459] [0460] 0.5 Minimal infiltration of pannus in cartilage and
subchondral bone, affects only marginal zones and affects only a
few joints [0461] 1 Minimal infiltration of pannus in cartilage and
subchondral bone, primarily affects marginal zones [0462] 2 Mild
infiltration (<1/4 of tibia or tarsals at marginal zones) [0463]
3 Moderate infiltration (1/4 to 1/3 of tibia or small tarsals
affected at marginal zones) [0464] 4 Marked infiltration (1/2 to
3/4 of tibia or tarsals affected at marginal zones) [0465] 5 Severe
infiltration (>3/4 of tibia or tarsals affected at marginal
zones, severe distortion of overall architecture)
Knee Pannus
[0465] [0466] 0 Normal [0467] 0.5 Minimal infiltration of pannus in
cartilage and subchondral bone, affects only marginal zones and
affects only a few joints [0468] 1 Minimal infiltration of pannus
in cartilage and subchondral bone, approximately 1-10% of cartilage
surface or subchondral bone affected [0469] 2 Mild infiltration
(extends over up to 1/4 of surface or subchondral area of tibia or
femur), approximately 11-25% of cartilage surface or subchondral
bone affected [0470] 3 Moderate infiltration (extends over >1/4
but <1/2 of surface or subchondral area of tibia or femur)
approximately 26-50% of cartilage surface or subchondral bone
affected [0471] 4 Marked infiltration (extends over 1/2 to 3/4 of
tibial or femoral surface) approximately 51-75% of cartilage
surface or subchondral bone affected [0472] 5 Severe infiltration
approximately 76-100% of cartilage surface or subchondral bone
affected
Ankle Cartilage Damage (Emphasis on Small Tarsals)
[0472] [0473] 0 Normal [0474] 0.5 Minimal decrease in T blue
staining, affects only marginal zones and affects only a few joints
[0475] 1 Minimal=minimal to mild loss of toluidine blue staining
with no obvious chondrocyte loss or collagen disruption [0476] 2
Mild=mild loss of toluidine blue staining with focal mild
(superficial) chondrocyte loss and/or collagen disruption [0477] 3
Moderate=moderate loss of toluidine blue staining with multifocal
moderate (depth to middle zone) chondrocyte loss and/or collagen
disruption, smaller tarsals affected to 1/2 to 3/4 depth with rare
areas of full thickness loss [0478] 4 Marked=marked loss of
toluidine blue staining with multifocal marked (depth to deep zone)
chondrocyte loss and/or collagen disruption, 1 or 2 small tarsals
surfaces have full thickness loss of cartilage [0479] 5
Severe=severe diffuse loss of toluidine blue staining with
multifocal severe (depth to tide mark) chondrocyte loss and/or
collagen disruption affecting more than 2 cartilage surfaces
Knee Cartilage Damage
[0479] [0480] 0 Normal [0481] 0.5 Minimal decrease in T blue
staining, affects only marginal zones [0482] 1 Minimal=minimal to
mild loss of toluidine blue staining with no obvious chondrocyte
loss or collagen disruption [0483] 2 Mild=mild loss of toluidine
blue staining with focal mild (superficial) chondrocyte loss and/or
collagen disruption, may have few small areas of 50% depth of
cartilage affected [0484] 3 Moderate=moderate loss of toluidine
blue staining with multifocal to diffuse moderate (depth to middle
zone) chondrocyte loss and/or collagen disruption, may have 1-2
small areas of full thickness loss affecting less than 1/4 of the
total width of a surface and not more than 25% of the total width
of all surfaces [0485] 4 Marked=marked loss of toluidine blue
staining with multifocal to diffuse marked (depth to deep zone)
chondrocyte loss and/or collagen disruption or 1 surface with near
total loss and partial loss on others, total overall loss less than
50% of width of all surfaces combined [0486] 5 Severe=severe
diffuse loss of toluidine blue staining with multifocal severe
(depth to tide mark) chondrocyte loss and/or collagen disruption on
both femurs and/or tibias, total overall loss greater than 50% of
width of all surfaces combined
Ankle Bone Resorption
[0486] [0487] 0 Normal [0488] 0.5 Minimal resorption affects only
marginal zones and affects only a few joints [0489] 1 Minimal=small
areas of resorption, not readily apparent on low magnification,
rare osteoclasts [0490] 2 Mild=more numerous areas of resorption,
not readily apparent on low magnification, osteoclasts more
numerous, <1/4 of tibia or tarsals at marginal zones resorbed
[0491] 3 Moderate=obvious resorption of medullary trabecular and
cortical bone without full thickness defects in cortex, loss of
some medullary trabeculae, lesion apparent on low magnification,
osteoclasts more numerous, 1/4 to 1/3 of tibia or tarsals affected
at marginal zones [0492] 4 Marked=Full thickness defects in
cortical bone, often with distortion of profile of remaining
cortical surface, marked loss of medullary bone, numerous
osteoclasts, 1/2 to 3/4 of tibia or tarsals affected at marginal
zones [0493] 5 Severe=Full thickness defects in cortical bone,
often with distortion of profile of remaining cortical surface,
marked loss of medullary bone, numerous osteoclasts, >3/4 of
tibia or tarsals affected at marginal zones, severe distortion of
overall architecture
Knee Bone Resorption
[0493] [0494] 0 Normal [0495] 0.5 Minimal resorption affects only
marginal zones [0496] 1 Minimal=small areas of resorption, not
readily apparent on low magnification, approximately 1-10% of total
joint width of subchondral bone affected [0497] 2 Mild=more
numerous areas of resorption, definite loss of subchondral bone,
approximately 11-25% of total joint width of subchondral bone
affected [0498] 3 Moderate=obvious resorption of subchondral bone
approximately 26-50% of total joint width of subchondral bone
affected [0499] 4 Marked=obvious resorption of subchondral bone
approximately 51-75% of total joint width of subchondral bone
affected [0500] 5 Severe=distortion of entire joint due to
destruction approximately 76-100% of total joint width of
subchondral bone affected
Results:
[0501] Disease severity in the disease control group increased from
days 1 to 5 with day 4-5 having the greatest daily increase. Then
the incremental increases were smaller to the peak at day 7. From
that point forward, acute swelling generally decreased and calliper
measures were decreased. The treatment groups followed this general
pattern as well.
[0502] Body weight loss was observed in all disease groups whereas
the normal control group had a weight increase. Body weight loss
was significantly (25%, p<0.05 by ANOVA) inhibited for rats
treated with 5 mg/kg SEQ ID NO: 172 as compared to vehicle treated
disease controls. When compared to disease controls using a
Student's t-test, inhibition of body weight loss was also
significant for rats treated with 1 mg/kg SEQ ID NO: 172 (21%,
p<0.05) or Dex (21%, p<0.05). Results of treatment with SEQ
ID NO: 172 were dose responsive for this parameter.
[0503] Daily ankle diameter measurements were significantly
(p<0.05 by 2-way RM ANOVA) reduced toward normal for rats
treated with 5 mg/kg SEQ ID NO: 172 (p<0.05 days 4-12) or Dex
(p<0.05 d3-14) as compared to disease controls.
[0504] Ankle diameter AUC was significantly (p<0.05 by ANOVA)
reduced toward normal for rats treated with 5 mg/kg SEQ ID NO: 172
(43% reduction), 1 mg/kg SEQ ID NO: 172 (27%), or Dex (97%) as
compared to disease controls. Results of treatment with SEQ ID NO:
172 were dose responsive for this parameter.
[0505] Final paw weights were significantly (p<0.05 by ANOVA)
reduced toward normal for rats treated with 5 mg/kg SEQ ID NO: 172
(26% reduction) or Dex (114%) as compared to disease controls.
Results of treatment with SEQ ID NO: 172 were dose responsive for
this parameter.
[0506] Relative liver weights were not significantly (by ANOVA)
affected for rats in any treatment group as compared to disease
controls.
[0507] Spleen weights relative to body weight were significantly
(p<0.05 by ANOVA) reduced for rats treated with Dex as compared
to disease controls. Relative spleen weights for Dex treated rats
were also significantly reduced as compared to normal controls.
Relative spleen weights were not significantly affected for rats
treated with SEQ ID NO: 172.
[0508] Thymus weights relative to body weight were significantly
(p<0.05 by ANOVA) reduced for rats treated with Dex as compared
to disease controls. Relative thymus weights for Dex treated rats
were also significantly reduced as compared to normal controls.
Relative thymus weights were not significantly affected for rats
treated with SEQ ID NO: 172.
[0509] All ankle histopathology parameters were significantly (by
Mann-Whitney U test) reduced toward normal for rats treated with 5
mg/kg SEQ ID NO: 172 (25% reduction of summed scores) as compared
to disease controls.
[0510] All knee histopathology parameters were significantly (by
Mann-Whitney U test) reduced toward normal for rats treated with 5
mg/kg SEQ ID NO: 172 (73% reduction of summed scores) as compared
to disease controls.
[0511] Results of this study indicated that daily intravenous
treatment with SEQ ID NO: 172 (5 mg/kg) had significant beneficial
effect on the clinical and histopathology parameters associated
with established type II collagen arthritis in rats. Treatment with
SEQ ID NO: 172 (1 mg/kg) resulted in significantly reduced ankle
diameter AUC. The beneficial effect on ankle diameter was observed
up to day 12 despite the reduction of swelling after day 7 in
disease control animals. Results of treatment with SEQ ID NO: 172
were dose responsive.
[0512] Treatment with SEQ ID NO: 172 had no adverse effect on organ
weights unlike dexamethasone.
Example 12
Effect of the all-D-Retro-Inverso JNK-Inhibitor (Poly-)Peptide of
SEQ ID NO: 197 and the JNK Inhibitor (Poly-)Peptide of SEQ ID NO:
172 at Three Doses in a Scopolamine-Induced Model of Dry Eye in
Mice
Study Concept
[0513] The objective of this study was to assess the effects of two
different compounds, the all-D-retro-inverso JNK-inhibitor
(poly-)peptide of SEQ ID NO: 197 and the JNK inhibitor
(poly-)peptide of SEQ ID NO: 172, at three dose levels in a mouse
model of scopolamine-induced dry eye.
[0514] The peptides of SEQ ID NO: 197 and SEQ ID NO: 172 were
tested for efficacy in this murine model of dry eye. The peptides
were both tested at a low, medium and a high dose. For the peptide
of SEQ ID NO: 197 the concentrations measured in the formulation
samples for low, medium and high dose levels were 0.06% (w/v),
0.25% (w/v) and 0.6% (w/v), respectively, and for SEQ ID NO: 172
the concentrations measured in the formulation samples for the low,
medium and high dose levels, were 0.05% (w/v), 0.2% (w/v) and 0.6%
(w/v), respectively. The vehicle, which also served as the negative
control, was 0.9% Sodium Chloride for Injection USP.
[0515] The study consisted of a total of 9 groups of female C57BL/6
mice, comprising 8 groups of 12 mice each and an additional group
of 4 mice. Bilateral short-term dry eye was induced by a
combination of scopolamine hydrobromide (Sigma-Aldrich Corp., St.
Louis, Mo.) injection (subcutaneous (SC), four times daily, 0.5
mg/dose, Days 0-21) and by exposing mice to the drying environment
of constant air draft. Starting on Day 1, mice of Groups 1-8 were
treated three times daily (TID) for 21 days with bilateral topical
ocular (oculus uterque; OU) administration (5 .mu.L/eye/dose) of
vehicle (0.9% sterile saline; negative control article); the
peptide of SEQ ID NO: 197 (0.06%, 0.25% and 0.6%), the peptide of
SEQ ID NO: 172 (0.05%, 0.2% and 0.6%); or cyclosporine (0.05%;
positive control, an immunosuppressant drug used to reduce the
activity of the immune system). Mice of Group 9 were maintained as
un-induced, (no dry eye) untreated controls.
[0516] During the in-life (treatment) period, clinical observations
were recorded once daily; slit-lamp examination (SLE) with corneal
fluorescein staining, tear break-up time test (TBUT), and phenol
red thread test (PRTT) were performed three times per week.
Necropsies were performed on Day 22; eyes, eye lids, conjunctivae,
and lacrimal glands were collected from both eyes of each animal.
Tissues from the right eyes (oculus dexter, OD) were fixed and then
evaluated microscopically. Tissues from the left eyes (oculus
sinister; OS) were flash-frozen in liquid nitrogen and stored
frozen at -80.degree. C. for possible subsequent analyses.
TABLE-US-00010 TABLE 5 Experimental Design Number Induction of
Treatment of Dry Eye (TID, OU, animals (QID, SC) 5 .mu.L/eye) Group
(females) Days 0 to 21 Days 1 to 21 1 12 Scopolamine Vehicle 2 12
(200 .mu.L of SEQ ID NO: 197 2.5 mg/mL (0.06%) 3 12 sol., 0.5 SEQ
ID NO: 197 mg/dose) (0.25%) 4 12 SEQ ID NO: 197 (0.6%) 5 12 SEQ ID
NO: 172 (0.05%) 6 12 SEQ ID NO: 172 (0.2%) 7 12 SEQ ID NO: 172
(0.6%) 8 12 Restasis .RTM.* (0.05%) 9 4 No dry eye No treatment
induction *Cyclosporine
Methods
1. Dose Preparation
[0517] The (poly-)peptide of SEQ ID NO: 197 was obtained from
Polypeptide Laboratories (France) as a 1.5-mL clear plastic
microfuge vial containing 300.65 mg of dry powder.
[0518] The (poly-)peptide of SEQ ID NO: 172 was obtained from
Polypeptide Laboratories (France) as a 1.5-mL clear plastic
microfuge vial containing 302.7 mg of dry powder.
[0519] Prior to the start of the study, the (poly-)peptides of SEQ
ID NO: 172 and of SEQ ID NO: 197 were formulated in sterile saline
(vehicle). Dosing solutions at each concentration were sterilized
using 0.2-.mu.m filters, aliquoted to multiple pre-labeled vials,
and frozen at -20.degree. C. The concentrations measured in the
formulation samples for the peptide of SEQ ID NO: 197 were 0.058%,
0.25% and 0.624%, rounded to 0.06%, 0.25% and 0.6%. The
concentrations measured in the formulation samples for the peptide
of SEQ ID NO: 172 were 0.053%, 0.217% and 0.562%, rounded to 0.05,
0.2% and 0.6%.
[0520] On each day of dosing, one set of dosing solutions was
thawed and used for that day's dose administrations. The controls
(vehicle, cyclosporine) were provided ready to dose; no dose
preparation was necessary.
2. Slit-Lamp Examinations (SLE)
[0521] Prior to entry into the study, each animal underwent a SLE
and indirect ophthalmic examination using topically-applied
fluorescein. Ocular findings were recorded using the Draize scale
ocular scoring. SLE and Draize scoring were repeated three times a
week during the in-life period.
3. Tear Break-Up Time (TBUT) Test and Subsequent Corneal
Examination
[0522] The TBUT test was conducted three times weekly by measuring
the time elapsed in seconds between a complete blink after
application of fluorescein to the cornea and the appearance of the
first random dry spot in the tear film. To perform the TBUT, 0.1%
liquid sodium fluorescein was dropped into the conjunctival sac,
the eyelids were manually closed three times and then held open
revealing a continuous fluorescein-containing tear film covering
the cornea, and the time (in seconds) required for the film to
break (appearance of a dry spot or streak) was recorded. At least
ninety seconds later, corneal epithelial damage was graded using a
slit-lamp with a cobalt blue filter after another drop of 0.1%
fluorescein was reapplied to the cornea; the cornea then was scored
per the Draize ocular scale.
4. Phenol Red Thread Tear Test (PRTT)
[0523] Tear production was measured three times a week in both eyes
using PRTT test strips (Zone-Quick; Menicon, Nagoya, Japan). Prior
to the first treatment of the day, a thread was applied to the
lateral canthus of the conjunctival formix of each eye for 30
seconds under slit-lamp biomicroscopy. Tear migration up the tread
(i.e., the length of the wetted cotton thread) was measured using a
millimeter scale.
5. Necropsy and Pathology
[0524] At necropsy on Day 22, both eyes from each animal, including
the globes, lacrimal glands, eyelids, and conjunctivae, were
excised. The right eye and associated tissues were fixed by
overnight submersion in modified Davidson's solution followed by
transfer to 10% neutral buffered formalin (NBF). The fixed tissues
of the right eye were dehydrated, embedded in paraffin, sectioned
at 3 to 5-.mu.m thicknesses, and slide-mounted tissues were stained
with hematoxylin and eosin (H & E). Stained slides were
evaluated via light microscopy. Detailed and complete
histopathologic assessment was conducted on all parts of the eye,
with at least two section levels being examined histopathologically
for each right eye. Special attention was paid to the cornea,
epithelia (including goblet cells) of the conjunctiva and cornea,
as well as the lacrimal gland. These tissues were scored for injury
based upon a 0-4 scale, with 0 being normal, 1 being minimal, 2
being mild, 3 being moderate, and 4 being severe. For each cornea,
scores were based on corneal epithelium thickness, and corneal
inflammation. Conjunctivae were scored for erosion and inflammation
as well as presence or absence of goblet cells.
Results
[0525] Four-times daily SC administration of scopolamine (0.5
mg/dose) induced a dry eye syndrome in female C57BL/6 mice
characterized by a decrease in the volume of aqueous tear
production and changes in the physiochemical properties of the
tears rendering them less capable of maintaining a stable tear film
able to effectively lubricate and protect the eye.
1. Tear Break-Up Time (TBUT) Teat and Corneal Examination
[0526] The tear break-up time tests (TBUTs) were performed prior to
the induction of dry eye, and again on Days 2, 4, 7, 9, 11, 14, 16,
18 and 21 after dry eye induction. After initiation of dosing with
scopolamine (dry eye induction) TBUT mean values began to decrease
in all animals, but appeared to decrease more slowly in Group 6
(mid-dose of SEQ ID NO: 172). The TBUT mean nadir for Groups 5, 6,
7 (low, mid and high-dose of the peptide of SEQ ID NO: 172), and
Group 8 (cyclosporine) occurred on Day 7, reaching similar values
(6.6.+-.0.4, 6.7.+-.0.4, 6.7.+-.0.3, and 6.4.+-.0.4 s,
respectively). Subsequently, the TBUT means of these groups
increased to a peak on Day 9. Groups 6 and 7 (SEQ ID NO: 172 mid
and high-dose groups) TBUT means rose to higher values (10.0.+-.0.7
s and 9.9.+-.0.8 s, respectively) than Group 8, the cyclosporine
group (8.5.+-.0.3 s), while the peak TBUT mean of Group 5, the
low-dose of SEQ ID NO: 172 (8.0.+-.0.4 s) was slightly below that
of Group 8 (cyclosporine). TBUT means for the mid and high-dose of
SEQ ID NO: 197-treated animals, Groups 3 and 4, continued to
decline after onset of dosing, reaching a nadir on Day 9, while the
low-dose Group 2 increased on Day 9. The low, medium and high-dose
TBUT means of SEQ ID NO: 172-treated animals (Groups 2, 3 and 4,
respectively) were above the vehicle group and generally below the
low, mid and high-dose group means of SEQ ID NO: 172-treated
animals.
[0527] When the area under the curve (AUC) for TBUT values from Day
7 to Day 21 was used to compare the various treatments with the
vehicle control, treatment with mid, low and high-dose of the
peptide of SEQ ID NO: 172 (0.05%, 0.2% and 0.6%, respectively),
Groups 5, 6, and 7, as well as animals treated with cyclosporine
(0.05%), Group 8, showed significant increases in the TBUT AUC
(Kruskal-Wallis nonparametric ANOVA). The peptide of SEQ ID NO: 172
appeared to produce a dose-dependent increase in TBUT, with the mid
and high-doses often producing similar effects. Furthermore, there
were no significant differences in TBUT AUC between the
cyclosporine-treated group, the groups treated with three dose
levels of SEQ ID NO: 172 and the un-induced group (Groups 5, 6, 7,
8, and 9). This finding suggests that all three doses of the
peptide of SEQ ID NO: 172 and cyclosporine were approximately
equally effective in improving or reversing the ophthalmological
changes that underlie the TBUT changes in this dry eye model.
[0528] Groups treated with low, mid and high dose levels of the
peptide of SEQ ID NO: 197 (Groups 2-4) showed slight generally
dose-dependent increases in TBUT which started to increase
approximately two days later than animals treated with SEQ ID NO:
172 or cyclosporine.
TABLE-US-00011 TABLE 6 Mean Calculated TBUT AUC Values: TBUT Group
AUC Group 1 71.19 Group 2 88.54 Group 3 91.19 Group 4 89.98 Group 5
102.98 Group 6 119.08 Group 7 119.31 Group 8 116.1 Group 9
124.54
2. Phenol Red Thread Tear Test (PRTT)
[0529] PRTT tests were performed prior to the induction of dry eye,
and again on Days 2, 4, 7, 9, 11, 14, 16, 18 and 21. PRTT values
from Day 0 to Day 4 decreased in all mice that had dry eye induced,
indicating a decrease in tear production after the administration
of scopolamine and exposure to a drying environment of increased
air draft created by the blowers. The nadir in PRTT in most groups
occurred at approximately Day 7. PRTT kept decreasing in the
vehicle control group (Group 1) reaching a nadir on Day 14. After
the nadir, there was an increase in all dry eye groups. These
findings indicate that initiation of scopolamine treatment one day
earlier than initiation of compound treatment was sufficient to
initiate physiological changes in the eye associated with dry eye
syndrome. Even the cyclosporine-treated group showed a decrease in
PRTT similar to other groups through approximately Day 7, then
increased to a peak on Days 11-14, followed by a slight decrease.
In the last PRTT test (Day 21) cyclosporine (Group 8), and Groups 6
and 7 all had similar PRTT values suggesting that both the mid and
high-dose of the peptide of SEQ ID NO: 172 treatments have
therapeutic effects similar to cyclosporine in increasing the
aqueous tear production in this murine dry eye model.
[0530] Animals treated with the low, mid or high-dose of the
peptide of SEQ ID NO: 172 produced significantly more aqueous tears
compared to vehicle-treated animals. Thus, similar to TBUT, the
peptide of SEQ ID NO: 172 produced generally dose-related
significant increases in the production of aqueous tears in this
model.
[0531] Groups treated with low, mid and high dose levels of the
peptide of SEQ ID NO: 197 (0.06%, 0.25% and 0.6%, Groups 2, 3 and
4, respectively) showed generally dose-dependent increases in
PRTT.
TABLE-US-00012 TABLE 7 Mean PRTT AUC Values PRTT Group AUC Group 1
35.02 Group 2 39.96 Group 3 42.79 Group 4 43.17 Group 5 44.38 Group
6 44.85 Group 7 46.10 Group 8 49.44 Group 9 113.63
3. Histopathology
[0532] In this study histologic changes were generally confined to
the cornea. Findings in the cornea consisted of increased
keratinization of the corneal epithelial surface, increased
thickness of the corneal epithelium, increased cellularity of the
corneal epithelium, mildly increased incidence of mitosis of the
basal epithelial layer consistent with increased epithelial cell
turnover. These findings are indicative of a physiologic adaptive
response to corneal drying and corneal surface irritation. Surface
ulceration, corneal stromal edema and inflammatory infiltrate into
the cornea were not seen in this study. The eyes in Group 9, the
untreated group (normal mice, no scopolamine treatment), were
within normal limits. There was some minimal nonsuppurative
inflammation of the eye lids scattered throughout all groups, but
the conjunctiva, retina, lacrimal glands and other parts of the eye
were within normal limits. Goblet cells appeared to be within
limits in all groups. Goblet cells are a primary producer of mucin
which helps the tears form a stronger more adhesive film.
[0533] Mild to moderate corneal changes were noted in all groups
except the untreated normal eye group (Group 9) and were slightly
more severe in Group 1, the vehicle-treated group and Group 2, the
low dose of the peptide of SEQ ID NO: 197, in comparison to the
other treatment groups. These findings were consistent with the
positive beneficial effects of increased tear production on the
cornea.
[0534] When histological scores of the various treatment groups
were compared to the histological scores in the cyclosporine group
to determine if any other treatments produced "similar score
reductions" to cyclosporine, Groups 4, 6, and 7 were found to be
not significantly different than the cyclosporine group scores.
Thus, these three treatments, mid and high-dose of the peptide of
SEQ ID NO: 172 and the high-dose of the peptide of SEQ ID NO: 197,
were the most effective, after cyclosporine, in
reducing/ameliorating the corneal changes associated with this
murine dry eye model.
Sequence CWU 1
1
200111PRTArtificialConsensus new JNK inhibitors 1Xaa Xaa Xaa Arg
Xaa Xaa Xaa Leu Xaa Leu Xaa 1 5 10 211PRTArtificialrPKRPTTLNLF JNK
inhibitor 2Arg Pro Lys Arg Pro Thr Thr Leu Asn Leu Phe 1 5 10
311PRTArtificialRPkRPTTLNLF JNK inhibitor 3Arg Pro Lys Arg Pro Thr
Thr Leu Asn Leu Phe 1 5 10 411PRTArtificialRPKRPaTLNLF JNK
inhibitor 4Arg Pro Lys Arg Pro Ala Thr Leu Asn Leu Phe 1 5 10
511PRTArtificialRPKRPTTLnLF JNK inhibitor 5Arg Pro Lys Arg Pro Thr
Thr Leu Asn Leu Phe 1 5 10 611PRTArtificialRPKRPTTLrLF JNK
inhibitor 6Arg Pro Lys Arg Pro Thr Thr Leu Arg Leu Phe 1 5 10
711PRTArtificialRPKRPTTLNLf JNK inhibitor 7Arg Pro Lys Arg Pro Thr
Thr Leu Asn Leu Phe 1 5 10 811PRTArtificialRPkRPaTLNLf JNK
inhibitor 8Arg Pro Lys Arg Pro Ala Thr Leu Asn Leu Phe 1 5 10
911PRTArtificialRPkRPTTLNLf JNK inhibitor 9Arg Pro Lys Arg Pro Thr
Thr Leu Asn Leu Phe 1 5 10 1011PRTArtificialRPkRPTTLrLf JNK
inhibitor 10Arg Pro Lys Arg Pro Thr Thr Leu Arg Leu Phe 1 5 10
1111PRTArtificialRRrRPTTLNLf JNK inhibitor 11Arg Arg Arg Arg Pro
Thr Thr Leu Asn Leu Phe 1 5 10 1211PRTArtificialQRrRPTTLNLf JNK
inhibitor 12Gln Arg Arg Arg Pro Thr Thr Leu Asn Leu Phe 1 5 10
1311PRTArtificialRPkRPTTLNLw JNK inhibitor 13Arg Pro Lys Arg Pro
Thr Thr Leu Asn Leu Trp 1 5 10 1411PRTArtificialRPkRPTDLNLf JNK
inhibitor 14Arg Pro Lys Arg Pro Thr Asp Leu Asn Leu Phe 1 5 10
1511PRTArtificialRRrRPTTLrLw JNK inhibitor 15Arg Arg Arg Arg Pro
Thr Thr Leu Arg Leu Trp 1 5 10 1611PRTArtificialQRrRPTTLrLw JNK
inhibitor 16Gln Arg Arg Arg Pro Thr Thr Leu Arg Leu Trp 1 5 10
1711PRTArtificialRRrRPTDLrLw JNK inhibitor 17Arg Arg Arg Arg Pro
Thr Asp Leu Arg Leu Trp 1 5 10 1811PRTArtificialQRrRPTDLrLw JNK
inhibitor 18Gln Arg Arg Arg Pro Thr Asp Leu Arg Leu Trp 1 5 10
1911PRTArtificialRRrRPaTLNLf JNK inhibitor 19Arg Arg Arg Arg Pro
Ala Thr Leu Asn Leu Phe 1 5 10 2011PRTArtificialQRrRPaTLNLf JNK
inhibitor 20Gln Arg Arg Arg Pro Ala Thr Leu Asn Leu Phe 1 5 10
2111PRTArtificialRrKRPaTLNLf JNK inhibitor 21Arg Arg Lys Arg Pro
Ala Thr Leu Asn Leu Phe 1 5 10 2211PRTArtificialRPkRPsTLNLf JNK
inhibitor 22Arg Pro Lys Arg Pro Ser Thr Leu Asn Leu Phe 1 5 10
2311PRTArtificialRPkRPqTLNLf JNK inhibitor 23Arg Pro Lys Arg Pro
Gln Thr Leu Asn Leu Phe 1 5 10 2411PRTArtificialRPkRPkTLNLf JNK
inhibitor 24Arg Pro Lys Arg Pro Lys Thr Leu Asn Leu Phe 1 5 10
2510PRTArtificialrGKRKALKLf JNK inhibitor 25Arg Gly Lys Arg Lys Ala
Leu Lys Leu Phe 1 5 10 2610PRTArtificialrGKRKALrLf JNK inhibitor
26Arg Gly Lys Arg Lys Ala Leu Arg Leu Phe 1 5 10
2710PRTArtificialRRrRKALrLf JNK inhibitor 27Arg Arg Arg Arg Lys Ala
Leu Arg Leu Phe 1 5 10 289PRTArtificial SequenceDescription of
artificial sequence generic subformula (Ib) DlLLLxDmLLLyDn 28Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 299PRTArtificial
SequenceDescription of artificial sequence generic subformula (Ie)
DLLLD(LLLD)a 29Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5
309PRTArtificial SequenceDescription of artificial sequence generic
subformula (If) DLLLDLLLD 30Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5
319PRTArtificialDescription of sequence consensus sequence
rXXXrXXXr 31Arg Xaa Xaa Xaa Arg Xaa Xaa Xaa Arg 1 5
329PRTArtificialr3 (generic; right half) 32Arg Lys Lys Arg Arg Xaa
Xaa Xaa Arg 1 5 339PRTArtificialr3 (generic; left half) 33Arg Xaa
Xaa Xaa Arg Gln Arg Arg Arg 1 5 349PRTArtificialr3 (generic;
individual) 34Arg Xaa Xaa Xaa Arg Xaa Xaa Xaa Arg 1 5 3586PRTHuman
immunodeficiency virus type 1misc_featureDescription of sequence
HIV-1 TAT sequence (aa 1-86) 35Met Glu Pro Val Asp Pro Arg Leu Glu
Pro Trp Lys His Pro Gly Ser 1 5 10 15 Gln Pro Lys Thr Ala Cys Thr
Asn Cys Tyr Cys Lys Lys Cys Cys Phe 20 25 30 His Cys Gln Val Cys
Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly 35 40 45 Arg Lys Lys
Arg Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser Gln Thr 50 55 60 His
Gln Val Ser Leu Ser Lys Gln Pro Thr Ser Gln Ser Arg Gly Asp 65 70
75 80 Pro Thr Gly Pro Lys Glu 85 3636PRTHuman immunodeficiency
virus type 1misc_featureDescription of sequence HIV-1 TAT sequence
(aa 37-72) 36Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg
Lys Lys Arg 1 5 10 15 Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser Gln
Thr His Gln Val Ser 20 25 30 Leu Ser Lys Gln 35 3722PRTHuman
immunodeficiency virus type 1misc_featureDescription of sequence
HIV-1 TAT sequence (aa 37-58) 37Cys Phe Ile Thr Lys Ala Leu Gly Ile
Ser Tyr Gly Arg Lys Lys Arg 1 5 10 15 Arg Gln Arg Arg Arg Pro 20
3824PRTHuman immunodeficiency virus type 1misc_featureDescription
of sequence HIV-1 TAT sequence (aa 38-58) including an additional
N-terminal GCC 38Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg
Lys Lys Arg Arg 1 5 10 15 Gln Arg Arg Arg Pro Gly Gly Cys 20
3915PRTHuman immunodeficiency virus type 1misc_featureDescription
of sequence HIV-1 TAT sequence (aa 47-58) including an additional
C-terminal GCC 39Cys Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg
Arg Arg Pro 1 5 10 15 4015PRTHuman immunodeficiency virus type
1misc_featureDescription of sequence HIV-1 TAT sequence (aa 47-58)
including an additional N-terminal GCC 40Tyr Gly Arg Lys Lys Arg
Arg Gln Arg Arg Arg Pro Gly Gly Cys 1 5 10 15 4156PRTHuman
immunodeficiency virus type 1misc_featureDescription of sequence
HIV-1 TAT sequence (aa 1-72) including a mutated Cys to Ala residue
at position 37 41Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys
His Pro Gly Ser 1 5 10 15 Gln Pro Lys Thr Ala Phe Ile Thr Lys Ala
Leu Gly Ile Ser Tyr Gly 20 25 30 Arg Lys Lys Arg Arg Gln Arg Arg
Arg Pro Pro Gln Gly Ser Gln Thr 35 40 45 His Gln Val Ser Leu Ser
Lys Gln 50 55 4210PRTArtificialDescription of sequence trafficking
sequence L-TAT (s1a) 42Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5
10 439PRTArtificial SequenceDescription of sequence trafficking
sequence L-TAT (s1b) 43Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5
4411PRTArtificial SequenceDescription of sequence trafficking
sequence L-TAT (s1c) 44Tyr Asp Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10 459PRTArtificial SequenceDescription of artificial sequence
D-TAT 45Arg Arg Arg Gln Arg Arg Lys Lys Arg 1 5 469PRTArtificial
Sequencetrafficking sequence r3-L-TAT 46Arg Lys Lys Arg Arg Gln Arg
Arg Arg 1 5 479PRTArtificial Sequencetrafficking sequence r3-L-TATi
47Arg Arg Arg Gln Arg Arg Lys Lys Arg 1 5 489PRTArtificial
SequenceDescription of sequence trafficking sequence betaA-r3-L-TAT
48Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5 499PRTArtificial
SequenceDescription of sequence trafficking sequence betaA-r3-L-TAT
49Arg Arg Arg Gln Arg Arg Lys Lys Arg 1 5 509PRTArtificial
SequenceDescription of sequence trafficking sequence
FITC-betaA-r3-L-TAT 50Arg Lys Lys Arg Arg Gln Arg Arg Arg 1 5
519PRTArtificial SequenceDescription of sequence trafficking
sequence FITC-betaA-r3-L-TAT 51Arg Arg Arg Gln Arg Arg Lys Lys Arg
1 5 529PRTArtificial SequenceDescription of sequence trafficking
sequence TAT(s2-1) 52Arg Ala Lys Arg Arg Gln Arg Arg Arg 1 5
539PRTArtificial SequenceDescription of sequence trafficking
sequence TAT(s2-2) 53Arg Lys Ala Arg Arg Gln Arg Arg Arg 1 5
549PRTArtificial SequenceDescription of sequence trafficking
sequence TAT(s2-3) 54Arg Lys Lys Ala Arg Gln Arg Arg Arg 1 5
559PRTArtificial SequenceDescription of sequence trafficking
sequence TAT(s2-4) 55Arg Lys Lys Arg Arg Ala Arg Arg Arg 1 5
569PRTArtificial SequenceDescription of sequence trafficking
sequence TAT(s2-5) 56Arg Lys Lys Arg Arg Gln Ala Arg Arg 1 5
579PRTArtificial SequenceDescription of sequence trafficking
sequence TAT(s2-6)) 57Arg Lys Lys Arg Arg Gln Arg Ala Arg 1 5
589PRTArtificial SequenceDescription of sequence trafficking
sequence TAT(s2-7) 58Arg Asp Lys Arg Arg Gln Arg Arg Arg 1 5
599PRTArtificial Sequencetrafficking sequence TAT(s2-8) 59Arg Lys
Asp Arg Arg Gln Arg Arg Arg 1 5 609PRTArtificial
Sequencetrafficking sequence TAT(s2-9) 60Arg Lys Lys Asp Arg Gln
Arg Arg Arg 1 5 619PRTArtificial Sequencetrafficking sequence
TAT(s2-10) 61Arg Lys Lys Arg Arg Asp Arg Arg Arg 1 5
629PRTArtificial Sequencetrafficking sequence TAT(s2-11) 62Arg Lys
Lys Arg Arg Gln Asp Arg Arg 1 5 639PRTArtificial
Sequencetrafficking sequence TAT(s2-12) 63Arg Lys Lys Arg Arg Gln
Arg Asp Arg 1 5 649PRTArtificial Sequencetrafficking sequence
TAT(s2-13) 64Arg Glu Lys Arg Arg Gln Arg Arg Arg 1 5
659PRTArtificial Sequencetrafficking sequence TAT(s2-14) 65Arg Lys
Glu Arg Arg Gln Arg Arg Arg 1 5 669PRTArtificial
Sequencetrafficking sequence TAT(s2-15) 66Arg Lys Lys Glu Arg Gln
Arg Arg Arg 1 5 679PRTArtificial Sequencetrafficking sequence
TAT(s2-16) 67Arg Lys Lys Arg Arg Glu Arg Arg Arg 1 5
689PRTArtificial Sequencetrafficking sequence TAT(s2-17) 68Arg Lys
Lys Arg Arg Gln Glu Arg Arg 1 5 699PRTArtificial
Sequencetrafficking sequence TAT(s2-18) 69Arg Lys Lys Arg Arg Gln
Arg Glu Arg 1 5 709PRTArtificial Sequencetrafficking sequence
TAT(s2-19) 70Arg Phe Lys Arg Arg Gln Arg Arg Arg 1 5
719PRTArtificial Sequencetrafficking sequence TAT(s2-20) 71Arg Lys
Phe Arg Arg Gln Arg Arg Arg 1 5 729PRTArtificial
Sequencetrafficking sequence TAT(s2-21) 72Arg Lys Lys Phe Arg Gln
Arg Arg Arg 1 5 739PRTArtificial Sequencetrafficking sequence
TAT(s2-22) 73Arg Lys Lys Arg Arg Phe Arg Arg Arg 1 5
749PRTArtificial Sequencetrafficking sequence TAT(s2-23) 74Arg Lys
Lys Arg Arg Gln Phe Arg Arg 1 5 759PRTArtificial
Sequencetrafficking sequence TAT(s2-24) 75Arg Lys Lys Arg Arg Gln
Arg Phe Arg 1 5 769PRTArtificial Sequencetrafficking sequence
TAT(s2-25) 76Arg Arg Lys Arg Arg Gln Arg Arg Arg 1 5
779PRTArtificial Sequencetrafficking sequence TAT(s2-26) 77Arg Lys
Arg Arg Arg Gln Arg Arg Arg 1 5 789PRTArtificial
Sequencetrafficking sequence TAT(s2-27) 78Arg Lys Lys Lys Arg Gln
Arg Arg Arg 1 5 799PRTArtificial Sequencetrafficking sequence
TAT(s2-28) 79Arg Lys Lys Arg Arg Arg Arg Arg Arg 1 5
809PRTArtificial Sequencetrafficking sequence TAT(s2-29) 80Arg Lys
Lys Arg Arg Gln Lys Arg Arg 1 5 819PRTArtificial
Sequencetrafficking sequence TAT(s2-30) 81Arg Lys Lys Arg Arg Gln
Arg Lys Arg 1 5 829PRTArtificial Sequencetrafficking sequence
TAT(s2-31) 82Arg His Lys Arg Arg Gln Arg Arg Arg 1 5
839PRTArtificial Sequencetrafficking sequence TAT(s2-32) 83Arg Lys
His Arg Arg Gln Arg Arg Arg 1 5 849PRTArtificial
Sequencetrafficking sequence TAT(s2-33) 84Arg Lys Lys His Arg Gln
Arg Arg Arg 1 5 859PRTArtificial Sequencetrafficking sequence
TAT(s2-34) 85Arg Lys Lys Arg Arg His Arg Arg Arg 1 5
869PRTArtificial Sequencetrafficking sequence TAT(s2-35) 86Arg Lys
Lys Arg Arg Gln His Arg Arg 1 5 879PRTArtificial
Sequencetrafficking sequence TAT(s2-36) 87Arg Lys Lys Arg Arg Gln
Arg His Arg 1 5 889PRTArtificial Sequencetrafficking sequence
TAT(s2-37) 88Arg Ile Lys Arg Arg Gln Arg Arg Arg 1 5
899PRTArtificial Sequencetrafficking sequence TAT(s2-38) 89Arg Lys
Ile Arg Arg Gln Arg Arg Arg 1 5 909PRTArtificial
Sequencetrafficking sequence TAT(s2-39) 90Arg Lys Lys Ile Arg Gln
Arg Arg Arg 1 5 919PRTArtificial Sequencetrafficking sequence
TAT(s2-40) 91Arg Lys Lys Arg Arg Ile Arg Arg Arg 1 5
929PRTArtificial Sequencetrafficking sequence TAT(s2-41) 92Arg Lys
Lys Arg Arg Gln Ile Arg Arg 1 5 939PRTArtificial
Sequencetrafficking sequence TAT(s2-42) 93Arg Lys Lys Arg Arg Gln
Arg Ile Arg 1 5 949PRTArtificial Sequencetrafficking sequence
TAT(s2-43) 94Arg Leu Lys Arg Arg Gln Arg Arg Arg 1 5
959PRTArtificial Sequencetrafficking sequence TAT(s2-44) 95Arg Lys
Leu Arg Arg Gln Arg Arg Arg 1 5 969PRTArtificial
Sequencetrafficking sequence TAT(s2-45) 96Arg Lys Lys Leu Arg Gln
Arg Arg Arg 1 5 979PRTArtificial Sequencetrafficking sequence
TAT(s2-46) 97Arg Lys Lys Arg Arg Leu Arg Arg Arg 1 5
989PRTArtificial Sequencetrafficking sequence TAT(s2-47) 98Arg Lys
Lys Arg Arg Gln Leu Arg Arg 1 5 999PRTArtificial
Sequencetrafficking sequence TAT(s2-48) 99Arg Lys Lys Arg Arg Gln
Arg Leu Arg 1 5 1009PRTArtificial Sequencetrafficking sequence
TAT(s2-49) 100Arg Met Lys Arg Arg Gln Arg Arg Arg 1 5
1019PRTArtificial Sequencetrafficking sequence TAT(s2-50) 101Arg
Lys Met Arg Arg Gln Arg Arg Arg 1 5 1029PRTArtificial
Sequencetrafficking sequence TAT(s2-51) 102Arg Lys Lys Met Arg Gln
Arg Arg Arg 1 5 1039PRTArtificial Sequencetrafficking sequence
TAT(s2-52) 103Arg Lys Lys Arg Arg Met Arg Arg Arg 1 5
1049PRTArtificial Sequencetrafficking sequence TAT(s2-53) 104Arg
Lys Lys Arg Arg Gln Met Arg Arg 1 5 1059PRTArtificial
Sequencetrafficking sequence TAT(s2-54) 105Arg Lys Lys Arg Arg Gln
Arg Met Arg 1 5 1069PRTArtificial Sequencetrafficking sequence
TAT(s2-55) 106Arg Asn Lys Arg Arg Gln Arg Arg Arg 1 5
1079PRTArtificial Sequencetrafficking sequence TAT(s2-56) 107Arg
Lys Asn Arg Arg Gln Arg Arg Arg 1 5 1089PRTArtificial
Sequencetrafficking sequence TAT(s2-57) 108Arg Lys Lys Asn Arg Gln
Arg Arg Arg 1 5 1099PRTArtificial Sequencetrafficking sequence
TAT(s2-58) 109Arg Lys Lys Arg Arg Asn Arg Arg Arg 1 5
1109PRTArtificial Sequencetrafficking sequence TAT(s2-59) 110Arg
Lys Lys Arg Arg Gln Asn
Arg Arg 1 5 1119PRTArtificial Sequencetrafficking sequence
TAT(s2-60) 111Arg Lys Lys Arg Arg Gln Arg Asn Arg 1 5
1129PRTArtificial Sequencetrafficking sequence TAT(s2-61) 112Arg
Gln Lys Arg Arg Gln Arg Arg Arg 1 5 1139PRTArtificial
Sequencetrafficking sequence TAT(s2-62) 113Arg Lys Gln Arg Arg Gln
Arg Arg Arg 1 5 1149PRTArtificial Sequencetrafficking sequence
TAT(s2-63) 114Arg Lys Lys Gln Arg Gln Arg Arg Arg 1 5
1159PRTArtificial Sequencetrafficking sequence TAT(s2-64) 115Arg
Lys Lys Arg Arg Lys Arg Arg Arg 1 5 1169PRTArtificial
Sequencetrafficking sequence TAT(s2-65) 116Arg Lys Lys Arg Arg Gln
Gln Arg Arg 1 5 1179PRTArtificial Sequencetrafficking sequence
TAT(s2-66) 117Arg Lys Lys Arg Arg Gln Arg Gln Arg 1 5
1189PRTArtificial Sequencetrafficking sequence TAT(s2-67) 118Arg
Ser Lys Arg Arg Gln Arg Arg Arg 1 5 1199PRTArtificial
Sequencetrafficking sequence TAT(s2-68) 119Arg Lys Ser Arg Arg Gln
Arg Arg Arg 1 5 1209PRTArtificial Sequencetrafficking sequence
TAT(s2-69) 120Arg Lys Lys Ser Arg Gln Arg Arg Arg 1 5
1219PRTArtificial Sequencetrafficking sequence TAT(s2-70) 121Arg
Lys Lys Arg Arg Ser Arg Arg Arg 1 5 1229PRTArtificial
Sequencetrafficking sequence TAT(s2-71) 122Arg Lys Lys Arg Arg Gln
Ser Arg Arg 1 5 1239PRTArtificial Sequencetrafficking sequence
TAT(s2-72) 123Arg Lys Lys Arg Arg Gln Arg Ser Arg 1 5
1249PRTArtificial Sequencetrafficking sequence TAT(s2-73) 124Arg
Thr Lys Arg Arg Gln Arg Arg Arg 1 5 1259PRTArtificial
Sequencetrafficking sequence TAT(s2-74) 125Arg Lys Thr Arg Arg Gln
Arg Arg Arg 1 5 1269PRTArtificial Sequencetrafficking sequence
TAT(s2-75) 126Arg Lys Lys Thr Arg Gln Arg Arg Arg 1 5
1279PRTArtificial Sequencetrafficking sequence TAT(s2-76) 127Arg
Lys Lys Arg Arg Thr Arg Arg Arg 1 5 1289PRTArtificial
Sequencetrafficking sequence TAT(s2-77) 128Arg Lys Lys Arg Arg Gln
Thr Arg Arg 1 5 1299PRTArtificial Sequencetrafficking sequence
TAT(s2-78) 129Arg Lys Lys Arg Arg Gln Arg Thr Arg 1 5
1309PRTArtificial Sequencetrafficking sequence TAT(s2-79) 130Arg
Val Lys Arg Arg Gln Arg Arg Arg 1 5 1319PRTArtificial
Sequencetrafficking sequence TAT(s2-80) 131Arg Lys Val Arg Arg Gln
Arg Arg Arg 1 5 1329PRTArtificial Sequencetrafficking sequence
TAT(s2-81) 132Arg Lys Lys Val Arg Gln Arg Arg Arg 1 5
1339PRTArtificial Sequencetrafficking sequence TAT(s2-82) 133Arg
Lys Lys Arg Arg Val Arg Arg Arg 1 5 1349PRTArtificial
Sequencetrafficking sequence TAT(s2-83) 134Arg Lys Lys Arg Arg Gln
Val Arg Arg 1 5 1359PRTArtificial Sequencetrafficking sequence
TAT(s2-84) 135Arg Lys Lys Arg Arg Gln Arg Val Arg 1 5
1369PRTArtificial Sequencetrafficking sequence TAT(s2-85) 136Arg
Trp Lys Arg Arg Gln Arg Arg Arg 1 5 1379PRTArtificial
Sequencetrafficking sequence TAT(s2-86) 137Arg Lys Trp Arg Arg Gln
Arg Arg Arg 1 5 1389PRTArtificial Sequencetrafficking sequence
TAT(s2-87) 138Arg Lys Lys Trp Arg Gln Arg Arg Arg 1 5
1399PRTArtificial Sequencetrafficking sequence TAT(s2-88) 139Arg
Lys Lys Arg Arg Trp Arg Arg Arg 1 5 1409PRTArtificial
Sequencetrafficking sequence TAT(s2-89) 140Arg Lys Lys Arg Arg Gln
Trp Arg Arg 1 5 1419PRTArtificial Sequencetrafficking sequence
TAT(s2-90) 141Arg Lys Lys Arg Arg Gln Arg Trp Arg 1 5
1429PRTArtificial Sequencetrafficking sequence TAT(s2-91) 142Arg
Tyr Lys Arg Arg Gln Arg Arg Arg 1 5 1439PRTArtificial
Sequencetrafficking sequence TAT(s2-92) 143Arg Lys Tyr Arg Arg Gln
Arg Arg Arg 1 5 1449PRTArtificial Sequencetrafficking sequence
TAT(s2-93) 144Arg Lys Lys Tyr Arg Gln Arg Arg Arg 1 5
1459PRTArtificial Sequencetrafficking sequence TAT(s2-94) 145Arg
Lys Lys Arg Arg Tyr Arg Arg Arg 1 5 1469PRTArtificial
Sequencetrafficking sequence TAT(s2-95) 146Arg Lys Lys Arg Arg Gln
Tyr Arg Arg 1 5 1479PRTArtificial SequenceTrafficking sequence
TAT(s2-96) 147Arg Lys Lys Arg Arg Gln Arg Tyr Arg 1 5
1488PRTArtificialTrafficking sequence TAT(s2-97) 148Arg Lys Lys Arg
Arg Gln Arg Arg 1 5 1499PRTArtificialTrafficking sequence
TAT(s2-98) 149Arg Lys Lys Arg Arg Gln Arg Arg Lys 1 5
1509PRTArtificialTrafficking sequence TAT(s2-99) 150Arg Lys Lys Arg
Arg Gln Arg Arg Arg 1 5 1519PRTArtificial Sequencetrafficking
sequence r3R6 151Arg Arg Arg Arg Arg Arg Arg Arg Arg 1 5
1529PRTArtificial Sequencetrafficking sequence L-R9 152Arg Arg Arg
Arg Arg Arg Arg Arg Arg 1 5 1538PRTArtificial Sequencetrafficking
sequence L-R8 153Arg Arg Arg Arg Arg Arg Arg Arg 1 5
1547PRTArtificial Sequencetrafficking sequence L-R7 154Arg Arg Arg
Arg Arg Arg Arg 1 5 1556PRTArtificial Sequencetrafficking sequence
L-R6 155Arg Arg Arg Arg Arg Arg 1 5 1565PRTArtificial
Sequencetrafficking sequence L-R5 156Arg Arg Arg Arg Arg 1 5
1579PRTArtificialall D transporter construct (all amino acid
residues are D-amino acids) 157Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 1589PRTArtificialDescription of sequence D/L transporter
construct (D and L amino acid residues alternate, beginning wit D
amino acids) 158Arg Arg Arg Arg Arg Arg Arg Arg Arg 1 5
1599PRTArtificialDescription of sequence DD/LL transporter
construct 159Arg Arg Arg Arg Arg Arg Arg Arg Arg 1 5
16011PRTArtificial Sequencetrafficking sequence PTD-4 160Tyr Ala
Arg Ala Ala Ala Arg Gln Ala Arg Ala 1 5 10 16111PRTArtificial
Sequencetrafficking sequence PTD-4 161Trp Ala Arg Ala Ala Ala Arg
Gln Ala Arg Ala 1 5 10 16211PRTArtificial Sequencetrafficking
sequence PTD-4 162Trp Ala Arg Ala Gln Arg Ala Ala Ala Arg Ala 1 5
10 16316PRTArtificial Sequencetrafficking sequence L-P1
(Penetratin) 163Arg Gln Val Lys Val Trp Phe Gln Asn Arg Arg Met Lys
Trp Lys Lys 1 5 10 15 16416PRTArtificial Sequencetrafficking
sequence D-P1 (Penetratin) 164Lys Lys Trp Lys Met Arg Arg Asn Gln
Phe Trp Val Lys Val Gln Arg 1 5 10 15 16517PRTArtificial
Sequencetrafficking sequence JNK1, bestfit 165Trp Lys Arg Ala Ala
Ala Arg Lys Ala Arg Ala Met Ser Leu Asn Leu 1 5 10 15 Phe
16617PRTArtificial Sequencetrafficking sequence JNK1, bestfit
(variant 1) 166Trp Lys Arg Ala Ala Ala Arg Ala Ala Arg Ala Met Ser
Leu Asn Leu 1 5 10 15 Phe 1679PRTArtificial Sequencetrafficking
sequence MDCK transcytose sequence 167Arg Tyr Arg Gly Asp Leu Gly
Arg Arg 1 5 1684PRTArtificial Sequencetrafficking sequence YKGL
168Tyr Lys Gly Leu 1 1694PRTArtificialtrafficking sequence RRTK
169Arg Arg Thr Lys 1 1704PRTArtificialtrafficking sequence RRPK
170Arg Arg Pro Lys 1 17120PRTArtificialrKKRrQRRrRPkRPTTLNLf JNK
inhibitor 171Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Lys Arg
Pro Thr Thr 1 5 10 15 Leu Asn Leu Phe 20
17220PRTArtificialrKKRrQRRrRPkRPaTLNLf JNK inhibitor 172Arg Lys Lys
Arg Arg Gln Arg Arg Arg Arg Pro Lys Arg Pro Ala Thr 1 5 10 15 Leu
Asn Leu Phe 20 17320PRTArtificialrKKRrQRRrRPkRPTTLrLf JNK inhibitor
173Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Lys Arg Pro Thr Thr
1 5 10 15 Leu Arg Leu Phe 20 17417PRTArtificialrKKRrQRRrRPTTLNLf
JNK inhibitor 174Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Thr
Thr Leu Asn Leu 1 5 10 15 Phe 17516PRTArtificialrKKRrQRrRPTTLNLf
JNK inhibitor 175Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Thr Thr
Leu Asn Leu Phe 1 5 10 15 17620PRTArtificialrKKRrQRRrRPkRPTTLNLw
JNK inhibitor 176Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Lys
Arg Pro Thr Thr 1 5 10 15 Leu Asn Leu Trp 20
17720PRTArtificialrKKRrQRRrRPkRPTDLNLf JNK inhibitor 177Arg Lys Lys
Arg Arg Gln Arg Arg Arg Arg Pro Lys Arg Pro Thr Asp 1 5 10 15 Leu
Asn Leu Phe 20 17817PRTArtificialrKKRrQRRrRPTTLrLw JNK inhibitor
178Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Thr Thr Leu Arg Leu
1 5 10 15 Trp 17916PRTArtificialrKKRrQRrRPTTLrLw JNK inhibitor
179Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Thr Thr Leu Arg Leu Trp
1 5 10 15 18017PRTArtificialrKKRrQRRrRPTDLrLw JNK inhibitor 180Arg
Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Thr Asp Leu Arg Leu 1 5 10
15 Trp 18116PRTArtificialrKKRrQRrRPTDLrLw JNK inhibitor 181Arg Lys
Lys Arg Arg Gln Arg Arg Arg Pro Thr Asp Leu Arg Leu Trp 1 5 10 15
18217PRTArtificialrKKRrQRRrRPaTLNLf JNK inhibitor 182Arg Lys Lys
Arg Arg Gln Arg Arg Arg Arg Pro Ala Thr Leu Asn Leu 1 5 10 15 Phe
18316PRTArtificialrKKRrQRrRPaTLNLf JNK inhibitor 183Arg Lys Lys Arg
Arg Gln Arg Arg Arg Pro Ala Thr Leu Asn Leu Phe 1 5 10 15
18417PRTArtificialrKKRrQRrKRPaTLNLf JNK inhibitor 184Arg Lys Lys
Arg Arg Gln Arg Arg Lys Arg Pro Ala Thr Leu Asn Leu 1 5 10 15 Phe
18520PRTArtificialrKKRrQRRrRPkRPsTLNLf JNK inhibitor 185Arg Lys Lys
Arg Arg Gln Arg Arg Arg Arg Pro Lys Arg Pro Ser Thr 1 5 10 15 Leu
Asn Leu Phe 20 18620PRTArtificialrKKRrQRRrRPkRPqTLNLf JNK inhibitor
186Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Lys Arg Pro Gln Thr
1 5 10 15 Leu Asn Leu Phe 20 18720PRTArtificialrKKRrQRRrRPkRPkTLNLf
JNK inhibitor 187Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Lys
Arg Pro Lys Thr 1 5 10 15 Leu Asn Leu Phe 20
18818PRTArtificialrKKRrQRRrGKRKALKLf JNK inhibitor 188Arg Lys Lys
Arg Arg Gln Arg Arg Arg Gly Lys Arg Lys Ala Leu Lys 1 5 10 15 Leu
Phe 18918PRTArtificialrKKRrQRRrGKRKALrLf JNK inhibitor 189Arg Lys
Lys Arg Arg Gln Arg Arg Arg Gly Lys Arg Lys Ala Leu Arg 1 5 10 15
Leu Phe 19016PRTArtificialrKKRrQRRrRKALrLf JNK inhibitor 190Arg Lys
Lys Arg Arg Gln Arg Arg Arg Arg Lys Ala Leu Arg Leu Phe 1 5 10 15
1918PRTArtificialRPTTLNLF JNK inhibitor 191Arg Pro Thr Thr Leu Asn
Leu Phe 1 5 1929PRTArtificialKRPTTLNLF JNK inhibitor 192Lys Arg Pro
Thr Thr Leu Asn Leu Phe 1 5 19311PRTArtificialL-IB1(s24) 193Arg Pro
Lys Arg Pro Thr Thr Leu Asn Leu Phe 1 5 10
19429PRTArtificialGRKKRRQRRRPPKRPTTLNLFPQVPRSQD JNK inhibitor
194Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Lys Arg Pro Thr
1 5 10 15 Thr Leu Asn Leu Phe Pro Gln Val Pro Arg Ser Gln Asp 20 25
19525PRTArtificialGRKKRRQRRRPTTLNLFPQVPRSQD JNK inhibitor 195Gly
Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Thr Thr Leu Asn Leu 1 5 10
15 Phe Pro Gln Val Pro Arg Ser Gln Asp 20 25
19631PRTArtificialL-TAT-IB1 196Gly Arg Lys Lys Arg Arg Gln Arg Arg
Arg Pro Pro Arg Pro Lys Arg 1 5 10 15 Pro Thr Thr Leu Asn Leu Phe
Pro Gln Val Pro Arg Ser Gln Asp 20 25 30
19731PRTArtificialD-TAT-IB1 197Asp Gln Ser Arg Pro Val Gln Pro Phe
Leu Asn Leu Thr Thr Pro Arg 1 5 10 15 Lys Pro Arg Pro Pro Arg Arg
Arg Gln Arg Arg Lys Lys Arg Gly 20 25 30 19839PRTArtificialcJun
(29-67) 198Ser Asn Pro Lys Ile Leu Lys Gln Ser Met Thr Leu Asn Leu
Ala Asp 1 5 10 15 Pro Val Gly Ser Leu Lys Pro His Leu Arg Ala Lys
Asn Ser Asp Leu 20 25 30 Leu Thr Ser Pro Asp Val Gly 35
19920PRTArtificialRKKRRQRRRRPKRPATLNLF antibody negative control
199Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg Pro Lys Arg Pro Ala Thr
1 5 10 15 Leu Asn Leu Phe 20 20020PRTArtificialrKKRrQRRrR
PkAAaAANAf JNK inhibitor 200Arg Lys Lys Arg Arg Gln Arg Arg Arg Arg
Pro Lys Ala Ala Ala Ala 1 5 10 15 Ala Asn Ala Phe 20
* * * * *